#BEGIN_DRUGCARD DB03814

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
39408

# Chemical_Formula:
C6H13NO4S

# Chemical_IUPAC_Name:
4-(2-sulfonatoethyl)morpholin-4-ium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2-(N-Morpholino)-Ethanesulfonic Acid

# HET_ID:
MES

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H13NO4S/c8-12(9,10)6-3-7-1-4-11-5-2-7/h1-6H2,(H,8,9,10)

# InChI_Key:
InChIKey=SXGZJKUKBWWHRA-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3814

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
195.237

# Molecular_Weight_Mono:
195.056528599

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1NWW

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.87

# Predicted_LogS:
-1.7

# Predicted_Water_Solubility:
4.58e+00 g/l

# Primary_Accession_No:
DB03814

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
4478249

# PubChem_Substance_ID:
46507795

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02154

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[O-]S(=O)(=O)CC[NH+]1CCOCC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:39 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
BCHE

# Phase_1_Metabolizing_Enzyme_1_ID:
3923

# Phase_1_Metabolizing_Enzyme_1_Name:
Cholinesterase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cholinesterase
MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP
YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC
LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG
FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG
SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI
LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY
GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV
VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER
RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT
KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV
GL

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P06276

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
Y18005

# Drug_Target_10_GenBank_ID_Protein:
4160334

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
limA

# Drug_Target_10_Gene_Sequence:
>450 bp
ATGACATCAAAGATCGAACAACCTCGCTGGGCGTCCAAGGACAGTGCCGCCGGCGCTGCC
TCGACTCCGGACGAAAAGATCGTTCTGGAGTTCATGGACGCACTGACCAGTAATGATGCT
GCAAAACTCATTGAGTACTTTGCAGAAGACACGATGTACCAGAACATGCCACTCCCCCCT
GCATACGGCCGCGACGCCGTCGAGCAAACTCTGGCTGGCCTGTTCACCGTCATGAGCATC
GATGCGGTGGAGACGTTCCATATCGGCTCGAGTAACGGACTTGTGTACACCGAACGTGTC
GATGTCCTACGCGCACTACCCACCGGCAAGAGCTACAACCTGTCAATCCTCGGAGTCTTC
CAGCTCACCGAGGGCAAGATTACGGGTTGGCGTGACTACTTCGATCTGCGCGAATTCGAA
GAAGCTGTCGACCTTCCCCTCCGCGGCTAA

# Drug_Target_10_General_Function:
Involved in limonene-1,2-epoxide hydrolase activity

# Drug_Target_10_General_References:
9748436	van der Werf MJ, Overkamp KM, de Bont JA: Limonene-1,2-epoxide hydrolase from Rhodococcus erythropolis DCL14 belongs to a novel class of epoxide hydrolases. J Bacteriol. 1998 Oct;180(19):5052-7.
9827564	Barbirato F, Verdoes JC, de Bont JA, van der Werf MJ: The Rhodococcus erythropolis DCL14 limonene-1,2-epoxide hydrolase gene encodes an enzyme belonging to a novel class of epoxide hydrolases. FEBS Lett. 1998 Nov 6;438(3):293-6.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
3399

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
16521

# Drug_Target_10_Name:
Limonene-1,2-epoxide hydrolase

# Drug_Target_10_Number_of_Residues:
149

# Drug_Target_10_PDB_ID:
1NWW

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF07858	LEH

# Drug_Target_10_Protein_Sequence:
>Limonene-1,2-epoxide hydrolase
MTSKIEQPRWASKDSAAGAASTPDEKIVLEFMDALTSNDAAKLIEYFAEDTMYQNMPLPP
AYGRDAVEQTLAGLFTVMSIDAVETFHIGSSNGLVYTERVDVLRALPTGKSYNLSILGVF
QLTEGKITGWRDYFDLREFEEAVDLPLRG

# Drug_Target_10_Reaction:
limonene-1,2-epoxide + H2O = limonene-1,2-diol

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Limonene-1,2-epoxide + H(2)O = limonene-1,2- diol

# Drug_Target_10_SwissProt_ID:
Q9ZAG3

# Drug_Target_10_SwissProt_Name:
LIMA_RHOER

# Drug_Target_10_Synonyms:
EC 3.3.2.8

# Drug_Target_10_Theoretical_pI:
4.21

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Cytoplasmic

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
X82179

# Drug_Target_11_GenBank_ID_Protein:
14594858

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
manA

# Drug_Target_11_Gene_Sequence:
>1272 bp
ATGAAAACTATTACCACTGCACGCCTTCCATGGGCTGCGCAGAGCTTTGCCTTGGGCATT
TGCCTGATAGCGCTGTTGGGTTGTAATCACGCCGCTAATAAATCATCGGCATCCAGGGCA
GATGTCAAACCTGTTACGGTCAAACTGGTCGATTCCCAGGCGACCATGGAAACCCGTTCC
CTGTTTGCGTTTATGCAGGAGCAGCGCAGACATTCCATTATGTTTGGGCACCAGCACGAA
ACAACCCAGGGACTCACTATTACCCGCACAGATGGTACCCAATCCGATACCTTTAATGCC
GTTGGTGATTTTGCAGCGGTCTATGGTTGGGACACGCTGTCTATTGTTGCCCCTAAAGCG
GAGGGCGATATTGTCGCCCAAGTAAAAAAGGCTTATGCGCGCGGGGGCATCATTACGGTG
AGCTCGCATTTTGATAATCCAAAAACCGATACCCAAAAGGGCGTATGGCCCGTTGGCACT
TCCTGGGATCAAACCCCGGCTGTTGTGGATTCCCTGCCTGGAGGCGCCTATAACCCGGTA
TTAAATGGCTATCTCGACCAGGTGGCCGAGTGGGCCAATAACCTGAAAGACGAGCAGGGG
CGGCTGATACCGGTCATCTTTCGCCTGTACCACGAAAATACCGGCAGTTGGTTCTGGTGG
GGAGATAAGCAATCAACCCCTGAACAATACAAGCAATTGTTCCGCTATTCCGTCGAGTAT
TTGCGCGATGTGAAAGGTGTGCGCAATTTCCTGTATGCCTATTCGCCCAACAACTTTTGG
GACGTGACCGAGGCCAATTACCTGGAGCGTTATCCGGGGGATGAGTGGGTGGATGTACTG
GGATTTGATACCTATGGCCCGGTGGCGGACAACGCTGACTGGTTCCGCAATGTGGTGGCC
AATGCGGCCTTGGTTGCCCGCATGGCGGAAGCGCGGGGCAAAATACCGGTGATCTCCGAG
ATAGGTATACGCGCTCCCGACATTGAAGCCGGGCTCTATGATAACCAGTGGTATCGCAAG
CTTATCTCCGGCCTCAAGGCCGATCCGGATGCACGCGAGATTGCCTTCCTGCTGGTATGG
CGCAATGCCCCGCAGGGAGTTCCTGGCCCCAATGGCACCCAGGTTCCCCATTATTGGGTG
CCTGCTAACCGCCCGGAGAATATCAACAATGGCACCCTGGAGGACTTCCAGGCCTTTTAT
GCCGATGAATTCACAGCGTTCAATCGCGACATCGAGCAGGTCTATCAGCGTCCGACCCTG
ATAGTTAAATAG

# Drug_Target_11_General_Function:
Involved in mannan endo-1,4-beta-mannosidase activity

# Drug_Target_11_General_References:
7848261	Braithwaite KL, Black GW, Hazlewood GP, Ali BR, Gilbert HJ: A non-modular endo-beta-1,4-mannanase from Pseudomonas fluorescens subspecies cellulosa. Biochem J. 1995 Feb 1;305 ( Pt 3):1005-10.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
3480

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
47488

# Drug_Target_11_Name:
Mannan endo-1,4-beta-mannosidase

# Drug_Target_11_Number_of_Residues:
423

# Drug_Target_11_PDB_ID:
1R7O

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF02156	Glyco_hydro_26

# Drug_Target_11_Protein_Sequence:
>Mannan endo-1,4-beta-mannosidase precursor
MKTITTARLPWAAQSFALGICLIALLGCNHAANKSSASRADVKPVTVKLVDSQATMETRS
LFAFMQEQRRHSIMFGHQHETTQGLTITRTDGTQSDTFNAVGDFAAVYGWDTLSIVAPKA
EGDIVAQVKKAYARGGIITVSSHFDNPKTDTQKGVWPVGTSWDQTPAVVDSLPGGAYNPV
LNGYLDQVAEWANNLKDEQGRLIPVIFRLYHENTGSWFWWGDKQSTPEQYKQLFRYSVEY
LRDVKGVRNFLYAYSPNNFWDVTEANYLERYPGDEWVDVLGFDTYGPVADNADWFRNVVA
NAALVARMAEARGKIPVISEIGIRAPDIEAGLYDNQWYRKLISGLKADPDAREIAFLLVW
RNAPQGVPGPNGTQVPHYWVPANRPENINNGTLEDFQAFYADEFTAFNRDIEQVYQRPTL
IVK

# Drug_Target_11_Reaction:
Random hydrolysis of 1,4-beta-D-mannosidic linkages in mannans, galactomannans and glucomannans ALL_REAC (other) R01332 R06207(G) REFERENCE 1 AUTHORS Eriksson, A.F.V. TITLE Purification and characterisation of a fungal beta-mannanase. JOURNAL Acta Chem. Scand. 22 (1968) 1924-1934. ORGANISM Aspergillus niger REFERENCE 2 AUTHORS Reese, E.T. TITLE beta-Mannanases of fungi. JOURNAL Can. J. Microbiol. 11 (1965) 167-183. ORGANISM Paecilomyces variotii, Penicillium funiculosum, Penicillium wortmanni, Penicillium verruculosum, Penicillium ochro-chloron, Fusicoccum sp., Aspergillus luchuensis, Aspergillus giganteus, Paecilomyces variotii

# Drug_Target_11_Signals:
1-31

# Drug_Target_11_Specific_Function:
Hydrolyzes mannan and galactomannan, but displays little activity towards other polysaccharides located in the plant cell wall. Preferentially hydrolyzes the larger oligosaccharides

# Drug_Target_11_SwissProt_ID:
P49424

# Drug_Target_11_SwissProt_Name:
MANA_CELJU

# Drug_Target_11_Synonyms:
EC 3.2.1.78
Mannan endo-1,4-beta-mannosidase precursor
Mannanase A

# Drug_Target_11_Theoretical_pI:
5.46

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Golgi stack
Golgi stack membrane
Isoform Long, isoform Short:Golgi apparatus
single-pass type II

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
B4GALT1

# Drug_Target_12_GenBank_ID_Gene:
X14085

# Drug_Target_12_GenBank_ID_Protein:
29424

# Drug_Target_12_GeneCard_ID:
B4GALT1

# Drug_Target_12_Gene_Name:
B4GALT1

# Drug_Target_12_Gene_Sequence:
>1203 bp
ATGAGGCTTCGGGAGCCGCTCCTGAGCGGCGCCGCGATGCCAGGCGCGTCCCTACAGCGG
GCCTGCCGCCTGCTCGTGGCCGTCTGCGCTCTGCACCTTGGCGTCACCCTCGTTTACTAC
CTGGCTGGCCGCGACCTGAGCCGCCTGCCCCAACTGGTCGGAGTCTCCACACCGCTGCAG
GGCGGCTCGAACAGTGCCGCCGCCATCGGGCAGTCCTCCGGGGAGCTCCGGACCGGAGGG
GCCCGGCCGCCGCCTCCTCTAGGCGCCTCCTCCCAGCCGCGCCCGGGTGGCGACTCCAGC
CCAGTCGTGGATTCTGGCCCTGGCCCCGCTAGCAACTTGACCTCGGTCCCAGTGCCCCAC
ACCACCGCACTGTCGCTGCCCGCCTGCCCTGAGGAGTCCCCGCTGCTTGTGGGCCCCATG
CTGATTGAGTTTAACATGCCTGTGGACCTGGAGCTCGTGGCAAAGCAGAACCCAAATGTG
AAGATGGGCGGCCGCTATGCCCCCAGGGACTGCGTCTCTCCTCACAAAGTGGCCATCATC
ATTCCATTCCGCAACCGGCAGGAGCACCTCAAGTACTGGCTATATTATTTGCACCCAGTC
CTGCAGCGCCAGCAGCTGGACTATGGCATCTATGGCATCTATGTTATCAACCAGGCGGGA
GACACTATATTCAATCGTGCTAAGCTCCTCAATGTTGGCTTTCAAGAAGCCTTGAAGGAC
TATGACTACACCTGCTTTGTGTTTAGTGACGTGGACCTCATCCCAATGAATGACCATAAT
GCGTACAGGTGTTTTTCACAGCCACGGCACATTTCCGTTGCAATGGATAAGTTTGGATTC
AGCCTACCTTATGTTCAGTATTTTGGAGGTGTCTCTGCTCTAAGTAAACAACAGTTTCTA
ACCATCAATGGATTTCCTAATAATTATTGGGGCTGGGGAGGAGAAGATGATGACATTTTT
AACAGATTAGTTTTTAGAGGCATGTCTATATCTCGCCCAAATGCTGTGGTCGGGAGGTGT
CGCATGATCCGCCACTCAAGAGACAAAAAAAATGAACCCAATCCTCAGAGGTTTGACCGA
ATTGCACACACAAAGGAGACAATGCTCTCTGATGGTTTGAACTCACTCACCTACCAGGTG
CTGGATGTACAGAGATACCCATTGTATACCCAAATCACAGTGGACATCGGGACACCGAGC
TAG

# Drug_Target_12_General_Function:
Involved in transferase activity, transferring glycosyl groups

# Drug_Target_12_General_References:
10580128	Amado M, Almeida R, Schwientek T, Clausen H: Identification and characterization of large galactosyltransferase gene families: galactosyltransferases for all functions. Biochim Biophys Acta. 1999 Dec 6;1473(1):35-53.
1384956	Uejima T, Uemura M, Nozawa S, Narimatsu H: Complementary DNA cloning for galactosyltransferase associated with tumor and determination of antigenic epitopes recognized by specific monoclonal antibodies. Cancer Res. 1992 Nov 15;52(22):6158-63.
1714903	Lopez LC, Youakim A, Evans SC, Shur BD: Evidence for a molecular distinction between Golgi and cell surface forms of beta 1,4-galactosyltransferase. J Biol Chem. 1991 Aug 25;266(24):15984-91.
1903938	Mengle-Gaw L, McCoy-Haman MF, Tiemeier DC: Genomic structure and expression of human beta-1,4-galactosyltransferase. Biochem Biophys Res Commun. 1991 May 15;176(3):1269-76.
2120039	Aoki D, Appert HE, Johnson D, Wong SS, Fukuda MN: Analysis of the substrate binding sites of human galactosyltransferase by protein engineering. EMBO J. 1990 Oct;9(10):3171-8.
2124683	Watzele G, Berger EG: Near identity of HeLa cell galactosyltransferase with the human placental enzyme. Nucleic Acids Res. 1990 Dec 11;18(23):7174.
3091013	Appert HE, Rutherford TJ, Tarr GE, Thomford NR, McCorquodale DJ: Isolation of galactosyltransferase from human milk and the determination of its N-terminal amino acid sequence. Biochem Biophys Res Commun. 1986 Jul 16;138(1):224-9.
3094506	Appert HE, Rutherford TJ, Tarr GE, Wiest JS, Thomford NR, McCorquodale DJ: Isolation of a cDNA coding for human galactosyltransferase. Biochem Biophys Res Commun. 1986 Aug 29;139(1):163-8.
3144273	Masri KA, Appert HE, Fukuda MN: Identification of the full-length coding sequence for human galactosyltransferase (beta-N-acetylglucosaminide: beta 1,4-galactosyltransferase). Biochem Biophys Res Commun. 1988 Dec 15;157(2):657-63.
7540104	Chatterjee SK, Mukerjee S, Tripathi PK: Analysis of the sequences of human beta-1,4-galactosyltransferase cDNA clones. Int J Biochem Cell Biol. 1995 Mar;27(3):329-36.
7579794	Kudo T, Narimatsu H: The beta 1,4-galactosyltransferase gene is post-transcriptionally regulated during differentiation of mouse F9 teratocarcinoma cells. Glycobiology. 1995 Jun;5(4):397-403.
7744867	Yamaguchi N, Fukuda MN: Golgi retention mechanism of beta-1,4-galactosyltransferase. Membrane-spanning domain-dependent homodimerization and association with alpha- and beta-tubulins. J Biol Chem. 1995 May 19;270(20):12170-6.

# Drug_Target_12_HGNC_ID:
HGNC:924

# Drug_Target_12_HPRD_ID:
00659

# Drug_Target_12_ID:
287

# Drug_Target_12_Locus:
9p13

# Drug_Target_12_Molecular_Weight:
43921

# Drug_Target_12_Name:
Beta-1,4-galactosyltransferase 1

# Drug_Target_12_Number_of_Residues:
398

# Drug_Target_12_PDB_ID:
1FR8

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF02709	Galactosyl_T_2

# Drug_Target_12_Protein_Sequence:
>Beta-1,4-galactosyltransferase 1
MRLREPLLSGSAAMPGASLQRACRLLVAVCALHLGVTLVYYLAGRDLSRLPQLVGVSTPL
QGGSNSAAAIGQSSGELRTGGARPPPPLGASSQPRPGGDSSPVVDSGPGPASNLTSVPVP
HTTALSLPACPEESPLLVGPMLIEFNMPVDLELVAKQNPNVKMGGRYAPRDCVSPHKVAI
IIPFRNRQEHLKYWLYYLHPVLQRQQLDYGIYVINQAGDTIFNRAKLLNVGFQEALKDYD
YTCFVFSDVDLIPMNDHNAYRCFSQPRHISVAMDKFGFSLPYVQYFGGVSALSKQQFLTI
NGFPNNYWGWGGEDDDIFNRLVFRGMSISRPNAVVGRCRMIRHSRDKKNEPNPQRFDRIA
HTKETMLSDGLNSLTYQVLDVQRYPLYTQITVDIGTPS

# Drug_Target_12_Reaction:
UDP-galactose + D-glucose = UDP + lactose

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
The cell surface form functions as a recognition molecule during a variety of cell to cell and cell to matrix interactions, as those occurring during development and egg fertilization, by binding to specific oligosaccharide ligands on opposing cells or in the extracellular matrix

# Drug_Target_12_SwissProt_ID:
P15291

# Drug_Target_12_SwissProt_Name:
B4GT1_HUMAN

# Drug_Target_12_Synonyms:
Beta-1,4-GalTase 1
Beta4Gal-T1
EC 2.4.1.-
EC 2.4.1.22
EC 2.4.1.90
N-acetyllactosamine synthase
UDP-Gal:beta-GlcNAc beta-1,4- galactosyltransferase 1
UDP-galactose:beta-N-acetylglucosamine beta- 1,4-galactosyltransferase 1
b4Gal-T1

# Drug_Target_12_Theoretical_pI:
8.77

# Drug_Target_12_Transmembrane_Regions:
25-44

# Drug_Target_13_Cellular_Location:
Not Available

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
Not Available

# Drug_Target_13_GenBank_ID_Gene:
V01541

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
ABL

# Drug_Target_13_Gene_Sequence:
Not Available

# Drug_Target_13_General_Function:
Involved in protein kinase activity

# Drug_Target_13_General_References:
6191223	Groffen J, Heisterkamp N, Reynolds FH Jr, Stephenson JR: Homology between phosphotyrosine acceptor site of human c-abl and viral oncogene products. Nature. 1983 Jul 14-20;304(5922):167-9.
6304726	Reddy EP, Smith MJ, Srinivasan A: Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3623-7.

# Drug_Target_13_HGNC_ID:
Not Available

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
3462

# Drug_Target_13_Locus:
Not Available

# Drug_Target_13_Molecular_Weight:
81873

# Drug_Target_13_Name:
Tyrosine-protein kinase transforming protein Abl

# Drug_Target_13_Number_of_Residues:
746

# Drug_Target_13_PDB_ID:
1OPK

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00017	SH2
PF07714	Pkinase_Tyr
PF08919	F_actin_bind

# Drug_Target_13_Protein_Sequence:
>Tyrosine-protein kinase transforming protein Abl
YITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHY
RINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTIYGVSPNYDK
WEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIK
HPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVSAVVLLYMATQISSAMEYL
EKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYN
KFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRA
CWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKRGTRGGAGSMLQAPELPTKTRT
CRRAAEQKASPPSLTPKLLRRQVTASPSSGLSHKKEATKGSASGMGTPATAEPAPPSNKV
GLSKASSEEMRVRRHKHSSESPGRDKGRLAKLKPAPPPPPACTGKAGKPAQSPSQEAGEA
GGPTKTKCTSLAMDAVNTDPTKAGPPGEGLRKPVPPSVPKPQSTAKPPGTPTSPVSTPST
APAPSPLAGDQQPSSAAFIPLISTRVSLRKTRQPPERIASGTITKGVVLDSTEALCLAIS
RNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLESNLRELQICPATA
SSGPAATQDFSKLLSSVKEISDIVRR

# Drug_Target_13_Reaction:
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate

# Drug_Target_13_SwissProt_ID:
P00521

# Drug_Target_13_SwissProt_Name:
ABL_MLVAB

# Drug_Target_13_Synonyms:
EC 2.7.10.2
V- abl

# Drug_Target_13_Theoretical_pI:
9.33

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Periplasm

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
M54884

# Drug_Target_14_GenBank_ID_Protein:
Not Available

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
dsbC

# Drug_Target_14_Gene_Sequence:
Not Available

# Drug_Target_14_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_14_General_References:
10700276	McCarthy AA, Haebel PW, Torronen A, Rybin V, Baker EN, Metcalf P: Crystal structure of the protein disulfide bond isomerase, DsbC, from Escherichia coli. Nat Struct Biol. 2000 Mar;7(3):196-9.
1987126	Lovett ST, Kolodner RD: Nucleotide sequence of the Escherichia coli recJ chromosomal region and construction of recJ-overexpression plasmids. J Bacteriol. 1991 Jan;173(1):353-64.
7536035	Zapun A, Missiakas D, Raina S, Creighton TE: Structural and functional characterization of DsbC, a protein involved in disulfide bond formation in Escherichia coli. Biochemistry. 1995 Apr 18;34(15):5075-89.
8168497	Shevchik VE, Condemine G, Robert-Baudouy J: Characterization of DsbC, a periplasmic protein of Erwinia chrysanthemi and Escherichia coli with disulfide isomerase activity. EMBO J. 1994 Apr 15;13(8):2007-12.
8168498	Missiakas D, Georgopoulos C, Raina S: The Escherichia coli dsbC (xprA) gene encodes a periplasmic protein involved in disulfide bond formation. EMBO J. 1994 Apr 15;13(8):2013-20.
9254601	Joly JC, Swartz JR: In vitro and in vivo redox states of the Escherichia coli periplasmic oxidoreductases DsbA and DsbC. Biochemistry. 1997 Aug 19;36(33):10067-72.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
3781

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
25622

# Drug_Target_14_Name:
Thiol:disulfide interchange protein dsbC precursor

# Drug_Target_14_Number_of_Residues:
236

# Drug_Target_14_PDB_ID:
1EEJ

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
Not Available

# Drug_Target_14_Protein_Sequence:
>Thiol:disulfide interchange protein dsbC precursor
MKKGFMLFTLLAAFSGFAQADDAAIQQTLAKMGIKSSDIQPAPVAGMKTVLTNSGVLYIT
DDGKHIIQGPMYDVSGTAPVNVTNKMLLKQLNALEKEMIVYKAPQEKHVITVFTDITCGY
CHKLHEQMADYNALGITVRYLAFPRQGLDSDAEKEMKAIWCAKDKNKAFDDVMAGKSVAP
ASCDVDIADHYALGVQLGVSGTPAVVLSNGTLVPGYQPPKEMKEFLDEHQKMTSGK

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
1-20

# Drug_Target_14_Specific_Function:
Required for disulfide bond formation in some periplasmic proteins. Acts by transferring its disulfide bond to other proteins and is reduced in the process. DsbC is reoxidized by a yet uncharacterized protein. Also acts as a disulfide isomerase

# Drug_Target_14_SwissProt_ID:
P0AEG6

# Drug_Target_14_SwissProt_Name:
DSBC_ECOLI

# Drug_Target_14_Synonyms:
Not Available

# Drug_Target_14_Theoretical_pI:
6.78

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Cytoplasm

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
Not Available

# Drug_Target_15_GenBank_ID_Gene:
X02662

# Drug_Target_15_GenBank_ID_Protein:
Not Available

# Drug_Target_15_GeneCard_ID:
Not Available

# Drug_Target_15_Gene_Name:
gapA

# Drug_Target_15_Gene_Sequence:
Not Available

# Drug_Target_15_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_15_General_References:
1862091	Nelson K, Whittam TS, Selander RK: Nucleotide polymorphism and evolution in the glyceraldehyde-3-phosphate dehydrogenase gene (gapA) in natural populations of Salmonella and Escherichia coli. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6667-71.
2124629	Doolittle RF, Feng DF, Anderson KL, Alberro MR: A naturally occurring horizontal gene transfer from a eukaryote to a prokaryote. J Mol Evol. 1990 Nov;31(5):383-8.
2990926	Branlant G, Branlant C: Nucleotide sequence of the Escherichia coli gap gene. Different evolutionary behavior of the NAD+-binding domain and of the catalytic domain of D-glyceraldehyde-3-phosphate dehydrogenase. Eur J Biochem. 1985 Jul 1;150(1):61-6.
7896119	Guttman DS, Dykhuizen DE: Detecting selective sweeps in naturally occurring Escherichia coli. Genetics. 1994 Dec;138(4):993-1003.
8636984	Duee E, Olivier-Deyris L, Fanchon E, Corbier C, Branlant G, Dideberg O: Comparison of the structures of wild-type and a N313T mutant of Escherichia coli glyceraldehyde 3-phosphate dehydrogenases: implication for NAD binding and cooperativity. J Mol Biol. 1996 Apr 12;257(4):814-38.
9097039	Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kasai H, Kashimoto K, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Horiuchi T, et al.: A 570-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 28.0-40.1 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):363-77.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.

# Drug_Target_15_HGNC_ID:
Not Available

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
3736

# Drug_Target_15_Locus:
Not Available

# Drug_Target_15_Molecular_Weight:
35533

# Drug_Target_15_Name:
Glyceraldehyde-3-phosphate dehydrogenase A

# Drug_Target_15_Number_of_Residues:
331

# Drug_Target_15_PDB_ID:
1S7C

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF00044	Gp_dh_N
PF02800	Gp_dh_C

# Drug_Target_15_Protein_Sequence:
>Glyceraldehyde-3-phosphate dehydrogenase A
MTIKVGINGFGRIGRIVFRAAQKRSDIEIVAINDLLDADYMAYMLKYDSTHGRFDGTVEV
KDGHLIVNGKKIRVTAERDPANLKWDEVGVDVVAEATGLFLTDETARKHITAGAKKVVMT
GPSKDNTPMFVKGANFDKYAGQDIVSNASCTTNCLAPLAKVINDNFGIIEGLMTTVHATT
ATQKTVDGPSHKDWRGGRGASQNIIPSSTGAAKAVGKVLPELNGKLTGMAFRVPTPNVSV
VDLTVRLEKAATYEQIKAAVKAAAEGEMKGVLGYTEDDVVSTDFNGEVCTSVFDAKAGIA
LNDNFVKLVSWYDNETGYSNKVLDLIAHISK

# Drug_Target_15_Reaction:
D-glyceraldehyde 3-phosphate + phosphate + NAD+ = 3-phospho-D-glyceroyl phosphate + NADH + H+

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
D-glyceraldehyde 3-phosphate + phosphate + NAD(+) = 3-phospho-D-glyceroyl phosphate + NADH

# Drug_Target_15_SwissProt_ID:
P0A9B2

# Drug_Target_15_SwissProt_Name:
G3P1_ECOLI

# Drug_Target_15_Synonyms:
EC 1.2.1.12
GAPDH-A

# Drug_Target_15_Theoretical_pI:
7.13

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Not Available

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
Not Available

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
Not Available

# Drug_Target_16_GenBank_ID_Gene:
AY143338

# Drug_Target_16_GenBank_ID_Protein:
Not Available

# Drug_Target_16_GeneCard_ID:
Not Available

# Drug_Target_16_Gene_Name:
mdlB

# Drug_Target_16_Gene_Sequence:
>1182 bp
TCATGCGTGTGTTCCTTTACCAATGAGGTGATCGACTGGAGCGGTGTTAGTCACTCCCTC
GTTTTGGAGGTAATCAGGAGAAAGGGAGGTGATGTCAGGGCATCCAATCTGGGCAAGGGT
GCGGTCGATATCCGCTTTTAGGAGGGTTAGCACCTCGTCAACACCCGTTTCACCTCGTGC
TGCAAGGCCATACAAAGTTGCACGACCCAGGAGTACAGCCTCAGCACCTAGCGCAAGTGC
TTTAACGATGTCCGAACCCCGTCGGAAGCCGCTATCGATAAGCACTGGTTTTCCAGTTTT
CGCTACCGATTGAGCCAAAACTTCCATTGGCGATATCGCGCAATCGAGTTGGCGACCGCC
GTGGTTTGATAGGATTACGCCGTCTGCACCTTCAGCGATGCACCGATCGGCGTCCTCAGC
ACTGAGCAACCCCTTTACGAGGAGTTTGTGCGGCCAGAGGTCACGCAGCCATCTCAATGC
CTCCCAGTTGAAACTGGCATCCATTTGGCGGCTCATCAATGCTGCCTGCATTTCTAAGCT
AGACGTTTGACTGCTGACGAAATTGGCCAGTTGCGGCATGCCGTGTCGCACGAAGTCGAG
CGACCAGCGCGGATGCAGGCATCCGTCCAGCACCACCTTTGCGGAGTAGCTCATTGGTAT
CTTGAATCGGTTATGCAGGTCGCGCTCGCGATAGCCGTTAACCGCCACATCCGTAGTAAG
CACCAGTGTCGTGTAACCAGTGTGCAGGGCTTTGAGCACCATCCCCTGCGCAATCTCTCG
GTGGATCACATAGAGCTGGAACCACAGATCGCCATCACACTGACGTGCGAGGTCTTCAAT
GGACATGTTGGAGGCGGTCGACAGCACGAACGGGATTCCGGCCTTGGTTGCTGCTCGAGC
TAAAGCGAGATCCCCCTTAGGCCACAGCGCACCGTTCAGCCCAGTAGGCCCAATCAAGAG
AGGCATCGACTGCCTCTTTCCAAGTACTTCCGCTTGGAGGCTGCGGCGGCTGACGTCTAC
TAGCCGCTTCGGTTTGAATCGCCATTGCTGGAAGACGTCGCGGTTGTGTTTCACCCCGTA
TTCGTCTTCAGCCCCACCTTCCAGATAGTCGTAGACCATCTTCGGCAAGCGCTTTTGCCG
AAGCTTGCGATAGTCCTCAACGTTAAAGAGATTCTGGCTCAT

# Drug_Target_16_General_Function:
Involved in catalytic activity

# Drug_Target_16_General_References:
2271624	Tsou AY, Ransom SC, Gerlt JA, Buechter DD, Babbitt PC, Kenyon GL: Mandelate pathway of Pseudomonas putida: sequence relationships involving mandelate racemase, (S)-mandelate dehydrogenase, and benzoylformate decarboxylase and expression of benzoylformate decarboxylase in Escherichia coli. Biochemistry. 1990 Oct 23;29(42):9856-62.

# Drug_Target_16_HGNC_ID:
Not Available

# Drug_Target_16_HPRD_ID:
Not Available

# Drug_Target_16_ID:
5180

# Drug_Target_16_Locus:
Not Available

# Drug_Target_16_Molecular_Weight:
43438

# Drug_Target_16_Name:
L(+)-mandelate dehydrogenase

# Drug_Target_16_Number_of_Residues:
393

# Drug_Target_16_PDB_ID:
Not Available

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF01070	FMN_dh

# Drug_Target_16_Protein_Sequence:
>L(+)-mandelate dehydrogenase
MSQNLFNVEDYRKLRQKRLPKMVYDYLEGGAEDEYGVKHNRDVFQQWRFKPKRLVDVSRR
SLQAEVLGKRQSMPLLIGPTGLNGALWPKGDLALARAATKAGIPFVLSTASNMSIEDLAR
QCDGDLWFQLYVIHREIAQGMVLKALHTGYTTLVLTTDVAVNGYRERDLHNRFKIPMSYS
AKVVLDGCLHPRWSLDFVRHGMPQLANFVSSQTSSLEMQAALMSRQMDASFNWEALRWLR
DLWPHKLLVKGLLSAEDADRCIAEGADGVILSNHGGRQLDCAISPMEVLAQSVAKTGKPV
LIDSGFRRGSDIVKALALGAEAVLLGRATLYGLAARGETGVDEVLTLLKADIDRTLAQIG
CPDITSLSPDYLQNEGVTNTAPVDHLIGKGTHA

# Drug_Target_16_Reaction:
Not Available

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
Reduction of L(+)-mandelate to benzoylformate

# Drug_Target_16_SwissProt_ID:
P20932

# Drug_Target_16_SwissProt_Name:
MDLB_PSEPU

# Drug_Target_16_Synonyms:
EC 1.-.-.-
MDH
S-mandelate dehydrogenase

# Drug_Target_16_Theoretical_pI:
8.22

# Drug_Target_16_Transmembrane_Regions:
None

# Drug_Target_17_Cellular_Location:
Not Available

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
Not Available

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
Not Available

# Drug_Target_17_GenBank_ID_Gene:
AF051831

# Drug_Target_17_GenBank_ID_Protein:
Not Available

# Drug_Target_17_GeneCard_ID:
Not Available

# Drug_Target_17_Gene_Name:
nir

# Drug_Target_17_Gene_Sequence:
>1083 bp
ATGAACGCATTACGGCCCACTTTGCTGGCGGCGGCGCTGGCTTTTACGATGGCCGCCGGG
ACCGCCTGGGCGCAGGACGCCGACAAGCTGCCCCATACCAAGGTCACGCTGGTCGCTCCG
CCCCAGGTGCATCCGCACGAGCAGGCGACCAAGTCGGGCCCCAAAGTCGTCGAATTCACC
ATGACCATCGAGGAAAAGAAGATGGTGATCGACGACAAGGGCACGACGCTGCAGGCCATG
ACGTTCAACGGCTCCATGCCCGGCCCCACGCTGGTGGTGCACGAGGGCGACTACGTCCAG
CTGACGCTGGTCAACCCGGCCACCAACGCCATGCCGCACAACGTCGACTTCCACGGCGCC
ACCGGCGCGCTGGGCGGCGCCAAGCTCACCAACGTCAACCCTGGCGAGCAGGCTACGCTG
CGCTTCAAGGCCGACCGCAGCGGCACCTTCGTCTACCACTGCGCGCCCGAAGGCATGGTG
CCCTGGCACGTGGTGTCGGGCATGAGCGGCACGCTGATGGTGCTGCCGCGCGACGGCCTG
AAGGATCCGCAGGGCAAGCCGCTGCATTACGACCGCGCCTACACCATCGGCGAGTTCGAC
CTGTACATCCCCAAGGGCCCGGACGGCAAGTACAAGGACTACGCCACGCTGGCCGAAAGC
TATGGCGACACGGTGCAGGTGATGCGCACGCTGACGCCGTCGCACATCGTCTTCAATGGC
AAGGTCGGCGCGCTGACCGGCGCCAACGCGCTCACCGCCAAGGTCGGCGAGACCGTGCTG
CTGATCCACTCGCAGGCCAATCGCGACACCCGCCCGCACCTGATCGGCGGCCATGGCGAC
TGGGTCTGGGAGACCGGCAAGTTCGCCAACCCGCCGCAGCGCGACCTGGAAACCTGGTTC
ATCCGCGGCGGGTCGGCCGGCGCCGCGCTCTACACCTTCAAGCAGCCTGGCGTGTATGCC
TACCTGAACCACAACCTGATCGAGGCCTTCGAACTGGGCGCGGCCGGCCACATCAAGGTC
GAGGGCAAGTGGAACGACGACCTGATGAAGCAGATCAAGGCGCCCGCGCCGATTCCGCGC
TGA

# Drug_Target_17_General_Function:
Involved in copper ion binding

# Drug_Target_17_General_References:
10049725	Suzuki E, Horikoshi N, Kohzuma T: Cloning, sequencing, and transcriptional studies of the gene encoding copper-containing nitrite reductase from Alcaligenes xylosoxidans NCIMB 11015. Biochem Biophys Res Commun. 1999 Feb 16;255(2):427-31.
9647763	Vandenberghe IH, Meyer TE, Cusanovich MA, Van Beeumen JJ: The covalent structure of the blue copper-containing nitrite reductase from Achromobacter xylosoxidans. Biochem Biophys Res Commun. 1998 Jun 29;247(3):734-40.

# Drug_Target_17_HGNC_ID:
Not Available

# Drug_Target_17_HPRD_ID:
Not Available

# Drug_Target_17_ID:
4771

# Drug_Target_17_Locus:
Not Available

# Drug_Target_17_Molecular_Weight:
38940

# Drug_Target_17_Name:
Dissimilatory copper-containing nitrite reductase

# Drug_Target_17_Number_of_Residues:
360

# Drug_Target_17_PDB_ID:
1BQ5

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF00394	Cu-oxidase
PF07732	Cu-oxidase_3

# Drug_Target_17_Protein_Sequence:
>Dissimilatory copper-containing nitrite reductase
MNALRPTLLAAALAFTMAAGTAWAQDADKLPHTKVTLVAPPQVHPHEQATKSGPKVVEFT
MTIEEKKMVIDDKGTTLQAMTFNGSMPGPTLVVHEGDYVQLTLVNPATNAMPHNVDFHGA
TGALGGAKLTNVNPGEQATLRFKADRSGTFVYHCAPEGMVPWHVVSGMSGTLMVLPRDGL
KDPQGKPLHYDRAYTIGEFDLYIPKGPDGKYKDYATLAESYGDTVQVMRTLTPSHIVFNG
KVGALTGANALTAKVGETVLLIHSQANRDTRPHLIGGHGDWVWETGKFANPPQRDLETWF
IRGGSAGAALYTFKQPGVYAYLNHNLIEAFELGAAGHIKVEGKWNDDLMKQIKAPAPIPR

# Drug_Target_17_Reaction:
Not Available

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
Not Available

# Drug_Target_17_SwissProt_ID:
O68601

# Drug_Target_17_SwissProt_Name:
O68601_ALCXX

# Drug_Target_17_Synonyms:
NiR) precursor
Nitrite Reductase

# Drug_Target_17_Theoretical_pI:
7.55

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Cytoplasm

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
Not Available

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
Not Available

# Drug_Target_18_GenBank_ID_Gene:
AP009048

# Drug_Target_18_GenBank_ID_Protein:
Not Available

# Drug_Target_18_GeneCard_ID:
Not Available

# Drug_Target_18_Gene_Name:
hslO

# Drug_Target_18_Gene_Sequence:
>879 bp
TTAATGAACTTGCGGATCTGCCGGAGACGCGTTGTTGCGGATTTCAGCAATATCCATCGC
ATTGAACAGATAGTGGTTACCGCAGTAATCACAATGCATGTCAATTTCGCCATCTTCCGC
CAGGATGCTATCAACTTCTTCATCAGGCAGCGTTTTCAGCGCATCGGCGCAACGTTCACG
CGAGCAGGTGCATTTGAACTCCACATCCTGCGGATCGTAAACCGTCACCTCTTCTTCGTG
ATACAAACGCCACAACACTTCGTTTGCCGGTAAGGTCAGCAGTTCTTCGGTTTTGATGGT
TTCGGTTAGCGTCGCCAGGTGGTCAAAGTCGTCCTGCTGGGCATTTTGCGCAGGCATTAC
CTGCAACAACATACCGCCTGCAGCCGGTTTGCCGTCTACGTCGCCGGTGCGAATAAACAG
GCGCGTCGGCAGCTGTTCAGAACGCATAAAGTAATCTTCCAGGCAGGCCGCCAGGGTATC
ACCTTCCAGACCAACTACGCCCTGATAGCGTTCGCCTTCGCTCGGGGTAATGGTGATCAC
CACGTAACCATTGCCGACCAGCGTTTTCAGGTCGGCATTTTCTGGAATTTCGCCCTGCAC
GCGCGCCACACCGCGCATCTGCTGGTTATTGTTACCGTTAATAACCGCCAGATTCATCGG
ACCGTCGCCCTGCAGCTGTACGGTGATATCACCATCAAACTTCAGCGTAGCGGTTAACAG
GCTGGTCGCAACCAGCAGTTCTGCCAGCACGTTTTTAACGGGCTGCGGATAATCGTGGTT
CTCAAGGATCTGTTGCAGGGTTTCCGAAACGGTTACCAGTTCGCCGCGCACGGCAAAGTT
TTCAAACAGATAGCGATGTAATTGGTCATGTTGCGGCAT

# Drug_Target_18_General_Function:
Involved in unfolded protein binding

# Drug_Target_18_General_References:
10025400	Jakob U, Muse W, Eser M, Bardwell JC: Chaperone activity with a redox switch. Cell. 1999 Feb 5;96(3):341-52.
10764757	Barbirz S, Jakob U, Glocker MO: Mass spectrometry unravels disulfide bond formation as the mechanism that activates a molecular chaperone. J Biol Chem. 2000 Jun 23;275(25):18759-66.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_18_HGNC_ID:
Not Available

# Drug_Target_18_HPRD_ID:
Not Available

# Drug_Target_18_ID:
5439

# Drug_Target_18_Locus:
Not Available

# Drug_Target_18_Molecular_Weight:
32535

# Drug_Target_18_Name:
33 kDa chaperonin

# Drug_Target_18_Number_of_Residues:
292

# Drug_Target_18_PDB_ID:
1I7F

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF01430	HSP33

# Drug_Target_18_Protein_Sequence:
>33 kDa chaperonin
MPQHDQLHRYLFENFAVRGELVTVSETLQQILENHDYPQPVKNVLAELLVATSLLTATLK
FDGDITVQLQGDGPMNLAVINGNNNQQMRGVARVQGEIPENADLKTLVGNGYVVITITPS
EGERYQGVVGLEGDTLAACLEDYFMRSEQLPTRLFIRTGDVDGKPAAGGMLLQVMPAQNA
QQDDFDHLATLTETIKTEELLTLPANEVLWRLYHEEEVTVYDPQDVEFKCTCSRERCADA
LKTLPDEEVDSILAEDGEIDMHCDYCGNHYLFNAMDIAEIRNNASPADPQVH

# Drug_Target_18_Reaction:
Not Available

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
Redox regulated molecular chaperone. Protects both thermally unfolding and oxidatively damaged proteins from irreversible aggregation. Plays an important role in the bacterial defense system toward oxidative stress

# Drug_Target_18_SwissProt_ID:
P0A6Y5

# Drug_Target_18_SwissProt_Name:
HSLO_ECOLI

# Drug_Target_18_Synonyms:
HSP33
Heat shock protein 33

# Drug_Target_18_Theoretical_pI:
4.10

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Not Available

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
Not Available

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
Not Available

# Drug_Target_19_GenBank_ID_Gene:
U00096

# Drug_Target_19_GenBank_ID_Protein:
Not Available

# Drug_Target_19_GeneCard_ID:
Not Available

# Drug_Target_19_Gene_Name:
yebR

# Drug_Target_19_Gene_Sequence:
>552 bp
TTATCCTGCGACGCTCGCAAAGAATTTTTTGTAATCCGTCGTTGCAAGCACTTTTTCAAG
CTGTGCCACAAGCTGACGTAAGCCTTGCTCGTCCTCGTCTGTAAAGCGACCGAAGACGGT
ACTATCGATGTCGAGAACACCAATAATCTGATTTTTCACCACCAGCGGCAGAACAATTTC
AGAATTACTCGCCGCATCACAGGCAATATGCCCGTCAAACACATGAACATCCTCGATACG
CTGCACTTGATTGCGGGCAACCGCAGTGCCGCACACGCCGCGCCCGACGGGTATCCGGAC
ACAGGCAATTTTGCCCTGAAATGGTCCGAGTACCAGTGTATCGTCCTCAAGCAAATAAAA
ACCTGCCCAGTTTATGTCAGTGAGACGCTCATATAACAACGCACTGGTGTTCGCAAGCGT
TGCCAGAAAACTGGTTTCTCCCGCCATCAGCGCGTTAAAGTCGCGATTTAAATCCGCGTA
AAATTCTGTTTTGTTCATTATATAATCACTTGGTTGTCTTACCTGGATCTGCCAGCCTAT
TAAAATAAGCAT

# Drug_Target_19_General_Function:
Signal transduction mechanisms

# Drug_Target_19_General_References:
10493123	Fountoulakis M, Takacs MF, Berndt P, Langen H, Takacs B: Enrichment of low abundance proteins of Escherichia coli by hydroxyapatite chromatography. Electrophoresis. 1999 Aug;20(11):2181-95.
9097040	Itoh T, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Kasai H, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Seki Y, Horiuchi T, et al.: A 460-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 40.1-50.0 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):379-92.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_19_HGNC_ID:
Not Available

# Drug_Target_19_HPRD_ID:
Not Available

# Drug_Target_19_ID:
5440

# Drug_Target_19_Locus:
Not Available

# Drug_Target_19_Molecular_Weight:
20277

# Drug_Target_19_Name:
UPF0067 protein yebR

# Drug_Target_19_Number_of_Residues:
183

# Drug_Target_19_PDB_ID:
1VHM

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF01590	GAF

# Drug_Target_19_Protein_Sequence:
>UPF0067 protein yebR
MLILIGWQIQVRQPSDYIMNKTEFYADLNRDFNALMAGETSFLATLANTSALLYERLTDI
NWAGFYLLEDDTLVLGPFQGKIACVRIPVGRGVCGTAVARNQVQRIEDVHVFDGHIACDA
ASNSEIVLPLVVKNQIIGVLDIDSTVFGRFTDEDEQGLRQLVAQLEKVLATTDYKKFFAS
VAG

# Drug_Target_19_Reaction:
Not Available

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
Not Available

# Drug_Target_19_SwissProt_ID:
P76270

# Drug_Target_19_SwissProt_Name:
YEBR_ECOLI

# Drug_Target_19_Synonyms:
Not Available

# Drug_Target_19_Theoretical_pI:
4.45

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ACHE

# Drug_Target_1_GenBank_ID_Gene:
M55040

# Drug_Target_1_GenBank_ID_Protein:
177975

# Drug_Target_1_GeneCard_ID:
ACHE

# Drug_Target_1_Gene_Name:
ACHE

# Drug_Target_1_Gene_Sequence:
>1845 bp
ATGAGGCCCCCGCAGTGTCTGCTGCACACGCCTTCCCTGGCTTCCCCACTCCTTCTCCTC
CTCCTCTGGCTCCTGGGTGGAGGAGTGGGGGCTGAGGGCCGGGAGGATGCAGAGCTGCTG
GTGACGGTGCGTGGGGGCCGGCTGCGGGGCATTCGCCTGAAGACCCCCGGGGGCCCTGTC
TCTGCTTTCCTGGGCATCCCCTTTGCGGAGCCACCCATGGGACCCCGTCGCTTTCTGCCA
CCGGAGCCCAAGCAGCCTTGGTCAGGGGTGGTAGACGCTACAACCTTCCAGAGTGTCTGC
TACCAATATGTGGACACCCTATACCCAGGTTTTGAGGGCACCGAGATGTGGAACCCCAAC
CGTGAGCTGAGCGAGGACTGCCTGTACCTCAACGTGTGGACACCATACCCCCGGCCTACA
TCCCCCACCCCTGTCCTCGTCTGGATCTATGGGGGTGGCTTCTACAGTGGGGCCTCCTCC
TTGGACGTGTACGATGGCCGCTTCTTGGTACAGGCCGAGAGGACTGTGCTGGTGTCCATG
AACTACCGGGTGGGAGCCTTTGGCTTCCTGGCCCTGCCGGGGAGCCGAGAGGCCCCGGGC
AATGTGGGTCTCCTGGATCAGAGGCTGGCCCTGCAGTGGGTGCAGGAGAACGTGGCAGCC
TTCGGGGGTGACCCGACATCAGTGACGCTGTTTGGGGAGAGCGCGGGAGCCGCCTCGGTG
GGCATGCACCTGCTGTCCCCGCCCAGCCGGGGCCTGTTCCACAGGGCCGTGCTGCAGAGC
GGTGCCCCCAATGGACCCTGGGCCACGGTGGGCATGGGAGAGGCCCGTCGCAGGGCCACG
CAGCTGGCCCACCTTGTGGGCTGTCCTCCAGGCGGCACTGGTGGGAATGACACAGAGCTG
GTAGCCTGCCTTCGGACACGACCAGCGCAGGTCCTGGTGAACCACGAATGGCACGTGCTG
CCTCAAGAAAGCGTCTTCCGGTTCTCCTTCGTGCCTGTGGTAGATGGAGACTTCCTCAGT
GACACCCCAGAGGCCCTCATCAACGCGGGAGACTTCCACGGCCTGCAGGTGCTGGTGGGT
GTGGTGAAGGATGAGGGCTCGTATTTTCTGGTTTACGGGGCCCCAGGCTTCAGCAAAGAC
AACGAGTCTCTCATCAGCCGGGCCGAGTTCCTGGCCGGGGTGCGGGTCGGGGTTCCCCAG
GTAAGTGACCTGGCAGCCGAGGCTGTGGTCCTGCATTACACAGACTGGCTGCATCCCGAG
GACCCGGCACGCCTGAGGGAGGCCCTGAGCGATGTGGTGGGCGACCACAATGTCGTGTGC
CCCGTGGCCCAGCTGGCTGGGCGACTGGCTGCCCAGGGTGCCCGGGTCTACGCCTACGTC
TTTGAACACCGTGCTTCCACGCTCTCCTGGCCCCTGTGGATGGGGGTGCCCCACGGCTAC
GAGATCGAGTTCATCTTTGGGATCCCCCTGGACCCCTCTCGAAACTACACGGCAGAGGAG
AAAATCTTCGCCCAGCGACTGATGCGATACTGGGCCAACTTTGCCCGCACAGGGGATCCC
AATGAGCCCCGAGACCCCAAGGCCCCACAATGGCCCCCGTACACGGCGGGGGCTCAGCAG
TACGTTAGTCTGGACCTGCGGCCGCTGGAGGTGCGGCGGGGGCTGCGCGCCCAGGCCTGC
GCCTTCTGGAACCGCTTCCTCCCCAAATTGCTCAGCGCCACCGACACGCTCGACGAGGCG
GAGCGCCAGTGGAAGGCCGAGTTCCACCGCTGGAGCTCCTACATGGTGCACTGGAAGAAC
CAGTTCGACCACTACAGCAAGCAGGATCGCTGCTCAGACCTGTGA

# Drug_Target_1_General_Function:
Lipid transport and metabolism

# Drug_Target_1_General_References:
11053835	Kryger G, Harel M, Giles K, Toker L, Velan B, Lazar A, Kronman C, Barak D, Ariel N, Shafferman A, Silman I, Sussman JL: Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystallogr. 2000 Nov;56(Pt 11):1385-94.
11239002	Wilson MD, Riemer C, Martindale DW, Schnupf P, Boright AP, Cheung TL, Hardy DM, Schwartz S, Scherer SW, Tsui LC, Miller W, Koop BF: Comparative analysis of the gene-dense ACHE/TFR2 region on human chromosome 7q22 with the orthologous region on mouse chromosome 5. Nucleic Acids Res. 2001 Mar 15;29(6):1352-65.
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
1517212	Shafferman A, Kronman C, Flashner Y, Leitner M, Grosfeld H, Ordentlich A, Gozes Y, Cohen S, Ariel N, Barak D, et al.: Mutagenesis of human acetylcholinesterase. Identification of residues involved in catalytic activity and in polypeptide folding. J Biol Chem. 1992 Sep 5;267(25):17640-8.
1748670	Velan B, Grosfeld H, Kronman C, Leitner M, Gozes Y, Lazar A, Flashner Y, Marcus D, Cohen S, Shafferman A: The effect of elimination of intersubunit disulfide bonds on the activity, assembly, and secretion of recombinant human acetylcholinesterase. Expression of acetylcholinesterase Cys-580----Ala mutant. J Biol Chem. 1991 Dec 15;266(35):23977-84.
2263619	Soreq H, Ben-Aziz R, Prody CA, Seidman S, Gnatt A, Neville L, Lieman-Hurwitz J, Lev-Lehman E, Ginzberg D, Lipidot-Lifson Y, et al.: Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G + C-rich attenuating structure. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9688-92.
2714437	Chhajlani V, Derr D, Earles B, Schmell E, August T: Purification and partial amino acid sequence analysis of human erythrocyte acetylcholinesterase. FEBS Lett. 1989 Apr 24;247(2):279-82.
8299725	Karpel R, Ben Aziz-Aloya R, Sternfeld M, Ehrlich G, Ginzberg D, Tarroni P, Clementi F, Zakut H, Soreq H: Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. Exp Cell Res. 1994 Feb;210(2):268-77.
8488842	Bartels CF, Zelinski T, Lockridge O: Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism. Am J Hum Genet. 1993 May;52(5):928-36.
9640563	Felder CE, Botti SA, Lifson S, Silman I, Sussman JL: External and internal electrostatic potentials of cholinesterase models. J Mol Graph Model. 1997 Oct;15(5):318-27, 335-7.

# Drug_Target_1_HGNC_ID:
HGNC:108

# Drug_Target_1_HPRD_ID:
00010

# Drug_Target_1_ID:
474

# Drug_Target_1_Locus:
7q22

# Drug_Target_1_Molecular_Weight:
67797

# Drug_Target_1_Name:
Acetylcholinesterase

# Drug_Target_1_Number_of_Residues:
614

# Drug_Target_1_PDB_ID:
1F8U

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00135	COesterase

# Drug_Target_1_Protein_Sequence:
>Acetylcholinesterase precursor
MRPPQCLLHTPSLASPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRGIRLKTPGGPV
SAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPN
RELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSM
NYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASV
GMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTEL
VACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVG
VVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPE
DPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGY
EIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQ
YVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLDEAERQWKAEFHRWSSYMVHWKN
QFDHYSKQDRCSDL

# Drug_Target_1_Reaction:
acetylcholine + H2O = choline + acetate

# Drug_Target_1_Signals:
1-31

# Drug_Target_1_Specific_Function:
Rapidly hydrolyzes choline released into the synapse

# Drug_Target_1_SwissProt_ID:
P22303

# Drug_Target_1_SwissProt_Name:
ACES_HUMAN

# Drug_Target_1_Synonyms:
AChE
Acetylcholinesterase precursor
EC 3.1.1.7

# Drug_Target_1_Theoretical_pI:
6.24

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_20_Cellular_Location:
Not Available

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
Not Available

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
Not Available

# Drug_Target_20_GenBank_ID_Gene:
AE015451

# Drug_Target_20_GenBank_ID_Protein:
Not Available

# Drug_Target_20_GeneCard_ID:
Not Available

# Drug_Target_20_Gene_Name:
PP3533

# Drug_Target_20_Gene_Sequence:
>1053 bp
ATGACGTATTTCATTGATGTTCCAACCATGTCGGACTTGGTGCATGACATTGGCGTAGCG
CCGTTTATTGGCGAGCTTGCCGCTGCCCTGCGGGACGATTTCAAACGCTGGCAGGCGTTT
GACAAGTCCGCGCGCGTTGCCAGCCACTCGGAAGTGGGCGTGATCGAACTGATGCCGGTC
GCCGACAAAAGCCGCTATGCCTTCAAATACGTCAACGGCCACCCGGCCAATACTGCACGC
AACCTGCATACGGTGATGGCCTTCGGTGTACTGGCCGATGTCGACTCCGGTTACCCGGTG
CTGCTGTCCGAACTGACCATCGCCACCGCCCTGCGCACCGCAGCGACTTCGCTGATGGCA
GCCCAGGCACTGGCCCGCCCGAACGCGCGCAAGATGGCGCTGATCGGCAACGGCGCGCAA
AGCGAATTCCAGGCCCTGGCCTTCCACAAGCACCTGGGCATCGAAGAAATCGTCGCCTAC
GACACCGACCCGCTGGCCACCGCCAAGCTTATCGCCAACCTCAAGGAATACAGCGGCTTG
ACCATCCGCCGGGCCAGCTCGGTAGCCGAGGCAGTGAAAGGCGTGGACATCATCACCACG
GTAACGGCCGACAAGGCCTACGCCACCATCATTACCCCCGACATGCTGGAGCCCGGTATG
CACCTGAACGCCGTGGGTGGTGACTGCCCTGGCAAAACCGAGCTGCACGCCGATGTGCTG
CGCAACGCGCGGGTGTTCGTCGAGTACGAGCCACAAACCCGTATCGAAGGTGAGATCCAG
CAGCTGCCGGCGGACTTTCCGGTGGTCGACCTGTGGCGCGTGCTGCGCGGAGAAACCGAG
GGCCGCCAAAGCGACAGCCAGGTCACTGTATTCGATTCGGTGGGCTTCGCCCTCGAAGAT
TACACCGTACTACGGTACGTACTACAGCAAGCCGAAAAGCGCGGGATGGGCACCAAGATC
GACCTGGTGCCGTGGGTGGAGGACGACCCGAAAGACCTGTTCAGCCACACCCGAGGCCGC
GCTGGCAAAAGGCGTATCCGACGGGTTGCCTGA

# Drug_Target_20_General_Function:
Amino acid transport and metabolism

# Drug_Target_20_General_References:
12534463	Nelson KE, Weinel C, Paulsen IT, Dodson RJ, Hilbert H, Martins dos Santos VA, Fouts DE, Gill SR, Pop M, Holmes M, Brinkac L, Beanan M, DeBoy RT, Daugherty S, Kolonay J, Madupu R, Nelson W, White O, Peterson J, Khouri H, Hance I, Chris Lee P, Holtzapple E, Scanlan D, Tran K, Moazzez A, Utterback T, Rizzo M, Lee K, Kosack D, Moestl D, Wedler H, Lauber J, Stjepandic D, Hoheisel J, Straetz M, Heim S, Kiewitz C, Eisen JA, Timmis KN, Dusterhoft A, Tummler B, Fraser CM: Complete genome sequence and comparative analysis of the metabolically versatile Pseudomonas putida KT2440. Environ Microbiol. 2002 Dec;4(12):799-808.

# Drug_Target_20_HGNC_ID:
Not Available

# Drug_Target_20_HPRD_ID:
Not Available

# Drug_Target_20_ID:
4498

# Drug_Target_20_Locus:
Not Available

# Drug_Target_20_Molecular_Weight:
38425

# Drug_Target_20_Name:
Ornithine cyclodeaminase

# Drug_Target_20_Number_of_Residues:
350

# Drug_Target_20_PDB_ID:
1X7D

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF02423	OCD_Mu_crystall

# Drug_Target_20_Protein_Sequence:
>Ornithine cyclodeaminase
MTYFIDVPTMSDLVHDIGVAPFIGELAAALRDDFKRWQAFDKSARVASHSEVGVIELMPV
ADKSRYAFKYVNGHPANTARNLHTVMAFGVLADVDSGYPVLLSELTIATALRTAATSLMA
AQALARPNARKMALIGNGAQSEFQALAFHKHLGIEEIVAYDTDPLATAKLIANLKEYSGL
TIRRASSVAEAVKGVDIITTVTADKAYATIITPDMLEPGMHLNAVGGDCPGKTELHADVL
RNARVFVEYEPQTRIEGEIQQLPADFPVVDLWRVLRGETEGRQSDSQVTVFDSVGFALED
YTVLRYVLQQAEKRGMGTKIDLVPWVEDDPKDLFSHTRGRAGKRRIRRVA

# Drug_Target_20_Reaction:
Not Available

# Drug_Target_20_Signals:
None

# Drug_Target_20_Specific_Function:
Not Available

# Drug_Target_20_SwissProt_ID:
Q88H32

# Drug_Target_20_SwissProt_Name:
Q88H32_PSEPK

# Drug_Target_20_Synonyms:
Not Available

# Drug_Target_20_Theoretical_pI:
6.25

# Drug_Target_20_Transmembrane_Regions:
None

# Drug_Target_21_Cellular_Location:
Not Available

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
QDPR

# Drug_Target_21_GenBank_ID_Gene:
X04882

# Drug_Target_21_GenBank_ID_Protein:
30819

# Drug_Target_21_GeneCard_ID:
QDPR

# Drug_Target_21_Gene_Name:
QDPR

# Drug_Target_21_Gene_Sequence:
>735 bp
ATGGCGGCGGCGGCGGCTGCAGGCGAGGCGCGCCGGGTGCTGGTGTACGGCGGCAGGGGC
GCTCTGGGTTCTCGATGCGTGCAGGCTTTTCGGGCCCGCAACTGGTGGGTTGCCAGCGTT
GATGTGGTGGAGAATGAAGAGGCCAGCGCTACGATCATTGTTAAAATGACAGACTCGTTC
ACTGAGCAGGCTGACCAGGTGACTGCTGAGGTTGGAAAGCTCTTGGGTGAAGAGAAGGTG
GATGCAATTCTTTGCGTTGCTGGAGGATGGGCCGGGGGCAATGCCAAATCCAAGTCTCTC
TTTAAGAACTGTGACCTGATGTGGAAGCAGAGCATATGGACATCGACCATCTCCAGCCAT
CTGGCTACCAAGCATCTCAAGGAAGGAGGCCTCCTGACCTTGGCTGGCGCAAAGGCTGCC
CTGGATGGGACTCCTGGTATGATCGGGTACGGCATGGCCAAGGGTGCTGTTCACCAGCTC
TGCCAGAGCCTGGCTGGGAAGAACAGCGGCATGCCGCCCGGGGCAGCCGCCATCGCTGTG
CTCCCGGTTACCCTGGATACCCCGATGAACAGGAAATCAATGCCTGAGGCTGACTTCAGC
TCCTGGACACCCTTAGAATTCCTAGTTGAAACTTTCCATGACTGGATCACAGGGAAAAAC
CGACCGAGCTCAGGAAGCCTAATCCAGGTGGTAACCACAGAAGGAAGGACGGAACTCACC
CCAGCATATTTTTAG

# Drug_Target_21_General_Function:
Lipid transport and metabolism

# Drug_Target_21_General_References:
10408783	Smooker PM, Gough TJ, Cotton RG, Alliaudi C, de Sanctis L, Dianzani I: A series of mutations in the dihydropteridine reductase gene resulting in either abnormal RNA splicing or DHPR protein defects. Mutations in brief no. 244. Online. Hum Mutat. 1999;13(6):503-4.
11153907	Romstad A, Kalkanoglu HS, Coskun T, Demirkol M, Tokatli A, Dursun A, Baykal T, Ozalp I, Guldberg P, Guttler F: Molecular analysis of 16 Turkish families with DHPR deficiency using denaturing gradient gel electrophoresis (DGGE). Hum Genet. 2000 Dec;107(6):546-53.
2116088	Howells DW, Forrest SM, Dahl HH, Cotton RG: Insertion of an extra codon for threonine is a cause of dihydropteridine reductase deficiency. Am J Hum Genet. 1990 Aug;47(2):279-85.
3031582	Dahl HH, Hutchison W, McAdam W, Wake S, Morgan FJ, Cotton RG: Human dihydropteridine reductase: characterisation of a cDNA clone and its use in analysis of patients with dihydropteridine reductase deficiency. Nucleic Acids Res. 1987 Mar 11;15(5):1921-32.
3033643	Lockyer J, Cook RG, Milstien S, Kaufman S, Woo SL, Ledley FD: Structure and expression of human dihydropteridine reductase. Proc Natl Acad Sci U S A. 1987 May;84(10):3329-33.
7627180	Smooker PM, Cotton RG: Molecular basis of dihydropteridine reductase deficiency. Hum Mutat. 1995;5(4):279-84.
8262916	Su Y, Varughese KI, Xuong NH, Bray TL, Roche DJ, Whiteley JM: The crystallographic structure of a human dihydropteridine reductase NADH binary complex expressed in Escherichia coli by a cDNA constructed from its rat homologue. J Biol Chem. 1993 Dec 25;268(36):26836-41.
8326489	Dianzani I, Howells DW, Ponzone A, Saleeba JA, Smooker PM, Cotton RG: Two new mutations in the dihydropteridine reductase gene in patients with tetrahydrobiopterin deficiency. J Med Genet. 1993 Jun;30(6):465-9.
9744478	Dianzani I, de Sanctis L, Smooker PM, Gough TJ, Alliaudi C, Brusco A, Spada M, Blau N, Dobos M, Zhang HP, Yang N, Ponzone A, Armarego WL, Cotton RG: Dihydropteridine reductase deficiency: physical structure of the QDPR gene, identification of two new mutations and genotype-phenotype correlations. Hum Mutat. 1998;12(4):267-73.

# Drug_Target_21_HGNC_ID:
HGNC:9752

# Drug_Target_21_HPRD_ID:
02025

# Drug_Target_21_ID:
597

# Drug_Target_21_Locus:
4p15.31

# Drug_Target_21_Molecular_Weight:
25804

# Drug_Target_21_Name:
Dihydropteridine reductase

# Drug_Target_21_Number_of_Residues:
244

# Drug_Target_21_PDB_ID:
1HDR

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_21_Protein_Sequence:
>Dihydropteridine reductase
MAAAAAAGEARRVLVYGGRGALGSRCVQAFRARNWWVASVDVVENEEASATIIVKMTDSF
TEQADQVTAEVGKLLGEEKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSH
LATKHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGAVHQLCQSLAGKNSGMPPGAAAIAV
LPVTLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGKNRPSSGSLIQVVTTEGRTELT
PAYF

# Drug_Target_21_Reaction:
a 5,6,7,8-tetrahydropteridine + NAD(P)+ = a 6,7-dihydropteridine + NAD(P)H + H+

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
The product of this enzyme, tetrahydrobiopterin (BH-4), is an essential cofactor for phenylalanine, tyrosine, and tryptophan hydroxylases

# Drug_Target_21_SwissProt_ID:
P09417

# Drug_Target_21_SwissProt_Name:
DHPR_HUMAN

# Drug_Target_21_Synonyms:
EC 1.5.1.34
HDHPR
Quinoid dihydropteridine reductase

# Drug_Target_21_Theoretical_pI:
7.45

# Drug_Target_21_Transmembrane_Regions:
None

# Drug_Target_22_Cellular_Location:
Not Available

# Drug_Target_22_Chromosome_Location:
Not Available

# Drug_Target_22_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
ASL

# Drug_Target_22_GenBank_ID_Gene:
Y00753

# Drug_Target_22_GenBank_ID_Protein:
28878

# Drug_Target_22_GeneCard_ID:
ASL

# Drug_Target_22_Gene_Name:
ASL

# Drug_Target_22_Gene_Sequence:
>1395 bp
ATGGCCTCGGAGAGTGGGAAGCTTTGGGGTGGCCGGTTTGTGGGTGCAGTGGACCCCATC
ATGGAGAAGTTCAACGCGTCCATTGCCTACGACCGGCACCTTTGGGAGGTGGATGTTCAA
GGCAGCAAAGCCTACAGCAGGGGCCTGGAGAAGGCAGGGCTCCTCACCAAGGCCGAGATG
GACCAGATACTCCATGGCCTAGACAAGGTGGCTGAGGAGTGGGCCCAGGGCACCTTCAAA
CTGAACTCCAATGATGAGGACATCCACACAGCCAATGAGCGCCGCCTGAAGGAGCTCATT
GGTGCAACGGCAGGGAAGCTGCACACGGGACGGAGCCGGAATGACCAGGTGGTCACAGAC
CTCAGGCTGTGGATGCGGCAGACCTGCTCCACGCTCTCGGGCCTCCTCTGGGAGCTCATT
AGGACCATGGTGGATCGGGCAGAGGCGGAACGTGATGTTCTCTTCCCGGGGTACACCCAT
TTGCAGAGGGCCCAGCCCATCCGCTGGAGCCACTGGATTCTGAGCCACGCCGTGGCACTG
ACCCGAGACTCTGAGCGGCTGCTGGAGGTGCGGAAGCGGATCAATGTCCTGCCCCTGGGG
AGTGGGGCCATTGCAGGCAATCCCCTGGGTGTGGACCGAGAGCTGCTCCGAGCAGAACTC
AACTTTGGGGCCATCACTCTCAACAGCATGGATGCCACTAGTGAGCGGGACTTTGTGGCC
GAGTTCCTGTTCTGGCGTTCGCTGTGCATGACCCATCTCAGCAGGATGGCCGAGGACCTC
ATCCTCTACTGCACCAAGGAATTCAGCTTCGTGCAGCTCTCAGATGCCTACAGCACGGGA
AGCAGCCTGATGCCCCAGAAGAAAAACCCCGACAGTTTGGAGCTGATCCGGAGCAAGGCT
GGGCGTGTGTTTGGGCGGTGTGCCGGGCTCCTGATGACCCTCAAGGGACTTCCCAGCACC
TACAACAAAGACTTACAGGAGGACAAGGAAGCTGTGTTTGAAGTGTCAGACACTATGAGT
GCCGTGCTCCAGGTGGCCACTGGCGTCATCTCTACGCTGCAGATTCACCAAGAGAACATG
GGACAGGCTCTCAGCCCCGACATGCTGGCCACTGACCTTGCCTATTACCTGGTCCGCAAA
GGGATGCCATTCCGCCAGGCCCATGAGGCCTCCGGGAAAGCTGTGTTCATGGCCGAGACC
AAGGGGGTCGCCCTCAACCAGCTGTCACTGCAGGAGCTGCAGACCATCAGCCCCCTGTTC
TCGGGCGACGTGATCTGCGTGTGGGACTACCGGCACAGTGTGGAGCAGTATGGTGCCCTG
GGCGGCACTGCGCGCTCCAGCGTCGACTGGCAAATCCGCCAGGTGCGGGCGCTACTGCAG
GCACAGCAGGCCTAG

# Drug_Target_22_General_Function:
Amino acid transport and metabolism

# Drug_Target_22_General_References:
11747432	Sampaleanu LM, Vallee F, Thompson GD, Howell PL: Three-dimensional structure of the argininosuccinate lyase frequently complementing allele Q286R. Biochemistry. 2001 Dec 25;40(51):15570-80.
12408190	Kleijer WJ, Garritsen VH, Linnebank M, Mooyer P, Huijmans JG, Mustonen A, Simola KO, Arslan-Kirchner M, Battini R, Briones P, Cardo E, Mandel H, Tschiedel E, Wanders RJ, Koch HG: Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. J Inherit Metab Dis. 2002 Sep;25(5):399-410.
1705937	Barbosa P, Cialkowski M, O'Brien WE: Analysis of naturally occurring and site-directed mutations in the argininosuccinate lyase gene. J Biol Chem. 1991 Mar 15;266(8):5286-90.
2263616	Walker DC, McCloskey DA, Simard LR, McInnes RR: Molecular analysis of human argininosuccinate lyase: mutant characterization and alternative splicing of the coding region. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9625-9.
2644168	Todd S, McGill JR, McCombs JL, Moore CM, Weider I, Naylor SL: cDNA sequence, interspecies comparison, and gene mapping analysis of argininosuccinate lyase. Genomics. 1989 Jan;4(1):53-9.
3391281	Matuo S, Tatsuno M, Kobayashi K, Saheki T, Miyata T, Iwanaga S, Amaya Y, Mori M: Isolation of cDNA clones of human argininosuccinate lyase and corrected amino acid sequence. FEBS Lett. 1988 Jul 18;234(2):395-9.
3463959	O'Brien WE, McInnes R, Kalumuck K, Adcock M: Cloning and sequence analysis of cDNA for human argininosuccinate lyase. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7211-5.
9256435	Turner MA, Simpson A, McInnes RR, Howell PL: Human argininosuccinate lyase: a structural basis for intragenic complementation. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9063-8.

# Drug_Target_22_HGNC_ID:
HGNC:746

# Drug_Target_22_HPRD_ID:
01948

# Drug_Target_22_ID:
577

# Drug_Target_22_Locus:
7cen-q11.2

# Drug_Target_22_Molecular_Weight:
51744

# Drug_Target_22_Name:
Argininosuccinate lyase

# Drug_Target_22_Number_of_Residues:
464

# Drug_Target_22_PDB_ID:
1K62

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
PF00206	Lyase_1

# Drug_Target_22_Protein_Sequence:
>Argininosuccinate lyase
MASESGKLWGGRFVGAVDPIMEKFNASIAYDRHLWEVDVQGSKAYSRGLEKAGLLTKAEM
DQILHGLDKVAEEWAQGTFKLNSNDEDIHTANERRLKELIGATAGKLHTGRSRNDQVVTD
LRLWMRQTCSTLSGLLWELIRTMVDRAEAERDVLFPGYTHLQRAQPIRWSHWILSHAVAL
TRDSERLLEVRKRINVLPLGSGAIAGNPLGVDRELLRAELNFGAITLNSMDATSERDFVA
EFLFWRSLCMTHLSRMAEDLILYCTKEFSFVQLSDAYSTGSSLMPQKKNPDSLELIRSKA
GRVFGRCAGLLMTLKGLPSTYNKDLQEDKEAVFEVSDTMSAVLQVATGVISTLQIHQENM
GQALSPDMLATDLAYYLVRKGMPFRQAHEASGKAVFMAETKGVALNQLSLQELQTISPLF
SGDVICVWDYGHSVEQYGALGGTARSSVDWQIRQVRALLQAQQA

# Drug_Target_22_Reaction:
2-(Nomega-L-arginino)succinate = fumarate + L-arginine

# Drug_Target_22_Signals:
None

# Drug_Target_22_Specific_Function:
Not Available

# Drug_Target_22_SwissProt_ID:
P04424

# Drug_Target_22_SwissProt_Name:
ARLY_HUMAN

# Drug_Target_22_Synonyms:
ASAL
Arginosuccinase
EC 4.3.2.1

# Drug_Target_22_Theoretical_pI:
6.59

# Drug_Target_22_Transmembrane_Regions:
None

# Drug_Target_23_Cellular_Location:
Not Available

# Drug_Target_23_Chromosome_Location:
Not Available

# Drug_Target_23_Drug_References:
Not Available

# Drug_Target_23_Essentiality:
Non-Essential

# Drug_Target_23_GenAtlas_ID:
Not Available

# Drug_Target_23_GenBank_ID_Gene:
U00096

# Drug_Target_23_GenBank_ID_Protein:
Not Available

# Drug_Target_23_GeneCard_ID:
Not Available

# Drug_Target_23_Gene_Name:
ymdB

# Drug_Target_23_Gene_Sequence:
>534 bp
ATGAAAACGCGTATTCATGTTGTGCAGGGTGATATTACCAAACTGGCCGTTGATGTGATT
GTGAATGCGGCTAATCCGTCATTAATGGGAGGCGGCGGCGTCGATGGGGCCATTCATCGC
GCAGCGGGTCCGGCCCTGCTGGATGCTTGTTTAAAAGTCAGGCAACAGCAGGGCGATTGC
CCTACGGGGCATGCCGTTATTACGCTTGCAGGCGATCTTCCCGCTAAAGCCGTAGTGCAC
ACCGTCGGGCCAGTCTGGCGTGGTGGTGAACAAAACGAAGACCAGCTTTTGCAGGATGCC
TATCTCAATAGCCTACGACTGGTGGCGGCAAACAGCTATACGTCAGTGGCTTTTCCTGCA
ATCAGTACTGGGGTTTATGGTTACCCTCGTGCGGCAGCGGCTGAAATCGCAGTAAAAACC
GTTTCAGAATTTATTACCCGTCACGCTTTACCCGAACAGGTATACTTTGTCTGTTATGAT
GAAGAAAACGCCCACCTCTACGAAAGACTCCTTACCCAACAAGGAGATGAATGA

# Drug_Target_23_General_Function:
Not Available

# Drug_Target_23_General_References:
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_23_HGNC_ID:
Not Available

# Drug_Target_23_HPRD_ID:
Not Available

# Drug_Target_23_ID:
5443

# Drug_Target_23_Locus:
Not Available

# Drug_Target_23_Molecular_Weight:
18881

# Drug_Target_23_Name:
UPF0189 protein ymdB

# Drug_Target_23_Number_of_Residues:
177

# Drug_Target_23_PDB_ID:
1SPV

# Drug_Target_23_Pathway:
Not Available

# Drug_Target_23_Pfam_Domain_Function:
PF01661	A1pp

# Drug_Target_23_Protein_Sequence:
>UPF0189 protein ymdB
MKTRIHVVQGDITKLAVDVIVNAANPSLMGGGGVDGAIHRAAGPALLDACLKVRQQQGDC
PTGHAVITLAGDLPAKAVVHTVGPVWRGGEQNEDQLLQDAYLNSLRLVAANSYTSVAFPA
ISTGVYGYPRAAAAEIAVKTVSEFITRHALPEQVYFVCYDEENAHLYERLLTQQGDE

# Drug_Target_23_Reaction:
Not Available

# Drug_Target_23_Signals:
None

# Drug_Target_23_Specific_Function:
Not Available

# Drug_Target_23_SwissProt_ID:
P0A8D6

# Drug_Target_23_SwissProt_Name:
YMDB_ECOLI

# Drug_Target_23_Synonyms:
Not Available

# Drug_Target_23_Theoretical_pI:
5.52

# Drug_Target_23_Transmembrane_Regions:
None

# Drug_Target_24_Cellular_Location:
Not Available

# Drug_Target_24_Chromosome_Location:
Not Available

# Drug_Target_24_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_24_Essentiality:
Non-Essential

# Drug_Target_24_GenAtlas_ID:
Not Available

# Drug_Target_24_GenBank_ID_Gene:
Not Available

# Drug_Target_24_GenBank_ID_Protein:
Not Available

# Drug_Target_24_GeneCard_ID:
Not Available

# Drug_Target_24_Gene_Name:
ARL3

# Drug_Target_24_Gene_Sequence:
Not Available

# Drug_Target_24_General_Function:
Not Available

# Drug_Target_24_General_References:
Not Available

# Drug_Target_24_HGNC_ID:
Not Available

# Drug_Target_24_HPRD_ID:
Not Available

# Drug_Target_24_ID:
7148

# Drug_Target_24_Locus:
Not Available

# Drug_Target_24_Molecular_Weight:
Not Available

# Drug_Target_24_Name:
ADP-ribosylation factor-like protein 3

# Drug_Target_24_Number_of_Residues:
0

# Drug_Target_24_PDB_ID:
Not Available

# Drug_Target_24_Pathway:
Not Available

# Drug_Target_24_Pfam_Domain_Function:
Not Available

# Drug_Target_24_Protein_Sequence:
Not Available

# Drug_Target_24_Reaction:
Not Available

# Drug_Target_24_Signals:
Not Available

# Drug_Target_24_Specific_Function:
Not Available

# Drug_Target_24_SwissProt_ID:
P36405

# Drug_Target_24_SwissProt_Name:
ARL3_HUMAN

# Drug_Target_24_Synonyms:
Not Available

# Drug_Target_24_Theoretical_pI:
Not Available

# Drug_Target_24_Transmembrane_Regions:
Not Available

# Drug_Target_25_Cellular_Location:
Cytoplasmic

# Drug_Target_25_Chromosome_Location:
Not Available

# Drug_Target_25_Drug_References:
Not Available

# Drug_Target_25_Essentiality:
Non-Essential

# Drug_Target_25_GenAtlas_ID:
Not Available

# Drug_Target_25_GenBank_ID_Gene:
X80128

# Drug_Target_25_GenBank_ID_Protein:
Not Available

# Drug_Target_25_GeneCard_ID:
Not Available

# Drug_Target_25_Gene_Name:
blaB

# Drug_Target_25_Gene_Sequence:
>903 bp
ATGACTATGTTTAAAACAACATTTCGCCAAACAGCGACGATTGCAGTTTCATTAATATCT
CTATTGGTATCTCCAATGCTATGGGCTAACACCAATAATACGATTGAAGAGCAATTAAGT
ACGCTTGAAAAATATAGCCAAGGTCGTTTAGGTGTTGCTTTAATCAACACGGAAGATAAT
TCACAAATAACATATCGTGGTGAAGAACGTTTTGCGATGGCAAGTACAAGTAAGGTTATG
GCTGTTGCGGCAGTTTTAAAAGAGAGTGAAAAACAAGCGGGATTATTAGATAAGAATATT
ACAATTAAAAAATCCGACTTAGTTGCTTACAGCCCTATTACAGAAAAACATTTAGTAACA
GGAATGTCTTTAGCTCAATTAAGTGCTGCTACGTTGCAATATAGCGATAATACAGCAATG
AATAAAATCTTAGATTATTTAGGTGGTCCAGCCAAAGTCACTCAATTTGCACGTTCAATT
AATGATGTAACTTATCGCCTAGATCGTAAAGAGCCTGAATTAAATACAGCAATTCATGGT
GATCCTCGTGATACGACTTCTCCAATTGCTATGGCTAAAAGCCTTCAAGCATTGACATTA
GGTGACGCATTAGGTCAATCTCAACGTCAACAGCTTGTTACTTGGTTAAAAGGCAATACA
ACAGGTGATCACAGTATTAAAGCGGGTTTACCAAAACACTGGATTGTTGGGGATAAAACT
GGCAGTGGTGATTATGGTACGACTAATGATATCGCCGTTATTTGGCCTAAAAACCATGCA
CCATTAATTTTAGTGGTCTATTTCACACAACAAGAACAAGATGCAAAATACCGTAAAGAT
ATTATTGTGAAAGCCACAGAGATTGTAACAAAAGAAATATCTAATTCACCTCAAACAAAA
TAA

# Drug_Target_25_General_Function:
Involved in beta-lactamase activity

# Drug_Target_25_General_References:
7957242	Datz M, Joris B, Azab EA, Galleni M, Van Beeumen J, Frere JM, Martin HH: A common system controls the induction of very different genes. The class-A beta-lactamase of Proteus vulgaris and the enterobacterial class-C beta-lactamase. Eur J Biochem. 1994 Nov 15;226(1):149-57.

# Drug_Target_25_HGNC_ID:
Not Available

# Drug_Target_25_HPRD_ID:
Not Available

# Drug_Target_25_ID:
5445

# Drug_Target_25_Locus:
Not Available

# Drug_Target_25_Molecular_Weight:
32992

# Drug_Target_25_Name:
Beta-lactamase

# Drug_Target_25_Number_of_Residues:
300

# Drug_Target_25_PDB_ID:
1HZO

# Drug_Target_25_Pathway:
Not Available

# Drug_Target_25_Pfam_Domain_Function:
PF00144	Beta-lactamase

# Drug_Target_25_Protein_Sequence:
>Beta-lactamase
MTMFKTTFRQTATIAVSLISLLVSPMLWANTNNTIEEQLSTLEKYSQGRLGVALINTEDN
SQITYRGEERFAMASTSKVMAVAAVLKESEKQAGLLDKNITIKKSDLVAYSPITEKHLVT
GMSLAQLSAATLQYSDNTAMNKILDYLGGPAKVTQFARSINDVTYRLDRKEPELNTAIHG
DPRDTTSPIAMAKSLQALTLGDALGQSQRQQLVTWLKGNTTGDHSIKAGLPKHWIVGDKT
GSGDYGTTNDIAVIWPKNHAPLILVVYFTQQEQDAKYRKDIIVKATEIVTKEISNSPQTK

# Drug_Target_25_Reaction:
Not Available

# Drug_Target_25_Signals:
1-29

# Drug_Target_25_Specific_Function:
Hydrolyzes broad-spectrum beta-lactam antibiotics. Active against cephalosporins such as cefuroxime and cefotaxime

# Drug_Target_25_SwissProt_ID:
P52664

# Drug_Target_25_SwissProt_Name:
BLAB_PROVU

# Drug_Target_25_Synonyms:
Beta-lactamase precursor
Cefuroximase
EC 3.5.2.6

# Drug_Target_25_Theoretical_pI:
9.35

# Drug_Target_25_Transmembrane_Regions:
None

# Drug_Target_26_Cellular_Location:
Cytoplasmic

# Drug_Target_26_Chromosome_Location:
Not Available

# Drug_Target_26_Drug_References:
Not Available

# Drug_Target_26_Essentiality:
Non-Essential

# Drug_Target_26_GenAtlas_ID:
Not Available

# Drug_Target_26_GenBank_ID_Gene:
L42023

# Drug_Target_26_GenBank_ID_Protein:
Not Available

# Drug_Target_26_GeneCard_ID:
Not Available

# Drug_Target_26_Gene_Name:
HI_1679

# Drug_Target_26_Gene_Sequence:
>543 bp
ATGCAACAAAAATTAGAAAATATTAAATTTGTCATTACTGATGTAGACGGCGTACTCACT
GATGGACAACTTCATTATGATGCCAATGGTGAAGCCATCAAAAGCTTTCATGTACGAGAT
GGTTTAGGCATAAAAATGCTGATGGATGCGGATATTCAAGTGGCAGTGCTTTCTGGTCGC
GACTCCCCTATTTTACGTCGTCGCATTGCCGATCTTGGTATTAAATTATTCTTTCTTGGC
AAACTTGAAAAAGAAACGGCTTGTTTTGATCTCATGAAACAAGCTGGCGTCACCGCCGAG
CAAACCGCTTATATTGGCGATGATAGCGTAGATCTCCCCGCCTTTGCAGCGTGTGGAACT
TCTTTTGCTGTGGCTGATGCCCCTATTTATGTGAAAAATGCTGTTGATCATGTACTTTCC
ACCCATGGCGGCAAAGGCGCATTCCGTGAAATGTCCGATATGATTTTACAGGCACAGGGA
AAATCTTCTGTGTTTGATACCGCCCAAGGTTTCCTAAAATCAGTGAAAAGTATGGGGCAG
TAA

# Drug_Target_26_General_Function:
Involved in catalytic activity

# Drug_Target_26_General_References:
11835514	Parsons JF, Lim K, Tempczyk A, Krajewski W, Eisenstein E, Herzberg O: From structure to function: YrbI from Haemophilus influenzae (HI1679) is a phosphatase. Proteins. 2002 Mar 1;46(4):393-404.
12639950	Wu J, Woodard RW: Escherichia coli YrbI is 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase. J Biol Chem. 2003 May 16;278(20):18117-23. Epub 2003 Mar 14.
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_26_HGNC_ID:
Not Available

# Drug_Target_26_HPRD_ID:
Not Available

# Drug_Target_26_ID:
5446

# Drug_Target_26_Locus:
Not Available

# Drug_Target_26_Molecular_Weight:
19433

# Drug_Target_26_Name:
3-deoxy-D-manno-octulosonate 8-phosphate phosphatase

# Drug_Target_26_Number_of_Residues:
180

# Drug_Target_26_PDB_ID:
1K1E

# Drug_Target_26_Pathway:
Not Available

# Drug_Target_26_Pfam_Domain_Function:
PF00702	Hydrolase

# Drug_Target_26_Protein_Sequence:
>3-deoxy-D-manno-octulosonate 8-phosphate phosphatase
MQQKLENIKFVITDVDGVLTDGQLHYDANGEAIKSFHVRDGLGIKMLMDADIQVAVLSGR
DSPILRRRIADLGIKLFFLGKLEKETACFDLMKQAGVTAEQTAYIGDDSVDLPAFAACGT
SFAVADAPIYVKNAVDHVLSTHGGKGAFREMSDMILQAQGKSSVFDTAQGFLKSVKSMGQ

# Drug_Target_26_Reaction:
Not Available

# Drug_Target_26_Signals:
None

# Drug_Target_26_Specific_Function:
Catalyzes the hydrolysis of KDO 8-P to KDO and inorganic phosphate

# Drug_Target_26_SwissProt_ID:
P45314

# Drug_Target_26_SwissProt_Name:
KDOP_HAEIN

# Drug_Target_26_Synonyms:
EC 3.1.3.45
KDO 8-P phosphatase

# Drug_Target_26_Theoretical_pI:
5.63

# Drug_Target_26_Transmembrane_Regions:
None

# Drug_Target_27_Cellular_Location:
Nucleus

# Drug_Target_27_Chromosome_Location:
Not Available

# Drug_Target_27_Drug_References:
Not Available

# Drug_Target_27_Essentiality:
Non-Essential

# Drug_Target_27_GenAtlas_ID:
L3MBTL

# Drug_Target_27_GenBank_ID_Gene:
U89358

# Drug_Target_27_GenBank_ID_Protein:
Not Available

# Drug_Target_27_GeneCard_ID:
Not Available

# Drug_Target_27_Gene_Name:
L3MBTL1

# Drug_Target_27_Gene_Sequence:
>2319 bp
ATGAGGCGAAGAGAGGGCCATGGCACCGACTCCGAGATGGGTCAAGGACCCGTACGGGAG
TCGCAATCCTCAGACCCTCCCGCGCTCCAGTTCCGGATAAGCGAGTATAAGCCGCTGAAC
ATGGCGGGAGTGGAGCAGCCCCCGAGCCCCGAGCTGCGGCAGGAAGGCGTGACCGAATAC
GAAGATGGCGGGGCCCCGGCGGGAGATGGCGAGGCGGGCCCCCAACAGGCGGAGGACCAC
CCCCAGAATCCTCCAGAAGATCCCAATCAGGACCCCCCAGAGGATGATAGCACCTGTCAG
TGCCAGGCGTGCGGGCCTCACCAAGCCGCGGGTCCAGATCTTGGTTCCTCTAATGATGGC
TGCCCTCAGCTGTTCCAGGAGCGGTCAGTCATAGTGGAGAACTCCTCAGGCTCTACCAGC
GCTTCTGAGCTCCTCAAACCCATGAAGAAGAGGAAGCGCAGGGAATACCAGAGCCCATCA
GAGGAGGAGTCGGAGCCAGAGGCCATGGAGAAGCAAGAAGAAGGAAAGGACCCAGAGGGA
CAACCCACTGCTAGCACCCCAGAGAGTGAGGAGTGGAGCAGCAGCCAGCCTGCAACAGGT
GAGAAGAAGGAATGCTGGTCGTGGGAGTCCTACCTAGAGGAGCAGAAGGCCATTACTGCT
CCAGTCAGCCTCTTCCAGGACTCCCAGGCAGTCACTCACAACAAGAATGGCTTCAAACTG
GGCATGAAGTTGGAAGGCATTGACCCTCAACACCCGTCCATGTACTTCATCCTCACCGTG
GCTGAGGTATGTGGCTATCGCCTACGCCTGCACTTTGATGGGTATTCTGAGTGCCATGAC
TTCTGGGTCAATGCCAACTCCCCTGACATTCACCCTGCTGGCTGGTTCGAGAAGACGGGC
CACAAGCTGCAGCTTCCCAAAGGTTACAAGGAGGAGGAGTTCAGCTGGAGCCAGTACATG
TGCAGCACAAGAGCTCAGGCTGCCCCCAAGCACATGTTTGTGAGCCAGAGCCACAGTCCC
CCACCCTTGGGCTTCCAGGTGGGCATGAAGCTGGAGGCTGTTGACCGCATGAACCCGTCC
CTTGTCTGCGTGGCCAGTGTGACCGATGTGGTGGACAGCCGCTTCCTGGTGCACTTTGAC
AACTGGGATGATACTTATGACTACTGGTGTGATCCCAGCAGCCCCTACATCCACCCAGTG
GGCTGGTGCCAGAAGCAAGGAAAGCCCCTCACCCCTCCACAAGACTACCCAGACCCTGAT
AACTTCTGTTGGGAGAAATATCTGGAAGAAACTGGGGCCTCTGCTGTCCCCACCTGGGCC
TTCAAGGTGCGACCCCCTCACAGCTTCCTGGTCAATATGAAGCTGGAGGCTGTGGACCGC
AGGAACCCAGCCCTGATTCGCGTGGCCAGCGTGGAGGATGTGGAGGACCATCGGATAAAG
ATCCACTTTGATGGCTGGAGTCATGGCTATGATTTCTGGATCGACGCTGATCACCCAGAC
ATCCACCCTGCCGGCTGGTGCTCCAAGACAGGACATCCCCTGCAGCCTCCTCTCGGACCC
AGAGAGCCCAGCTCTGCCTCCCCTGGGGGCTGTCCCCCTCTCAGCTATAGGAGCCTGCCC
CACACTAGGACCTCCAAATACAGCTTTCACCACCGGAAGTGCCCCACTCCTGGTTGCGAC
GGCTCTGGCCATGTCACAGGCAAGTTCACAGCTCACCATTGCCTCTCAGGCTGCCCACTG
GCTGAGAGGAACCAGAGCCGGCTGAAAGCGGAGCTGTCTGACCCGGAGGCCTCAGCCCGC
AAGAAGAACCTCTCAGGCTTCTCCCCAAGGAAGAAGCCTCGCCATCACGGCCGAATTGGA
CGCCCTCCGAAGTATCGAAAGATTCCGCAGGAAGATTTCCAGACCCTCACGCCCGATGTC
GTGCACCAGTCCCTCTTCATGTCAGCCCTGTCGGCCCACCCTGACCGCTCACTCTCAGTG
TGCTGGGAGCAGCACTGCAAGCTCCTGCCAGGAGTAGCGGGCATCTCAGCCTCGACAGTC
GCCAAGTGGACCATCGATGAGGTCTTCGGCTTTGTTCAGACCCTGACAGGTTGTGAGGAC
CAAGCACGCCTCTTCAAAGACGAGGCAAGAATAGTCAGAGTGACCCATGTATCTGGGAAG
ACTCTAGTCTGGACTGTGGCCCAGCTTGGGGACCTTGTGTGCTCAGATCATCTTCAGGAA
GGAAAAGGCATCCTGGAGACAGGAGTCCATTCACTCCTCTGCTCTCTACCCACTCATTTG
CTTGCCAAACTTAGCTTTGCCAGTGATAGTCAATATTAA

# Drug_Target_27_General_Function:
Involved in transcription factor activity

# Drug_Target_27_General_References:
10445843	Koga H, Matsui S, Hirota T, Takebayashi S, Okumura K, Saya H: A human homolog of Drosophila lethal(3)malignant brain tumor (l(3)mbt) protein associates with condensed mitotic chromosomes. Oncogene. 1999 Jul 1;18(26):3799-809.
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
12588862	Boccuni P, MacGrogan D, Scandura JM, Nimer SD: The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6). J Biol Chem. 2003 Apr 25;278(17):15412-20. Epub 2003 Feb 14.
12842041	Wang WK, Tereshko V, Boccuni P, MacGrogan D, Nimer SD, Patel DJ: Malignant brain tumor repeats: a three-leaved propeller architecture with ligand/peptide binding pockets. Structure. 2003 Jul;11(7):775-89.
9734811	Ishikawa K, Nagase T, Suyama M, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O: Prediction of the coding sequences of unidentified human genes. X. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA Res. 1998 Jun 30;5(3):169-76.

# Drug_Target_27_HGNC_ID:
HGNC:15905

# Drug_Target_27_HPRD_ID:
Not Available

# Drug_Target_27_ID:
5447

# Drug_Target_27_Locus:
20q13.12

# Drug_Target_27_Molecular_Weight:
85917

# Drug_Target_27_Name:
Lethal(3)malignant brain tumor-like protein

# Drug_Target_27_Number_of_Residues:
772

# Drug_Target_27_PDB_ID:
1OZ2

# Drug_Target_27_Pathway:
Not Available

# Drug_Target_27_Pfam_Domain_Function:
PF01530	zf-C2HC
PF02820	MBT

# Drug_Target_27_Protein_Sequence:
>Lethal(3)malignant brain tumor-like protein
MRRREGHGTDSEMGQGPVRESQSSDPPALQFRISEYKPLNMAGVEQPPSPELRQEGVTEY
EDGGAPAGDGEAGPQQAEDHPQNPPEDPNQDPPEDDSTCQCQACGPHQAAGPDLGSSNDG
CPQLFQERSVIVENSSGSTSASELLKPMKKRKRREYQSPSEEESEPEAMEKQEEGKDPEG
QPTASTPESEEWSSSQPATGEKKECWSWESYLEEQKAITAPVSLFQDSQAVTHNKNGFKL
GMKLEGIDPQHPSMYFILTVAEVCGYRLRLHFDGYSECHDFWVNANSPDIHPAGWFEKTG
HKLQPPKGYKEEEFSWSQYLRSTRAQAAPKHLFVSQSHSPPPLGFQVGMKLEAVDRMNPS
LVCVASVTDVVDSRFLVHFDNWDDTYDYWCDPSSPYIHPVGWCQKQGKPLTPPQDYPDPD
NFCWEKYLEETGASAVPTWAFKVRPPHSFLVNMKLEAVDRRNPALIRVASVEDVEDHRIK
IHFDGWSHGYDFWIDADHPDIHPAGWCSKTGHPLQPPLGPREPSSASPGGCPPLSYRSLP
HTRTSKYSFHHRKCPTPGCDGSGHVTGKFTAHHCLSGCPLAERNQSRLKAELSDSEASAR
KKNLSGFSPRKKPRHHGRIGRPPKYRKIPQEDFQTLTPDVVHQSLFMSALSAHPDRSLSV
CWEQHCKLLPGVAGISASTVAKWTIDEVFGFVQTLTGCEDQARLFKDEARIVRVTHVSGK
TLVWTVAQLGDLVCSDHLQEGKGILETGVHSLLCSLPTHLLAKLSFASDSQY

# Drug_Target_27_Reaction:
Not Available

# Drug_Target_27_Signals:
None

# Drug_Target_27_Specific_Function:
Polycomb group (PcG) protein. PcG proteins maintain the transcriptionally repressive state of genes, probably via a modification of chromatin, rendering it heritably changed in its expressibility. Participates in the ETV6-mediated repression. Probably plays a role in cell proliferation. Overexpression induces multinucleated cells, suggesting that it is required to accomplish normal mitosis

# Drug_Target_27_SwissProt_ID:
Q9Y468

# Drug_Target_27_SwissProt_Name:
LMBL1_HUMAN

# Drug_Target_27_Synonyms:
H-L(3)MBT
H-l(3)mbt protein
L(3)mbt protein homolog
L(3)mbt-like
L3MBTL1

# Drug_Target_27_Theoretical_pI:
6.04

# Drug_Target_27_Transmembrane_Regions:
None

# Drug_Target_28_Cellular_Location:
Cytoplasmic

# Drug_Target_28_Chromosome_Location:
Not Available

# Drug_Target_28_Drug_References:
Not Available

# Drug_Target_28_Essentiality:
Non-Essential

# Drug_Target_28_GenAtlas_ID:
BCHE

# Drug_Target_28_GenBank_ID_Gene:
M32391

# Drug_Target_28_GenBank_ID_Protein:
1311630

# Drug_Target_28_GeneCard_ID:
BCHE

# Drug_Target_28_Gene_Name:
BCHE

# Drug_Target_28_Gene_Sequence:
>1809 bp
ATGCATAGCAAAGTCACAATCATATGCATCAGATTTCTCTTTTGGTTTCTTTTGCTCTGC
ATGCTTATTGGGAAGTCACATACTGAAGATGACATCATAATTGCAACAAAGAATGGAAAA
GTCAGAGGGATGAACTTGACAGTTTTTGGTGGCACGGTAACAGCCTTTCTTGGAATTCCC
TATGCACAGCCACCTCTTGGTAGACTTCGATTCAAAAAGCCACAGTCTCTGACCAAGTGG
TCTGATATTTGGAATGCCACAAAATATGCAAATTCTTGCTGTCAGAACATAGATCAAAGT
TTTCCAGGCTTCCATGGATCAGAGATGTGGAACCCAAACACTGACCTCAGTGAAGACTGT
TTATATCTAAATGTATGGATTCCAGCACCTAAACCAAAAAATGCCACTGTATTGATATGG
ATTTATGGTGGTGGTTTTCAAACTGGAACATCATCTTTACATGTTTATGATGGCAAGTTT
CTGGCTCGGGTTGAAAGAGTTATTGTAGTGTCAATGAACTATAGGGTGGGTGCCCTAGGA
TTCTTAGCTTTGCCAGGAAATCCTGAGGCTCCAGGGAACATGGGTTTATTTGATCAACAG
TTGGCTCTTCAGTGGGTTCAAAAAAATATAGCAGCCTTTGGTGGAAATCCTAAAAGTGTA
ACTCTCTTTGGAGAAAGTGCAGGAGCAGCTTCAGTTAGCCTGCATTTGCTTTCTCCTGGA
AGCCATTCATTGTTCACCAGAGCCATTCTGCAAAGTGGATCCTTTAATGCTCCTTGGGCG
GTAACATCTCTTTATGAAGCTAGGAACAGAACGTTGAACTTAGCTAAATTGACTGGTTGC
TCTAGAGAGAATGAGACTGAAATAATCAAGTGTCTTAGAAATAAAGATCCCCAAGAAATT
CTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG
ACCGTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT
AAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT
GGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA
GGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT
TACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT
GTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG
GGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA
TGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA
AGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGTTGGGCA
AATTTTGCAAAATATGGGAATCCAAATGAGACTCAGAACAATAGCACAAGCTGGCCTGTC
TTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG
AAACTACGTGCTCAACAATGTCGATTCTGGACATCATTTTTTCCAAAAGTCTTGGAAATG
ACAGGAAATATTGATGAAGCAGAATGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT
TACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG
GGTCTCTAA

# Drug_Target_28_General_Function:
Lipid transport and metabolism

# Drug_Target_28_General_References:
2322535	Arpagaus M, Kott M, Vatsis KP, Bartels CF, La Du BN, Lockridge O: Structure of the gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry. 1990 Jan 9;29(1):124-31.
2915989	McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van der Spek AF, Lockridge O, La Du BN: Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci U S A. 1989 Feb;86(3):953-7.
3035536	Prody CA, Zevin-Sonkin D, Gnatt A, Goldberg O, Soreq H: Isolation and characterization of full-length cDNA clones coding for cholinesterase from fetal human tissues. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3555-9.
3067729	Lockridge O: Structure of human serum cholinesterase. Bioessays. 1988 Oct;9(4):125-8.
3115973	Lockridge O, Adkins S, La Du BN: Location of disulfide bonds within the sequence of human serum cholinesterase. J Biol Chem. 1987 Sep 25;262(27):12945-52.
3477799	McTiernan C, Adkins S, Chatonnet A, Vaughan TA, Bartels CF, Kott M, Rosenberry TL, La Du BN, Lockridge O: Brain cDNA clone for human cholinesterase. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6682-6.
3542989	Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE, Johnson LL: Complete amino acid sequence of human serum cholinesterase. J Biol Chem. 1987 Jan 15;262(2):549-57.

# Drug_Target_28_HGNC_ID:
HGNC:983

# Drug_Target_28_HPRD_ID:
01519

# Drug_Target_28_ID:
3923

# Drug_Target_28_Locus:
3q26.1-q26.2

# Drug_Target_28_Molecular_Weight:
68419

# Drug_Target_28_Name:
Cholinesterase

# Drug_Target_28_Number_of_Residues:
602

# Drug_Target_28_PDB_ID:
1P0Q

# Drug_Target_28_Pathway:
Heroin Pathway	SMP00407
Irinotecan Pathway	SMP00433

# Drug_Target_28_Pfam_Domain_Function:
PF00135	COesterase
PF08674	AChE_tetra

# Drug_Target_28_Protein_Sequence:
>Cholinesterase
MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP
YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC
LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG
FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG
SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI
LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY
GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV
VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER
RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT
KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV
GL

# Drug_Target_28_Reaction:
an acylcholine + H2O = choline + a carboxylate

# Drug_Target_28_Signals:
1-28

# Drug_Target_28_Specific_Function:
An acylcholine + H(2)O = choline + a carboxylate

# Drug_Target_28_SwissProt_ID:
P06276

# Drug_Target_28_SwissProt_Name:
CHLE_HUMAN

# Drug_Target_28_Synonyms:
Acylcholine acylhydrolase
Butyrylcholine esterase
Choline esterase II
Cholinesterase precursor
EC 3.1.1.8
Pseudocholinesterase

# Drug_Target_28_Theoretical_pI:
7.47

# Drug_Target_28_Transmembrane_Regions:
None

# Drug_Target_29_Cellular_Location:
Not Available

# Drug_Target_29_Chromosome_Location:
Not Available

# Drug_Target_29_Drug_References:
Not Available

# Drug_Target_29_Essentiality:
Non-Essential

# Drug_Target_29_GenAtlas_ID:
Not Available

# Drug_Target_29_GenBank_ID_Gene:
D84432

# Drug_Target_29_GenBank_ID_Protein:
Not Available

# Drug_Target_29_GeneCard_ID:
Not Available

# Drug_Target_29_Gene_Name:
rnz

# Drug_Target_29_Gene_Sequence:
>924 bp
GTGGAATTACTTTTTTTAGGGACGGGAGCCGGCATCCCCGCCAAGGCGAGAAATGTAACG
TCGGTGGCATTAAAATTGCTTGAAGAAAGGCGTTCGGTATGGCTTTTTGACTGCGGGGAA
GCCACACAGCATCAAATTTTACATACAACGATTAAACCTCGTAAAATAGAGAAAATCTTT
ATTACACACATGCACGGCGATCATGTATACGGACTTCCGGGGCTTCTGGGGAGCCGTTCC
TTTCAAGGCGGAGAGGACGAGCTGACAGTGTACGGACCTAAAGGGATCAAGGCGTTTATT
GAAACAAGCCTTGCCGTCACGAAAACCCATTTGACATATCCGCTTGCGATCCAGGAAATT
GAAGAAGGAATCGTGTTTGAGGACGATCAGTTTATTGTCACAGCGGTATCTGTTATTCAT
GGAGTGGAAGCCTTCGGGTACCGTGTGCAGGAAAAAGACGTACCGGGTTCCTTGAAGGCT
GACGTATTAAAAGAAATGAACATCCCGCCCGGACCTGTATATCAGAAAATCAAAAAAGGC
GAAACGGTAACGCTTGAAGACGGACGAATCATCAATGGGAATGATTTTCTGGAGCCTCCT
AAAAAGGGAAGATCTGTTGTGTTCTCCGGTGATACGAGAGTAAGTGACAAACTAAAAGAG
CTTGCGAGGGATTGTGATGTGCTTGTTCATGAAGCAACCTTTGCTAAGGAAGACCGTAAA
CTTGCTTATGATTATTATCACAGTACAACGGAACAAGCGGCTGTAACAGCGAAAGAAGCA
AGAGCGAAGCAGCTCATTTTAACCCATATCAGCGCAAGATATCAGGGAGATGCTTCTTTG
GAGCTTCAAAAAGAAGCGGTTGACGTTTTCCCCAATAGCGTGGCGGCATATGATTTCTTA
GAGGTAAACGTCCCGCGAGGCTGA

# Drug_Target_29_General_Function:
Involved in hydrolase activity

# Drug_Target_29_General_References:
8969508	Mizuno M, Masuda S, Takemaru K, Hosono S, Sato T, Takeuchi M, Kobayashi Y: Systematic sequencing of the 283 kb 210 degrees-232 degrees region of the Bacillus subtilis genome containing the skin element and many sporulation genes. Microbiology. 1996 Nov;142 ( Pt 11):3103-11.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_29_HGNC_ID:
Not Available

# Drug_Target_29_HPRD_ID:
Not Available

# Drug_Target_29_ID:
5448

# Drug_Target_29_Locus:
Not Available

# Drug_Target_29_Molecular_Weight:
34023

# Drug_Target_29_Name:
Ribonuclease Z

# Drug_Target_29_Number_of_Residues:
307

# Drug_Target_29_PDB_ID:
1Y44

# Drug_Target_29_Pathway:
Not Available

# Drug_Target_29_Pfam_Domain_Function:
PF00753	Lactamase_B

# Drug_Target_29_Protein_Sequence:
>Ribonuclease Z
MELLFLGTGAGIPAKARNVTSVALKLLEERRSVWLFDCGEATQHQILHTTIKPRKIEKIF
ITHMHGDHVYGLPGLLGSRSFQGGEDELTVYGPKGIKAFIETSLAVTKTHLTYPLAIQEI
EEGIVFEDDQFIVTAVSVIHGVEAFGYRVQEKDVPGSLKADVLKEMNIPPGPVYQKIKKG
ETVTLEDGRIINGNDFLEPPKKGRSVVFSGDTRVSDKLKELARDCDVLVHEATFAKEDRK
LAYDYYHSTTEQAAVTAKEARAKQLILTHISARYQGDASLELQKEAVDVFPNSVAAYDFL
EVNVPRG

# Drug_Target_29_Reaction:
Not Available

# Drug_Target_29_Signals:
None

# Drug_Target_29_Specific_Function:
Zinc phosphodiesterase, which displays some tRNA 3'- processing endonuclease activity. Probably involved in tRNA maturation, by removing a 3' trailer from precursor tRNA

# Drug_Target_29_SwissProt_ID:
P54548

# Drug_Target_29_SwissProt_Name:
RNZ_BACSU

# Drug_Target_29_Synonyms:
EC 3.1.26.11
RNase Z
tRNA 3 endonuclease
tRNase Z

# Drug_Target_29_Theoretical_pI:
6.19

# Drug_Target_29_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X01631

# Drug_Target_2_GenBank_ID_Protein:
43268

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
glmS

# Drug_Target_2_Gene_Sequence:
>1830 bp
ATGTGTGGAATTGTTGGCGCGATCGCGCAACGTGATGTAGCAGAAATCCTTCTTGAAGGT
TTACGTCGTCTGGAATACCGCGGATATGACTCTGCCGGTCTGGCCGTTGTTGATGCAGAA
GGTCATATGACCCGCCTGCGTCGCCTCGGTAAAGTCCAGATGCTGGCACAGGCAGCGGAA
GAACATCCTCTGCATGGCGGCACTGGTATTGCTCACACTCGCTGGGCGACCCACGGTGAA
CCTTCAGAAGTGAATGCGCATCCGCATGTTTCTGAACACATTGTGGTGGTGCATAACGGC
ATCATCGAAAACCATGAACCGCTGCGTGAAGAGCTAAAAGCGCGTGGCTATACCTTCGTT
TCTGAAACCGACACCGAAGTGATTGCCCATCTGGTGAACTGGGAGCTGAAACAAGGCGGG
ACTCTGCGTGAGGCCGTTCTGCGTGCTATCCCGCAGCTGCGTGGTGCGTACGGTACAGTG
ATCATGGACTCCCGTCACCCGGATACCCTGCTGGCGGCACGTTCTGGTAGTCCGCTGGTG
ATTGGCCTGGGGATGGGCGAAAACTTTATCGCTTCTGACCAGCTGGCGCTGTTGCCGGTG
ACCCGTCGCTTTATCTTCCTTGAAGAGGGCGATATTGCGGAAATCACTCGCCGTTCGGTA
AACATCTTCGATAAAACTGGCGCGGAAGTAAAACGTCAGGATATCGAATCCAATCTGCAA
TATGACGCGGGCGATAAAGGCATTTACCGTCACTACATGCAGAAAGAGATCTACGAACAG
CCGAACGCGATCAAAAACACCCTTACCGGACGCATCAGCCACGGTCAGGTTGATTTAAGC
GAGCTGGGACCGAACGCCGACGAACTGCTGTCGAAGGTTGAGCATATTCAGATCCTCGCC
TGTGGTACTTCTTATAACTCCGGTATGGTTTCCCGCTACTGGTTTGAATCGCTAGCAGGT
ATTCCGTGCGACGTCGAAATCGCCTCTGAATTCCGCTATCGCAAATCTGCCGTGCGTCGT
AACAGCCTGATGATCACCTTGTCACAGTCTGGCGAAACCGCGGATACCCTGGCTGGCCTG
CGTCTGTCGAAAGAGCTGGGTTACCTTGGTTCACTGGCAATCTGTAACGTTCCGGGTTCT
TCTCTGGTGCGCGAATCCGATCTGGCGCTAATGACCAACGCGGGTACAGAAATCGGCGTG
GCATCCACTAAAGCATTCACCACTCAGTTAACTGTGCTGTTGATGCTGGTGGCGAACGTG
TCTCGCCTGAAAGGTCTGGATGCCTCCATTGAACATGACATCGTGCATGGTCTGCAGGCG
CTGCCGAGCCGTATTGAGCAGATGCTGTCTCAGGACAAACGCATTGAAGCGCTGGCAGAA
GATTTCTCTGACAAACATCACGCGCTGTTCCTGGGCCGTGGCGATCAGTACCCAATCGCG
CTGGAAGGCGCATTGAAGTTGAAAGAGATCTCTTACATTCACGCTGAAGCCTACGCTGCT
GGCGAACTGAAACACGGTCCGCTGGCGCTAATTGATGCCGATATGCCGGTTATTGTTGTT
GCACCGAACAACGAATTGCTGGAAAAACTGAAATCCAACATTGAAGAAGTTCGCGCGCGT
GGCGGTCAGTTGTATGTCTTCGCCGATCAGGATGCGGGTTTTGTAAGTAGCGATAACATG
CACATCATCGAGATGCCGCATGTGGAAGAGGTGATTGCACCGATCTTCTACACCGTTCCG
CTGCAGCTGCTGGCTTACCATGTCGCGCTGATCAAAGGCACCGACGTTGACCAGCCGCGT
AACCTGGCAAAATCGGTTACGGTTGAGTAA

# Drug_Target_2_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_2_General_References:
10091662	Teplyakov A, Obmolova G, Badet-Denisot MA, Badet B: The mechanism of sugar phosphate isomerization by glucosamine 6-phosphate synthase. Protein Sci. 1999 Mar;8(3):596-602.
1915361	Golinelli-Pimpaneau B, Badet B: Possible involvement of Lys603 from Escherichia coli glucosamine-6-phosphate synthase in the binding of its substrate fructose 6-phosphate. Eur J Biochem. 1991 Oct 1;201(1):175-82.
2826397	McKown RL, Orle KA, Chen T, Craig NL: Sequence requirements of Escherichia coli attTn7, a specific site of transposon Tn7 insertion. J Bacteriol. 1988 Jan;170(1):352-8.
3010949	Gay NJ, Tybulewicz VL, Walker JE: Insertion of transposon Tn7 into the Escherichia coli glmS transcriptional terminator. Biochem J. 1986 Feb 15;234(1):111-7.
3134953	Dutka-Malen S, Mazodier P, Badet B: Molecular cloning and overexpression of the glucosamine synthetase gene from Escherichia coli. Biochimie. 1988 Feb;70(2):287-90.
6283361	Lichtenstein C, Brenner S: Unique insertion site of Tn7 in the E. coli chromosome. Nature. 1982 Jun 17;297(5867):601-3.
6395859	Walker JE, Gay NJ, Saraste M, Eberle AN: DNA sequence around the Escherichia coli unc operon. Completion of the sequence of a 17 kilobase segment containing asnA, oriC, unc, glmS and phoS. Biochem J. 1984 Dec 15;224(3):799-815.
7686882	Burland V, Plunkett G 3rd, Daniels DL, Blattner FR: DNA sequence and analysis of 136 kilobases of the Escherichia coli genome: organizational symmetry around the origin of replication. Genomics. 1993 Jun;16(3):551-61.
8805567	Isupov MN, Obmolova G, Butterworth S, Badet-Denisot MA, Badet B, Polikarpov I, Littlechild JA, Teplyakov A: Substrate binding is required for assembly of the active conformation of the catalytic site in Ntn amidotransferases: evidence from the 1.8 A crystal structure of the glutaminase domain of glucosamine 6-phosphate synthase. Structure. 1996 Jul 15;4(7):801-10.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9739095	Teplyakov A, Obmolova G, Badet-Denisot MA, Badet B, Polikarpov I: Involvement of the C terminus in intramolecular nitrogen channeling in glucosamine 6-phosphate synthase: evidence from a 1.6 A crystal structure of the isomerase domain. Structure. 1998 Aug 15;6(8):1047-55.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2597

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
66895

# Drug_Target_2_Name:
Glucosamine--fructose-6-phosphate aminotransferase [isomerizing]

# Drug_Target_2_Number_of_Residues:
609

# Drug_Target_2_PDB_ID:
1JXA

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00310	GATase_2
PF01380	SIS

# Drug_Target_2_Protein_Sequence:
>Glucosamine--fructose-6-phosphate aminotransferase [isomerizing]
MCGIVGAIAQRDVAEILLEGLRRLEYRGYDSAGLAVVDAEGHMTRLRRLGKVQMLAQAAE
EHPLHGGTGIAHTRWATHGEPSEVNAHPHVSEHIVVVHNGIIENHEPLREELKARGYTFV
SETDTEVIAHLVNWELKQGGTLREAVLRAIPQLRGAYGTVIMDSRHPDTLLAARSGSPLV
IGLGMGENFIASDQLALLPVTRRFIFLEEGDIAEITRRSVNIFDKTGAEVKRQDIESNLQ
YDAGDKGIYRHYMQKEIYEQPNAIKNTLTGRISHGQVDLSELGPNADELLSKVEHIQILA
CGTSYNSGMVSRYWFESLAGIPCDVEIASEFRYRKSAVRRNSLMITLSQSGETADTLAGL
RLSKELGYLGSLAICNVPGSSLVRESDLALMTNAGTEIGVASTKAFTTQLTVLLMLVAKL
SRLKGLDASIEHDIVHGLQALPSRIEQMLSQDKRIEALAEDFSDKHHALFLGRGDQYPIA
LEGALKLKEISYIHAEAYAAGELKHGPLALIDADMPVIVVAPNNELLEKLKSNIEEVRAR
GGQLYVFADQDAGFVSSDNMHIIEMPHVEEVIAPIFYTVPLQLLAYHVALIKGTDVDQPR
NLAKSVTVE

# Drug_Target_2_Reaction:
L-glutamine + D-fructose 6-phosphate = L-glutamate + D-glucosamine 6-phosphate

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes the first step in hexosamine metabolism, converting fructose-6P into glucosamine-6P using glutamine as a nitrogen source

# Drug_Target_2_SwissProt_ID:
P17169

# Drug_Target_2_SwissProt_Name:
GLMS_ECOLI

# Drug_Target_2_Synonyms:
D-fructose-6- phosphate amidotransferase
EC 2.6.1.16
GFAT
Glucosamine-6-phosphate synthase
Hexosephosphate aminotransferase
L-glutamine-D-fructose-6-phosphate amidotransferase

# Drug_Target_2_Theoretical_pI:
5.74

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_30_Cellular_Location:
Not Available

# Drug_Target_30_Chromosome_Location:
Not Available

# Drug_Target_30_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_30_Essentiality:
Non-Essential

# Drug_Target_30_GenAtlas_ID:
Not Available

# Drug_Target_30_GenBank_ID_Gene:
Not Available

# Drug_Target_30_GenBank_ID_Protein:
Not Available

# Drug_Target_30_GeneCard_ID:
Not Available

# Drug_Target_30_Gene_Name:
PRDX6

# Drug_Target_30_Gene_Sequence:
Not Available

# Drug_Target_30_General_Function:
Not Available

# Drug_Target_30_General_References:
Not Available

# Drug_Target_30_HGNC_ID:
Not Available

# Drug_Target_30_HPRD_ID:
Not Available

# Drug_Target_30_ID:
7151

# Drug_Target_30_Locus:
Not Available

# Drug_Target_30_Molecular_Weight:
Not Available

# Drug_Target_30_Name:
Peroxiredoxin-6

# Drug_Target_30_Number_of_Residues:
0

# Drug_Target_30_PDB_ID:
Not Available

# Drug_Target_30_Pathway:
Not Available

# Drug_Target_30_Pfam_Domain_Function:
Not Available

# Drug_Target_30_Protein_Sequence:
Not Available

# Drug_Target_30_Reaction:
Not Available

# Drug_Target_30_Signals:
Not Available

# Drug_Target_30_Specific_Function:
Not Available

# Drug_Target_30_SwissProt_ID:
P30041

# Drug_Target_30_SwissProt_Name:
PRDX6_HUMAN

# Drug_Target_30_Synonyms:
Not Available

# Drug_Target_30_Theoretical_pI:
Not Available

# Drug_Target_30_Transmembrane_Regions:
Not Available

# Drug_Target_31_Cellular_Location:
Not Available

# Drug_Target_31_Chromosome_Location:
Not Available

# Drug_Target_31_Drug_References:
Not Available

# Drug_Target_31_Essentiality:
Non-Essential

# Drug_Target_31_GenAtlas_ID:
Not Available

# Drug_Target_31_GenBank_ID_Gene:
L09121

# Drug_Target_31_GenBank_ID_Protein:
Not Available

# Drug_Target_31_GeneCard_ID:
Not Available

# Drug_Target_31_Gene_Name:
mglB

# Drug_Target_31_Gene_Sequence:
>492 bp
ATGGTGGAGCCTTCCCTGGTCCTTTACGGCGCCCCCTACGAGCGGGCCGTGGAGGTCCTC
GAGGAGACCCTAAGGGAAACGGGTGCCCGCTACGCCCTCCTCATTGACCGCAAGGGCTTC
GTCCTCGCCCACAAGGAGGCCCTCTGGGCCCCCAAGCCTCCCCCCCTGGACACCCTCGCC
ACCCTGGTGGCGGGGAACGCCGCCGCCACCCAGGCCCTGGCCAAGCTCCTGGGCGAAGCC
CGCTTCCAAGAGGAGGTCCACCAGGGGGAGAGGATGGGCCTCTACGTGGACGAGGCCGGG
GAGCACGCCCTCCTCGTCCTCGTCTTTGACGAGACCGCGCCCCTCGGCAAGGTGAAGCTC
CACGGCAAGCGGGCCGCGGAGGCCCTCGCCCGCATCGCCGAGGAGGCCCTGGCCAATCCG
CCCCGCCTCGCCCTGGACACGGAGTACCGGGAAGGGGCGGAAGCCCTCCTGGACGACCTC
CTCCGCAACTAA

# Drug_Target_31_General_Function:
Not Available

# Drug_Target_31_General_References:
Not Available

# Drug_Target_31_HGNC_ID:
Not Available

# Drug_Target_31_HPRD_ID:
Not Available

# Drug_Target_31_ID:
5449

# Drug_Target_31_Locus:
Not Available

# Drug_Target_31_Molecular_Weight:
17775

# Drug_Target_31_Name:
Hypothetical gliding protein

# Drug_Target_31_Number_of_Residues:
163

# Drug_Target_31_PDB_ID:
1J3W

# Drug_Target_31_Pathway:
Not Available

# Drug_Target_31_Pfam_Domain_Function:
PF03259	Robl_LC7

# Drug_Target_31_Protein_Sequence:
>Hypothetical gliding protein
MVEPSLVLYGAPYERAVEVLEETLRETGARYALLIDRKGFVLAHKEALWAPKPPPLDTLA
TLVAGNAAATQALAKLLGEARFQEEVHQGERMGLYVDEAGEHALLVLVFDETAPLGKVKL
HGKRAAEALARIAEEALANPPRLALDTEYREGAEALLDDLLRN

# Drug_Target_31_Reaction:
Not Available

# Drug_Target_31_Signals:
None

# Drug_Target_31_Specific_Function:
Not Available

# Drug_Target_31_SwissProt_ID:
Q9X9L0

# Drug_Target_31_SwissProt_Name:
Q9X9L0_THETH

# Drug_Target_31_Synonyms:
Not Available

# Drug_Target_31_Theoretical_pI:
4.70

# Drug_Target_31_Transmembrane_Regions:
None

# Drug_Target_32_Cellular_Location:
Cytoplasmic

# Drug_Target_32_Chromosome_Location:
Not Available

# Drug_Target_32_Drug_References:
Not Available

# Drug_Target_32_Essentiality:
Non-Essential

# Drug_Target_32_GenAtlas_ID:
Not Available

# Drug_Target_32_GenBank_ID_Gene:
AF127082

# Drug_Target_32_GenBank_ID_Protein:
Not Available

# Drug_Target_32_GeneCard_ID:
Not Available

# Drug_Target_32_Gene_Name:
pep

# Drug_Target_32_Gene_Sequence:
>2070 bp
ATGTCCTACCCGGCGACCCGGGCGGAGCAGGTTGTCGACACGTTGCACGGCGTCCAGGTA
GCGGACCCGTATCGCTGGCTCGAGGACGAGAAGGCCCCCGAGGTCCAGACGTGGATGACG
GCGCAGAACGCGCACGCCCGCGAAGCGCTGGCGAAGTTCCCCGGCCGTGAGGCCCTGGCC
GCGCGCTTCAAGGAGCTGTTCTACACCGACTCCGTCTCCACCCCGTCGCGCCGCAACGGG
CGCTTCTTCTACGTCCGCACCCACAAGGACAAGGAGAAGGCCATCCTCTACTGGCGCCAG
GGGGAGAGCGGGCAGGAGAAGGTGCTGTTGGATCCGAACGGCTGGAGCAAGGACGGCACC
GTGTCCCTGGGGACGTGGGCCGTGTCCTGGGACGGCAAGAAGGTGGCCTTCGCCCAGAAG
CCCAACGCCGCGGATGAGGCGGTGCTGCACGTCATCGACGTGGACTCTGGCGAGTGGTCC
AAGGTGGACGTCATCGAGGGCGGCAAGTACGCCACGCCCAAGTGGACGCCCGACAGCAAG
GGCTTCTATTACGAGTGGCTGCCCACGGACCCGTCCATCAAGGTGGACGAGCGCCCCGGC
TACACCACCATCCGCTACCACACGCTGGGCACGGAGCCGTCGAAGGACACCGTGGTGCAC
GAGCGCACCGGCGACCCGACGACGTTCCTCCAGAGCGACCTGAGCCGCGACGGCAAGTAC
CTGTTCGTCTACATCCTCCGCGGCTGGAGCGAGAACGACGTCTACTGGAAGCGGCCGGGT
GAGAAGGACTTCCGCCTGCTGGTGAAGGGCGTGGGCGCCAAGTACGAGGTGCACGCCTGG
AAGGACCGCTTCTACGTCCTCACCGACGAGGGCGCCCCGCGCCAGCGCGTCTTCGAGGTG
GATCCGGCGAAGCCGGCCCGCGCGTCGTGGAAGGAGATTGTCCCCGAGGACTCGTCCGCG
TCCCTGCTGTCCGTCAGCATCGTCGGCGGGCACCTGTCGCTGGAGTACCTCAAGGACGCG
ACGTCCGAGGTGCGCGTGGCCACGCTGAAGGGCAAGCCGGTGCGCACGGTGCAGCTGCCG
GGCGTGGGCGCGGCGTCCAACCTGATGGGGCTGGAGGACCTGGATGACGCCTACTACGTC
TTCACGTCCTTCACCACGCCCCGTCAAATCTACAAGACGTCCGTCAGCACCGGGAAGTCT
GAGCTCTGGGCCAAGGTGGACGTGCCCATGAACCCGGAGCAGTACCAGGTCGAGCAGGTC
TTCTACGCGTCCAAGGACGGGACGAAGGTGCCCATGTTCGTGGTGCACCGCAAGGACCTG
AAGCGTGACGGCAACGCGCCCACGCTGCTCTACGGCTACGGCGGCTTCAACGTGAACATG
GAGGCCAACTTCCGCTCGAGCATCCTGCCCTGGCTGGACGCGGGCGGCGTGTACGCGGTG
GCCAACCTGCGCGGCGGCGGCGAGTACGGCAAGGCCTGGCACGACGCCGGCCGCCTGGAC
AAGAAGCAGAACGTCTTCGACGACTTCCACGCGGCGGCCGAGTACTTGGTCCAGCAGAAG
TACACGCAGCCCAAGCGGCTGGCCATCTACGGCGGCAGCAACGGCGGCCTGCTGGTGGGC
GCGGCCATGACGCAGCGGCCGGAGCTGTACGGCGCGGTGGTGTGCGCGGTGCCCCTGCTG
GACATGGTGCGCTACCACCTCTTCGGCAGCGGCCGGACCTGGATTCCGGAGTACGGCACG
GCGGAGAAGCCCGAGGACTTCAAGACGCTGCACGCCTACTCGCCCTACCACCACGTGCGG
CCGGACGTGCGCTACCCCGCGCTGCTGATGATGGCGGCGGACCACGACGACCGGGTGGAC
CCCATGCACGCCCGCAAGTTCGTGGCGGCGGTGCAGAACTCGCCCGGAAACCCGGCGACG
GCCCTGCTGCGCATCGAGGCCAACGCGGGCCACGGTGGCGCGGATCAGGTGGCCAAGGCC
ATTGAGTCCAGCGTGGACCTGTATTCGTTCCTGTTCCAAGTCCTGGATGTCCAGGGGGCA
CAGGGTGGGGTGGCGGCGCAGGGCCGCTGA

# Drug_Target_32_General_Function:
Involved in prolyl oligopeptidase activity

# Drug_Target_32_General_References:
Not Available

# Drug_Target_32_HGNC_ID:
Not Available

# Drug_Target_32_HPRD_ID:
Not Available

# Drug_Target_32_ID:
5450

# Drug_Target_32_Locus:
Not Available

# Drug_Target_32_Molecular_Weight:
76848

# Drug_Target_32_Name:
Prolyl endopeptidase Pep

# Drug_Target_32_Number_of_Residues:
689

# Drug_Target_32_PDB_ID:
2BKL

# Drug_Target_32_Pathway:
Not Available

# Drug_Target_32_Pfam_Domain_Function:
PF00326	Peptidase_S9
PF02897	Peptidase_S9_N

# Drug_Target_32_Protein_Sequence:
>Prolyl endopeptidase Pep
MSYPATRAEQVVDTLHGVQVADPYRWLEDEKAPEVQTWMTAQNAHAREALAKFPGREALA
ARFKELFYTDSVSTPSRRNGRFFYVRTHKDKEKAILYWRQGESGQEKVLLDPNGWSKDGT
VSLGTWAVSWDGKKVAFAQKPNAADEAVLHVIDVDSGEWSKVDVIEGGKYATPKWTPDSK
GFYYEWLPTDPSIKVDERPGYTTIRYHTLGTEPSKDTVVHERTGDPTTFLQSDLSRDGKY
LFVYILRGWSENDVYWKRPGEKDFRLLVKGVGAKYEVHAWKDRFYVLTDEGAPRQRVFEV
DPAKPARASWKEIVPEDSSASLLSVSIVGGHLSLEYLKDATSEVRVATLKGKPVRTVQLP
GVGAASNLMGLEDLDDAYYVFTSFTTPRQIYKTSVSTGKSELWAKVDVPMNPEQYQVEQV
FYASKDGTKVPMFVVHRKDLKRDGNAPTLLYGYGGFNVNMEANFRSSILPWLDAGGVYAV
ANLRGGGEYGKAWHDAGRLDKKQNVFDDFHAAAEYLVQQKYTQPKRLAIYGGSNGGLLVG
AAMTQRPELYGAVVCAVPLLDMVRYHLFGSGRTWIPEYGTAEKPEDFKTLHAYSPYHHVR
PDVRYPALLMMAADHDDRVDPMHARKFVAAVQNSPGNPATALLRIEANAGHGGADQVAKA
IESSVDLYSFLFQVLDVQGAQGGVAAQGR

# Drug_Target_32_Reaction:
Not Available

# Drug_Target_32_Signals:
None

# Drug_Target_32_Specific_Function:
Not Available

# Drug_Target_32_SwissProt_ID:
Q9X5N2

# Drug_Target_32_SwissProt_Name:
Q9X5N2_MYXXA

# Drug_Target_32_Synonyms:
Not Available

# Drug_Target_32_Theoretical_pI:
7.04

# Drug_Target_32_Transmembrane_Regions:
None

# Drug_Target_33_Cellular_Location:
Not Available

# Drug_Target_33_Chromosome_Location:
Not Available

# Drug_Target_33_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_33_Essentiality:
Non-Essential

# Drug_Target_33_GenAtlas_ID:
Not Available

# Drug_Target_33_GenBank_ID_Gene:
Not Available

# Drug_Target_33_GenBank_ID_Protein:
Not Available

# Drug_Target_33_GeneCard_ID:
Not Available

# Drug_Target_33_Gene_Name:
SFTPA1

# Drug_Target_33_Gene_Sequence:
Not Available

# Drug_Target_33_General_Function:
Not Available

# Drug_Target_33_General_References:
Not Available

# Drug_Target_33_HGNC_ID:
Not Available

# Drug_Target_33_HPRD_ID:
Not Available

# Drug_Target_33_ID:
6991

# Drug_Target_33_Locus:
Not Available

# Drug_Target_33_Molecular_Weight:
Not Available

# Drug_Target_33_Name:
Pulmonary surfactant-associated protein A1

# Drug_Target_33_Number_of_Residues:
0

# Drug_Target_33_PDB_ID:
Not Available

# Drug_Target_33_Pathway:
Not Available

# Drug_Target_33_Pfam_Domain_Function:
Not Available

# Drug_Target_33_Protein_Sequence:
Not Available

# Drug_Target_33_Reaction:
Not Available

# Drug_Target_33_Signals:
Not Available

# Drug_Target_33_Specific_Function:
Not Available

# Drug_Target_33_SwissProt_ID:
Q8IWL2

# Drug_Target_33_SwissProt_Name:
SFTA1_HUMAN

# Drug_Target_33_Synonyms:
Not Available

# Drug_Target_33_Theoretical_pI:
Not Available

# Drug_Target_33_Transmembrane_Regions:
Not Available

# Drug_Target_34_Cellular_Location:
Not Available

# Drug_Target_34_Chromosome_Location:
Not Available

# Drug_Target_34_Drug_References:
Not Available

# Drug_Target_34_Essentiality:
Non-Essential

# Drug_Target_34_GenAtlas_ID:
Not Available

# Drug_Target_34_GenBank_ID_Gene:
D87070

# Drug_Target_34_GenBank_ID_Protein:
Not Available

# Drug_Target_34_GeneCard_ID:
Not Available

# Drug_Target_34_Gene_Name:
Not Available

# Drug_Target_34_Gene_Sequence:
>801 bp
ATGTTCAAACATACAAGAAAACTGCAATACAACGCAAAACCTGATCGTTCAGATCCAATT
ATGGCAAGACGCTTACAAGAATCTCTTGGTGGTCAATGGGGAGAAACCACTGGGATGATG
TCTTATCTCTCACAAGGTTGGGCGTCAACTGGTGCTGAAAAATATAAAGATTTATTATTA
GATACTGGTACAGAAGAAATGGCACACGTTGAAATGATTTCTACAATGATTGGCTACTTA
CTTGAAGATGCCCCATTTGGTCCAGAAGATTTAAAAAGAGATCCGTCATTGGCAACTACA
ATGGCCGGCATGGACCCAGAACACTCGTTAGTTCACGGTTTAAACGCTAGTTTAAATAAT
CCTAATGGTGCTGCTTGGAATGCTGGATATGTGACATCAAGTGGTAATTTAGTTGCTGAT
ATGAGATTTAATGTTGTTCGTGAATCTGAAGCCAGATTACAAGTTAGTCGTCTGTACTCA
ATGACTGAAGATGAAGGTGTGCGTGACATGCTTAAATTCCTATTAGCTCGTGAAACTCAA
CATCAATTACAATTTATGAAAGCTCAAGAAGAATTAGAAGAAAAATATGGGATAATTGTA
CCTGGCGATATGAAAGAGATCGAGCATAGTGAATTTAGTCATGTACTTATGAATTTCTCA
GATGGTGATGGATCAAAAGCATTTGAAGGACAAGTTGCTAAAGATGGTGAAAAATTCACC
TATCAAGAAAACCCAGAAGCAATGGGTGGTATTCCACATATTAAACCGGGTGATCCTAGA
TTACACAACCACCAAGGTTAG

# Drug_Target_34_General_Function:
Involved in oxidoreductase activity

# Drug_Target_34_General_References:
Not Available

# Drug_Target_34_HGNC_ID:
Not Available

# Drug_Target_34_HPRD_ID:
Not Available

# Drug_Target_34_ID:
4705

# Drug_Target_34_Locus:
Not Available

# Drug_Target_34_Molecular_Weight:
29744

# Drug_Target_34_Name:
Manganese catalase

# Drug_Target_34_Number_of_Residues:
266

# Drug_Target_34_PDB_ID:
1JKV

# Drug_Target_34_Pathway:
Not Available

# Drug_Target_34_Pfam_Domain_Function:
PF05067	Mn_catalase

# Drug_Target_34_Protein_Sequence:
>Manganese catalase
MFKHTRKLQYNAKPDRSDPIMARRLQESLGGQWGETTGMMSYLSQGWASTGAEKYKDLLL
DTGTEEMAHVEMISTMIGYLLEDAPFGPEDLKRDPSLATTMAGMDPEHSLVHGLNASLNN
PNGAAWNAGYVTSSGNLVADMRFNVVRESEARLQVSRLYSMTEDEGVRDMLKFLLARETQ
HQLQFMKAQEELEEKYGIIVPGDMKEIEHSEFSHVLMNFSDGDGSKAFEGQVAKDGEKFT
YQENPEAMGGIPHIKPGDPRLHNHQG

# Drug_Target_34_Reaction:
Not Available

# Drug_Target_34_Signals:
None

# Drug_Target_34_Specific_Function:
2 H(2)O(2) = O(2) + 2 H(2)O

# Drug_Target_34_SwissProt_ID:
P60355

# Drug_Target_34_SwissProt_Name:
MCAT_LACPL

# Drug_Target_34_Synonyms:
EC 1.11.1.6
Pseudocatalase

# Drug_Target_34_Theoretical_pI:
4.87

# Drug_Target_34_Transmembrane_Regions:
None

# Drug_Target_35_Cellular_Location:
Not Available

# Drug_Target_35_Chromosome_Location:
Not Available

# Drug_Target_35_Drug_References:
Not Available

# Drug_Target_35_Essentiality:
Non-Essential

# Drug_Target_35_GenAtlas_ID:
Not Available

# Drug_Target_35_GenBank_ID_Gene:
AY196198

# Drug_Target_35_GenBank_ID_Protein:
Not Available

# Drug_Target_35_GeneCard_ID:
Not Available

# Drug_Target_35_Gene_Name:
aroG

# Drug_Target_35_Gene_Sequence:
>369 bp
ATGGTCCGGGGCATCCGCGGCGCCATCACCGTGGAAGAGGACACCCCGGAGGCCATCCAC
CAGGCCACCCGGGAACTCCTCCTGAAGATGCTGGAGGCGAACGGCATCCAGAGCTACGAG
GAGCTCGCCGCCGTCATCTTCACCGTCACCGAGGACCTCACCTCCGCCTTCCCCGCCGAG
GCCGCGCGGCAGATCGGCATGCACCGGGTGCCCCTCCTCTCCGCCCGGGAGGTGCCGGTG
CCGGGAAGCCTCCCCCGGGTGATCCGCGTCCTCGCCCTCTGGAACACGGACACCCCCCAG
GACCGGGTGCGCCACGTCTACCTCAGGGAGGCGGTGCGGCTCCGGCCCGACCTGGAAAGC
GCCCAGTAG

# Drug_Target_35_General_Function:
Not Available

# Drug_Target_35_General_References:
Not Available

# Drug_Target_35_HGNC_ID:
Not Available

# Drug_Target_35_HPRD_ID:
Not Available

# Drug_Target_35_ID:
4611

# Drug_Target_35_Locus:
Not Available

# Drug_Target_35_Molecular_Weight:
13650

# Drug_Target_35_Name:
Chorismate mutase

# Drug_Target_35_Number_of_Residues:
122

# Drug_Target_35_PDB_ID:
1UFY

# Drug_Target_35_Pathway:
Not Available

# Drug_Target_35_Pfam_Domain_Function:
PF07736	CM_1

# Drug_Target_35_Protein_Sequence:
>Chorismate mutase
MVRGIRGAITVEEDTPEAIHQATRELLLKMLEANGIQSYEELAAVIFTVTEDLTSAFPAE
AARQIGMHRVPLLSAREVPVPGSLPRVIRVLALWNTDTPQDRVRHVYLREAVRLRPDLES
AQ

# Drug_Target_35_Reaction:
Not Available

# Drug_Target_35_Signals:
None

# Drug_Target_35_Specific_Function:
Not Available

# Drug_Target_35_SwissProt_ID:
Q84FH6

# Drug_Target_35_SwissProt_Name:
Q84FH6_THETH

# Drug_Target_35_Synonyms:
EC 5.4.99.5

# Drug_Target_35_Theoretical_pI:
5.68

# Drug_Target_35_Transmembrane_Regions:
None

# Drug_Target_36_Cellular_Location:
Not Available

# Drug_Target_36_Chromosome_Location:
Not Available

# Drug_Target_36_Drug_References:
Not Available

# Drug_Target_36_Essentiality:
Non-Essential

# Drug_Target_36_GenAtlas_ID:
Not Available

# Drug_Target_36_GenBank_ID_Gene:
AL939108

# Drug_Target_36_GenBank_ID_Protein:
Not Available

# Drug_Target_36_GeneCard_ID:
Not Available

# Drug_Target_36_Gene_Name:
SCO1207

# Drug_Target_36_Gene_Sequence:
>1215 bp
ATGACTGAAGAAACGATTTCCCAGGCCGTGCCACCCGTCCGGGACTGGCCGGCCGTCGAC
CTTCCCGGCAGCGACTTCGACCCGGTGCTGACCGAGCTGATGCGCGAGGGTCCCGTCACC
CGGATCTCGCTGCCCAACGGCGAGGGCTGGGCCTGGCTCGTGACCCGCCACGACGACGTC
CGCCTGGTCACCAACGACCCCCGGTTCGGGCGCGAGGCCGTCATGGACCGCCAGGTCACC
CGGCTGGCCCCGCACTTCATCCCGGCGCGCGGCGCGGTGGGCTTCCTGGACCCGCCCGAC
CACACCCGGCTGCGCCGCTCGGTGGCCGCGGCCTTCACCGCGCGGGGCGTGGAGCGGGTG
CGCGAGCGGTCCCGGGGCATGCTCGACGAGCTGGTCGACGCCATGCTGAGGGCCGGTCCG
CCCGCCGACCTCACCGAGGCGGTGCTGAGCCCGTTCCCCATCGCGGTGATCTGCGAGCTG
ATGGGTGTGCCGGCCACCGACCGGCACTCCATGCACACCTGGACCCAGCTGATCCTGTCC
TCCTCGCACGGCGCCGAGGTCAGCGAGCGGGCCAAGAACGAGATGAACGCCTACTTCTCG
GATCTCATCGGGCTCCGCTCCGACAGCGCGGGCGAGGACGTCACCTCGCTGCTGGGTGCC
GCCGTGGGGCGGGACGAGATCACGCTGTCGGAGGCCGTCGGGCTCGCGGTGCTGCTCCAG
ATCGGCGGCGAGGCGGTCACCAACAACAGCGGGCAGATGTTCCACCTGCTGCTGAGCCGC
CCGGAGCTGGCCGAACGCCTGCGCTCCGAGCCGGAGATCCGCCCCCGGGCCATCGACGAG
CTGCTGCGCTGGATCCCGCACCGCAACGCCGTGGGGCTGTCCCGGATCGCCCTGGAGGAC
GTGGAGATCAAGGGGGTGCGGATCCGCGCGGGCGACGCCGTCTACGTCTCGTACCTGGCG
GCCAACCGCGACCCGGAGGTGTTCCCCGACCCGGACCGCATCGACTTCGAGCGCTCCCCC
AACCCGCACGTCTCCTTCGGCTTCGGCCCGCACTACTGTCCCGGCGGCATGCTGGCGCGG
CTGGAGTCGGAGCTGCTCGTCGACGCGGTCCTGGACCGCGTGCCGGGGCTGAAGCTCGCG
GTGGCGCCGGAGGACGTGCCCTTCAAGAAGGGTGCGCTGATCCGCGGGCCCGAGGCCCTG
CCGGTGACGTGGTGA

# Drug_Target_36_General_Function:
Involved in monooxygenase activity

# Drug_Target_36_General_References:
12000953	Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James KD, Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke L, Murphy L, Oliver K, O'Neil S, Rabbinowitsch E, Rajandream MA, Rutherford K, Rutter S, Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A, Woodward J, Barrell BG, Parkhill J, Hopwood DA: Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature. 2002 May 9;417(6885):141-7.

# Drug_Target_36_HGNC_ID:
Not Available

# Drug_Target_36_HPRD_ID:
Not Available

# Drug_Target_36_ID:
4608

# Drug_Target_36_Locus:
Not Available

# Drug_Target_36_Molecular_Weight:
44355

# Drug_Target_36_Name:
Putative cytochrome P450

# Drug_Target_36_Number_of_Residues:
404

# Drug_Target_36_PDB_ID:
1T93

# Drug_Target_36_Pathway:
Not Available

# Drug_Target_36_Pfam_Domain_Function:
PF00067	p450

# Drug_Target_36_Protein_Sequence:
>Putative cytochrome P450
MTEETISQAVPPVRDWPAVDLPGSDFDPVLTELMREGPVTRISLPNGEGWAWLVTRHDDV
RLVTNDPRFGREAVMDRQVTRLAPHFIPARGAVGFLDPPDHTRLRRSVAAAFTARGVERV
RERSRGMLDELVDAMLRAGPPADLTEAVLSPFPIAVICELMGVPATDRHSMHTWTQLILS
SSHGAEVSERAKNEMNAYFSDLIGLRSDSAGEDVTSLLGAAVGRDEITLSEAVGLAVLLQ
IGGEAVTNNSGQMFHLLLSRPELAERLRSEPEIRPRAIDELLRWIPHRNAVGLSRIALED
VEIKGVRIRAGDAVYVSYLAANRDPEVFPDPDRIDFERSPNPHVSFGFGPHYCPGGMLAR
LESELLVDAVLDRVPGLKLAVAPEDVPFKKGALIRGPEALPVTW

# Drug_Target_36_Reaction:
Not Available

# Drug_Target_36_Signals:
None

# Drug_Target_36_Specific_Function:
Not Available

# Drug_Target_36_SwissProt_ID:
Q9FCA6

# Drug_Target_36_SwissProt_Name:
Q9FCA6_STRCO

# Drug_Target_36_Synonyms:
Not Available

# Drug_Target_36_Theoretical_pI:
5.02

# Drug_Target_36_Transmembrane_Regions:
None

# Drug_Target_37_Cellular_Location:
Not Available

# Drug_Target_37_Chromosome_Location:
Not Available

# Drug_Target_37_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_37_Essentiality:
Non-Essential

# Drug_Target_37_GenAtlas_ID:
Not Available

# Drug_Target_37_GenBank_ID_Gene:
Not Available

# Drug_Target_37_GenBank_ID_Protein:
Not Available

# Drug_Target_37_GeneCard_ID:
Not Available

# Drug_Target_37_Gene_Name:
IRGC

# Drug_Target_37_Gene_Sequence:
Not Available

# Drug_Target_37_General_Function:
Not Available

# Drug_Target_37_General_References:
Not Available

# Drug_Target_37_HGNC_ID:
Not Available

# Drug_Target_37_HPRD_ID:
Not Available

# Drug_Target_37_ID:
7144

# Drug_Target_37_Locus:
Not Available

# Drug_Target_37_Molecular_Weight:
Not Available

# Drug_Target_37_Name:
Interferon-inducible GTPase 5

# Drug_Target_37_Number_of_Residues:
0

# Drug_Target_37_PDB_ID:
Not Available

# Drug_Target_37_Pathway:
Not Available

# Drug_Target_37_Pfam_Domain_Function:
Not Available

# Drug_Target_37_Protein_Sequence:
Not Available

# Drug_Target_37_Reaction:
Not Available

# Drug_Target_37_Signals:
Not Available

# Drug_Target_37_Specific_Function:
Not Available

# Drug_Target_37_SwissProt_ID:
Q6NXR0

# Drug_Target_37_SwissProt_Name:
IIGP5_HUMAN

# Drug_Target_37_Synonyms:
Not Available

# Drug_Target_37_Theoretical_pI:
Not Available

# Drug_Target_37_Transmembrane_Regions:
Not Available

# Drug_Target_38_Cellular_Location:
Cell wall

# Drug_Target_38_Chromosome_Location:
Not Available

# Drug_Target_38_Drug_References:
Not Available

# Drug_Target_38_Essentiality:
Non-Essential

# Drug_Target_38_GenAtlas_ID:
Not Available

# Drug_Target_38_GenBank_ID_Gene:
AJ012346

# Drug_Target_38_GenBank_ID_Protein:
Not Available

# Drug_Target_38_GeneCard_ID:
Not Available

# Drug_Target_38_Gene_Name:
inlA

# Drug_Target_38_Gene_Sequence:
>2403 bp
GTGAGAAAAAAACGATATGTATGGTTGAAAAGTATACTAGTAGCAATATTAGTATTTGGC
AGCGGAGTATGGATTAACACGAGTAACGGGACAAATGCTCAGGCAGCTACAATTACACAA
GATACTCCTATTAATCAGATTTTTACAGATACAGCTCTAGCGGAAAAAATGAAGACGGTC
TTAGGAAAAACGAATGTAACAGACACGGTCTCACAAACAGATCTAGACCAAGTTACAACG
CTTCAGGCGGATAGATTAGGGATAAAATCTATCGATGGAGTGGAATACTTGAACAATTTA
ACACAAATAAATTTCAGCAATAATCAACTTACGGACATAACGCCACTTAAAAATTTAACT
AAGTTAGTTGATATTTTGATGAATAATAATCAAATAGCAGATATAACTCCGCTAGCTAAT
TTGACGAATCTAACTGGTTTGACTTTGTTCAACAATCAGATAACGGATATAGACCCGCTT
AAAAATCTAACAAATTTAAATCGGCTAGAACTATCCAGTAACACGATTAGTGATATTAGT
GCGCTTTCAGGTTTAACTAGTCTACAGCAATTATCTTTTGGTAATCAAGTGACAGATTTA
AAACCATTAGCTAATTTAACAACACTAGAACGACTAGATATTTCAAGTAATAAGGTGTCG
GATATTAGTGTTCTGGCTAAATTAACCAATTTAGAAAGTCTTATCGCTACTAACAACCAA
ATAAGTGATATAACTCCACTTGGGATTTTAACAAATTTGGACGAATTATCCTTAAATGGT
AACCAGTTAAAAGATATAGGCACATTGGCGAGTTTAACAAACCTTACAGATTTAGATTTA
GCAAATAACCAAATTAGTAATCTAGCACCACTGTCGGGTCTAACAAAACTAACTGAGTTA
AAACTTGGAGCTAACCAAATAAGTAACATCAGTCCCCTAGCAGGTTTAACCGCACTCACT
AACTTAGAGCTTAATGAAAATCAGCTGGAAGATATTAGCCCAATTTCTAACCTGAAAAAT
CTCACATATTTAACTTTGTACTTTAATAATATAAGTGATATAAGCCCAGTTTCTAGTTTA
ACAAAGCTTCAAAGATTATTTTTCTATAATAACAAGGTAAGTGACGTAAGCTCACTTGCG
AACTTAACAAATATTAATTGGCTTTCAGCTGGGCATAACCAAATTAGCGATCTTACACCA
TTGGCTAATTTAACAAGAATCACCCAACTAGGGTTGAATGATCAAGCATGGACAAATGCA
CCAGTAAACTACAAAGCAAATGTATCCATTCCAAACACGGTGAAAAATGTGACTGGCGCT
TTAATTGCACCAGCTACTATTAGCGATGGCGGTAGTTACACAGAGCCTGATATAACATGG
AACTTACCTAGTTATACAAATGAAGTAAGCTATACCTTTAGCCAACCTGTCACTATTGGA
AAAGGAACGACAACATTTAGTGGAACCGTGACGCAGCCACTTAAGGCAATTTTTAATGTT
AAGTTTCATGTGGACGGCAAAGAAACAACCAAAGAAGTGGAAGCTGGGAATTTATTGACT
GAACCAGCTAAGCCCGTAAAAGAAGGTCACACATTTGTTGGTTGGTTTGATGCCCAAACA
GGCGGAACTAAATGGAATTTCAGTACGGATAAAATGCCGACAAATGACATCAATTTATAT
GCACAATTTAGTATTAACAGCTACACAGCAACCTTTGATAATGACGGTGTAACAACATCT
CAAACAGTAGATTATCAAGGCTTGTTACAAGAACCTACGGCACCAACAAAAGAAGGTTAT
ACTTTTAAAGGCTGGTATGACGCAAAAACTGGTGGTGACAAGTGGGATTTCGCAACTAGC
AAAATGCCTGCTAAAAACATCACCTTATATGCCCAATATAGCGCCAATAGCTATACAGCA
ACGTTTGATGTTGATGGAAAATCAACGACTCAAGCAGTAGACTATCAAGGACTTCTAAAA
GAACCAAAGGCACCAACGAAAGCCGGATATACTTTCAAAGGCTGGTATGACGAAAAAACA
GATGGGAAAAAATGGGATTTTGCGACGGATAAAATGCCAGCAAATGACATTACGCTGTAC
GCTCAATTTACGAAAAATCCTGTGGCACCACCAACAACTGGAGGGAACACACCGCCTACA
ACAAATAACGGCGGGAATACTACACCACCTTCCGCAAATATACCTGGAAGCGACACATCT
AACACATCAACTGGGAATTCAGCCAGCACAACAAGTACAATGAACGCTTATGACCCTTAT
AATTCAAAAGAAGCTTCACTCCCTACAACTGGCGATAGCGATAATGCGCTCTACCTTTTG
TTAGGGTTATTAGCAGTAGGAACTGCAATGGCTCTTACTAAAAAAGCACGTGCTAGTAAA
TAG

# Drug_Target_38_General_Function:
Involved in protein binding

# Drug_Target_38_General_References:
11679669	Glaser P, Frangeul L, Buchrieser C, Rusniok C, Amend A, Baquero F, Berche P, Bloecker H, Brandt P, Chakraborty T, Charbit A, Chetouani F, Couve E, de Daruvar A, Dehoux P, Domann E, Dominguez-Bernal G, Duchaud E, Durant L, Dussurget O, Entian KD, Fsihi H, Garcia-del Portillo F, Garrido P, Gautier L, Goebel W, Gomez-Lopez N, Hain T, Hauf J, Jackson D, Jones LM, Kaerst U, Kreft J, Kuhn M, Kunst F, Kurapkat G, Madueno E, Maitournam A, Vicente JM, Ng E, Nedjari H, Nordsiek G, Novella S, de Pablos B, Perez-Diaz JC, Purcell R, Remmel B, Rose M, Schlueter T, Simoes N, Tierrez A, Vazquez-Boland JA, Voss H, Wehland J, Cossart P: Comparative genomics of Listeria species. Science. 2001 Oct 26;294(5543):849-52.
12526809	Schubert WD, Urbanke C, Ziehm T, Beier V, Machner MP, Domann E, Wehland J, Chakraborty T, Heinz DW: Structure of internalin, a major invasion protein of Listeria monocytogenes, in complex with its human receptor E-cadherin. Cell. 2002 Dec 13;111(6):825-36.
1905979	Gaillard JL, Berche P, Frehel C, Gouin E, Cossart P: Entry of L. monocytogenes into cells is mediated by internalin, a repeat protein reminiscent of surface antigens from gram-positive cocci. Cell. 1991 Jun 28;65(7):1127-41.
7934917	Dramsi S, Dehoux P, Cossart P: Common features of gram-positive bacterial proteins involved in cell recognition. Mol Microbiol. 1993 Sep;9(5):1119-21.
9541569	Vines A, Swaminathan B: Identification and characterization of nucleotide sequence differences in three virulence-associated genes of listeria monocytogenes strains representing clinically important serotypes. Curr Microbiol. 1998 May;36(5):309-18.

# Drug_Target_38_HGNC_ID:
Not Available

# Drug_Target_38_HPRD_ID:
Not Available

# Drug_Target_38_ID:
5454

# Drug_Target_38_Locus:
Not Available

# Drug_Target_38_Molecular_Weight:
86494

# Drug_Target_38_Name:
Internalin-A

# Drug_Target_38_Number_of_Residues:
800

# Drug_Target_38_PDB_ID:
1O6V

# Drug_Target_38_Pathway:
Not Available

# Drug_Target_38_Pfam_Domain_Function:
PF00560	LRR_1
PF00746	Gram_pos_anchor
PF08191	LRR_adjacent

# Drug_Target_38_Protein_Sequence:
>Internalin-A
MRKKRYVWLKSILVAILVFGSGVWINTSNGTNAQAATITQDTPINQIFTDTALAEKMKTV
LGKTNVTDTVSQTDLDQVTTLQADRLGIKSIDGVEYLNNLTQINFSNNQLTDITPLKNLT
KLVDILMNNNQIADITPLANLTNLTGLTLFNNQITDIDPLKNLTNLNRLELSSNTISDIS
ALSGLTSLQQLSFGNQVTDLKPLANLTTLERLDISSNKVSDISVLAKLTNLESLIATNNQ
ISDITPLGILTNLDELSLNGNQLKDIGTLASLTNLTDLDLANNQISNLAPLSGLTKLTEL
KLGANQISNISPLAGLTALTNLELNENQLEDISPISNLKNLTYLTLYFNNISDISPVSSL
TKLQRLFFYNNKVSDVSSLANLTNINWLSAGHNQISDLTPLANLTRITQLGLNDQAWTNA
PVNYKANVSIPNTVKNVTGALIAPATISDGGSYTEPDITWNLPSYTNEVSYTFSQPVTIG
KGTTTFSGTVTQPLKAIFNVKFHVDGKETTKEVEAGNLLTEPAKPVKEGHTFVGWFDAQT
GGTKWNFSTDKMPTNDINLYAQFSINSYTATFDNDGVTTSQTVDYQGLLQEPTAPTKEGY
TFKGWYDAKTGGDKWDFATSKMPAKNITLYAQYSANSYTATFDVDGKSTTQAVDYQGLLK
EPKAPTKAGYTFKGWYDEKTDGKKWDFATDKMPANDITLYAQFTKNPVAPPTTGGNTPPT
TNNGGNTTPPSANIPGSDTSNTSTGNSASTTSTMNAYDPYNSKEASLPTTGDSDNALYLL
LGLLAVGTAMALTKKARASK

# Drug_Target_38_Reaction:
Not Available

# Drug_Target_38_Signals:
1-35

# Drug_Target_38_Specific_Function:
Mediates the entry of Listeria monocytogenes into cells

# Drug_Target_38_SwissProt_ID:
P25146

# Drug_Target_38_SwissProt_Name:
INLA_LISMO

# Drug_Target_38_Synonyms:
Internalin-A precursor

# Drug_Target_38_Theoretical_pI:
4.71

# Drug_Target_38_Transmembrane_Regions:
None

# Drug_Target_39_Cellular_Location:
Secreted protein. Cytoplasmic granule. Note=Mast cell granules

# Drug_Target_39_Chromosome_Location:
Not Available

# Drug_Target_39_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_39_Essentiality:
Non-Essential

# Drug_Target_39_GenAtlas_ID:
CMA1

# Drug_Target_39_GenBank_ID_Gene:
M64269

# Drug_Target_39_GenBank_ID_Protein:
180542

# Drug_Target_39_GeneCard_ID:
CMA1

# Drug_Target_39_Gene_Name:
CMA1

# Drug_Target_39_Gene_Sequence:
>744 bp
ATGCTGCTTCTTCCTCTCCCCCTGCTGCTCTTTCTCTTGTGCTCCAGAGCTGAAGCTGGG
GAGATCATCGGGGGCACAGAATGCAAGCCACATTCCCGCCCCTACATGGCCTACCTGGAA
ATTGTAACTTCCAACGGTCCCTCAAAATTTTGTGGTGGTTTCCTTATAAGACGGAACTTT
GTGCTGACGGCTGCTCATTGTGCAGGAAGGTCTATAACAGTCACCCTTGGAGCCCATAAC
ATAACAGAGGAAGAAGACACATGGCAGAAGCTTGAGGTTATAAAGCAATTCCGTCATCCA
AAATATAACACTTCTACTCTTCACCACGATATCATGTTACTAAAGTTGAAGGAGAAAGCC
AGCCTGACCCTGGCTGTGGGGACACTCCCCTTCCCATCACAATTCAACTTTGTCCCACCT
GGGAGAATGTGCCGGGTGGCTGGCTGGGGAAGAACAGGTGTGTTGAAGCCGGGCTCAGAC
ACTCTGCAAGAGGTGAAGCTGAGACTCATGGATCCCCAGGCCTGCAGCCACTTCAGAGAC
TTTGACCACAATCTTCAGCTGTGTGTGGGCAATCCCAGGAAGACAAAATCTGCATTTAAG
GGAGACTCTGGGGGCCCTCTTCTGTGTGCTGGGGTGGCCCAGGGCATCGTATCCTATGGA
CGGTCGGATGCAAAGCCCCCTGCTGTCTTCACCCGAATCTCCCATTACCGGCCCTGGATC
AACCAGATCCTGCAGGCAAATTAA

# Drug_Target_39_General_Function:
Involved in protease activity

# Drug_Target_39_General_References:
1894611	Urata H, Kinoshita A, Perez DM, Misono KS, Bumpus FM, Graham RM, Husain A: Cloning of the gene and cDNA for human heart chymase. J Biol Chem. 1991 Sep 15;266(26):17173-9.
2049082	Jenne DE, Tschopp J: Angiotensin II-forming heart chymase is a mast-cell-specific enzyme. Biochem J. 1991 Jun 1;276 ( Pt 2):567-8.
2071582	Caughey GH, Zerweck EH, Vanderslice P: Structure, chromosomal assignment, and deduced amino acid sequence of a human gene for mast cell chymase. J Biol Chem. 1991 Jul 15;266(20):12956-63.
8495723	Sukenaga Y, Kido H, Neki A, Enomoto M, Ishida K, Takagi K, Katunuma N: Purification and molecular cloning of chymase from human tonsils. FEBS Lett. 1993 May 24;323(1-2):119-22.
9400368	McGrath ME, Mirzadegan T, Schmidt BF: Crystal structure of phenylmethanesulfonyl fluoride-treated human chymase at 1.9 A. Biochemistry. 1997 Nov 25;36(47):14318-24.
9931257	Pereira PJ, Wang ZM, Rubin H, Huber R, Bode W, Schechter NM, Strobl S: The 2.2 A crystal structure of human chymase in complex with succinyl-Ala-Ala-Pro-Phe-chloromethylketone: structural explanation for its dipeptidyl carboxypeptidase specificity. J Mol Biol. 1999 Feb 12;286(1):163-73.

# Drug_Target_39_HGNC_ID:
HGNC:2097

# Drug_Target_39_HPRD_ID:
00346

# Drug_Target_39_ID:
1615

# Drug_Target_39_Locus:
14q11.2

# Drug_Target_39_Molecular_Weight:
27325

# Drug_Target_39_Name:
Chymase

# Drug_Target_39_Number_of_Residues:
247

# Drug_Target_39_PDB_ID:
1NN6

# Drug_Target_39_Pathway:
Not Available

# Drug_Target_39_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_39_Protein_Sequence:
>Chymase precursor
MLLLPLPLLLFLLCSRAEAGEIIGGTECKPHSRPYMAYLEIVTSNGPSKFCGGFLIRRNF
VLTAAHCAGRSITVTLGAHNITEEEDTWQKLEVIKQFRHPKYNTSTLHHDIMLLKLKEKA
SLTLAVGTLPFPSQFNFVPPGRMCRVAGWGRTGVLKPGSDTLQEVKLRLMDPQACSHFRD
FDHNLQLCVGNPRKTKSAFKGDSGGPLLCAGVAQGIVSYGRSDAKPPAVFTRISHYRPWI
NQILQAN

# Drug_Target_39_Reaction:
Preferential cleavage: Phe! > Tyr! > Trp! > Leu!

# Drug_Target_39_Signals:
1-19

# Drug_Target_39_Specific_Function:
Major secreted protease of mast cells with suspected roles in vasoactive peptide generation, extracellular matrix degradation, and regulation of gland secretion

# Drug_Target_39_SwissProt_ID:
P23946

# Drug_Target_39_SwissProt_Name:
CMA1_HUMAN

# Drug_Target_39_Synonyms:
Chymase precursor
EC 3.4.21.39
Mast cell protease I

# Drug_Target_39_Theoretical_pI:
9.71

# Drug_Target_39_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X78968

# Drug_Target_3_GenBank_ID_Protein:
563852

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
DFR1

# Drug_Target_3_Gene_Sequence:
>579 bp
ATGCTGAAACCAAATGTTGCAATCATTGTCGCGGCATTAAAGCCTGCTTTGGGAATTGGA
TACAAAGGTAAAATGCCTTGGAGACTCCGTAAGGAAATAAGATATTTCAAAGACGTCACC
ACCAGAACAACGAAACCAAATACTCGTAATGCTGTTATTATGGGAAGAAAGACGTGGGAA
TCCATACCACAGAAGTTTAGACCTCTTCCAGATAGATTAAACATAATATTATCTAGATCA
TACGAAAATAAAATTATTGATGACAATATCATTCATGCCAGCTCAATTGAGTCGTCACTT
AATCTTGTATCTGATGTCGAAAGAGTTTTCATAATTGGAGGGGCAGAAATTTACAATGAA
TTGATAAATAATTCTTTAGTGAGTCATCTATTAATTACAGAAATCGAACATCCAAGCCCA
GAGTCTATTGAAATGGATACCTTTTTGAAATTCCCATTGGAAAGTTGGACCAAACAACCA
AAATCAGAGTTGCAGAAATTTGTTGGAGATACTGTATTAGAAGACGATATCAAGGAAGGT
GATTTTACCTATAATTATACGCTATGGACAAGAAAATAA

# Drug_Target_3_General_Function:
Coenzyme transport and metabolism

# Drug_Target_3_General_References:
2642898	Baccanari DP, Tansik RL, Joyner SS, Fling ME, Smith PL, Freisheim JH: Characterization of Candida albicans dihydrofolate reductase. J Biol Chem. 1989 Jan 15;264(2):1100-7.
7916311	Daly S, Mastromei G, Yacoub A, Lorenzetti R: Sequence of a dihydrofolate reductase-encoding gene from Candida albicans. Gene. 1994 Sep 15;147(1):115-8.
9374515	Whitlow M, Howard AJ, Stewart D, Hardman KD, Kuyper LF, Baccanari DP, Fling ME, Tansik RL: X-ray crystallographic studies of Candida albicans dihydrofolate reductase. High resolution structures of the holoenzyme and an inhibited ternary complex. J Biol Chem. 1997 Nov 28;272(48):30289-98.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2381

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
22139

# Drug_Target_3_Name:
Dihydrofolate reductase

# Drug_Target_3_Number_of_Residues:
192

# Drug_Target_3_PDB_ID:
1IA4

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00186	DHFR_1

# Drug_Target_3_Protein_Sequence:
>Dihydrofolate reductase
MSKPNVAIIVAALKPALGIGYKGKMPWRLRKEIRYFKDVTTRTTKPNTRNAVIMGRKTWE
SIPQKFRPLPDRLNIILSRSYENKIIDDNIIHASSIESSLNLVSDVERVFIIGGAEIYNE
LINNSLVSHLLITEIEHPSPESIEMDTFLKFPLESWTKQPKSELQKFVGDTVLEDDIKEG
DFTYNYTLWTRK

# Drug_Target_3_Reaction:
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
5,6,7,8-tetrahydrofolate + NADP(+) = 7,8- dihydrofolate + NADPH

# Drug_Target_3_SwissProt_ID:
P22906

# Drug_Target_3_SwissProt_Name:
DYR_CANAL

# Drug_Target_3_Synonyms:
EC 1.5.1.3

# Drug_Target_3_Theoretical_pI:
9.25

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_40_Cellular_Location:
Not Available

# Drug_Target_40_Chromosome_Location:
Not Available

# Drug_Target_40_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_40_Essentiality:
Non-Essential

# Drug_Target_40_GenAtlas_ID:
GSTP1

# Drug_Target_40_GenBank_ID_Gene:
M24485

# Drug_Target_40_GenBank_ID_Protein:
31946

# Drug_Target_40_GeneCard_ID:
GSTP1

# Drug_Target_40_Gene_Name:
GSTP1

# Drug_Target_40_Gene_Sequence:
>633 bp
ATGCCGCCCTACACCGTGGTCTATTTCCCAGTTCGAGGCCGCTGCGCGGCCCTGCGCATG
CTGCTGGCAGATCAGGGCCAGAGCTGGAAGGAGGAGGTGGTGACCGTGGAGACGTGGCAG
GAGGGCTCACTCAAAGCCTCCTGCCTATACGGGCAGCTCCCCAAGTTCCAGGACGGAGAC
CTCACCCTGTACCAGTCCAATACCATCCTGCGTCACCTGGGCCGCACCCTTGGGCTCTAT
GGGAAGGACCAGCAGGAGGCAGCCCTGGTGGACATGGTGAATGACGGCGTGGAGGACCTC
CGCTGCAAATACATCTCCCTCATCTACACCAACTATGAGGCGGGCAAGGATGACTATGTG
AAGGCACTGCCCGGGCAACTGAAGCCTTTTGAGACCCTGCTGTCCCAGAACCAGGGAGGC
AAGACCTTCATTGTGGGAGACCAGATCTCCTTCGCTGACTACAACCTGCTGGACTTGCTG
CTGATCCATGAGGTCCTAGCCCCTGGCTGCCTGGATGCGTTCCCCCTGCTCTCAGCATAT
GTGGGGCGCCTCAGCGCCCGGCCCAAGCTCAAGGCCTTCCTGGCCTCCCCTGAGTACGTG
AACCTCCCCATCAATGGCAACGGGAAACAGTGA

# Drug_Target_40_General_Function:
Involved in glutathione transferase activity

# Drug_Target_40_General_References:
10441116	Ji X, Blaszczyk J, Xiao B, O'Donnell R, Hu X, Herzog C, Singh SV, Zimniak P: Structure and function of residue 104 and water molecules in the xenobiotic substrate-binding site in human glutathione S-transferase P1-1. Biochemistry. 1999 Aug 10;38(32):10231-8.
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
1522586	Reinemer P, Dirr HW, Ladenstein R, Huber R, Lo Bello M, Federici G, Parker MW: Three-dimensional structure of class pi glutathione S-transferase from human placenta in complex with S-hexylglutathione at 2.8 A resolution. J Mol Biol. 1992 Sep 5;227(1):214-26.
2327795	Ahmad H, Wilson DE, Fritz RR, Singh SV, Medh RD, Nagle GT, Awasthi YC, Kurosky A: Primary and secondary structural analyses of glutathione S-transferase pi from human placenta. Arch Biochem Biophys. 1990 May 1;278(2):398-408.
2466554	Moscow JA, Fairchild CR, Madden MJ, Ransom DT, Wieand HS, O'Brien EE, Poplack DG, Cossman J, Myers CE, Cowan KH: Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res. 1989 Mar 15;49(6):1422-8.
2542132	Morrow CS, Cowan KH, Goldsmith ME: Structure of the human genomic glutathione S-transferase-pi gene. Gene. 1989 Jan 30;75(1):3-11.
3196325	Cowell IG, Dixon KH, Pemble SE, Ketterer B, Taylor JB: The structure of the human glutathione S-transferase pi gene. Biochem J. 1988 Oct 1;255(1):79-83.
3395118	Singh SV, Ahmad H, Kurosky A, Awasthi YC: Purification and characterization of unique glutathione S-transferases from human muscle. Arch Biochem Biophys. 1988 Jul;264(1):13-22.
3664469	Kano T, Sakai M, Muramatsu M: Structure and expression of a human class pi glutathione S-transferase messenger RNA. Cancer Res. 1987 Nov 1;47(21):5626-30.
3864155	Mannervik B, Alin P, Guthenberg C, Jensson H, Tahir MK, Warholm M, Jornvall H: Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci U S A. 1985 Nov;82(21):7202-6.
3979555	Alin P, Mannervik B, Jornvall H: Structural evidence for three different types of glutathione transferase in human tissues. FEBS Lett. 1985 Mar 25;182(2):319-22.
8433974	Kong KH, Inoue H, Takahashi K: Site-directed mutagenesis study on the roles of evolutionally conserved aspartic acid residues in human glutathione S-transferase P1-1. Protein Eng. 1993 Jan;6(1):93-9.
9012673	Oakley AJ, Rossjohn J, Lo Bello M, Caccuri AM, Federici G, Parker MW: The three-dimensional structure of the human Pi class glutathione transferase P1-1 in complex with the inhibitor ethacrynic acid and its glutathione conjugate. Biochemistry. 1997 Jan 21;36(3):576-85.
9092542	Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J: Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem. 1997 Apr 11;272(15):10004-12.
9150948	Ji H, Reid GE, Moritz RL, Eddes JS, Burgess AW, Simpson RJ: A two-dimensional gel database of human colon carcinoma proteins. Electrophoresis. 1997 Mar-Apr;18(3-4):605-13.
9245401	Ji X, Tordova M, O'Donnell R, Parsons JF, Hayden JB, Gilliland GL, Zimniak P: Structure and function of the xenobiotic substrate-binding site and location of a potential non-substrate-binding site in a class pi glutathione S-transferase. Biochemistry. 1997 Aug 12;36(32):9690-702.
9351803	Prade L, Huber R, Manoharan TH, Fahl WE, Reuter W: Structures of class pi glutathione S-transferase from human placenta in complex with substrate, transition-state analogue and inhibitor. Structure. 1997 Oct 15;5(10):1287-95.
9398518	Oakley AJ, Lo Bello M, Battistoni A, Ricci G, Rossjohn J, Villar HO, Parker MW: The structures of human glutathione transferase P1-1 in complex with glutathione and various inhibitors at high resolution. J Mol Biol. 1997 Nov 21;274(1):84-100.
9485454	Nicotra M, Paci M, Sette M, Oakley AJ, Parker MW, Lo Bello M, Caccuri AM, Federici G, Ricci G: Solution structure of glutathione bound to human glutathione transferase P1-1: comparison of NMR measurements with the crystal structure. Biochemistry. 1998 Mar 3;37(9):3020-7.

# Drug_Target_40_HGNC_ID:
HGNC:4638

# Drug_Target_40_HPRD_ID:
00614

# Drug_Target_40_ID:
904

# Drug_Target_40_Locus:
11q13

# Drug_Target_40_Molecular_Weight:
23225

# Drug_Target_40_Name:
Glutathione S-transferase P

# Drug_Target_40_Number_of_Residues:
209

# Drug_Target_40_PDB_ID:
13GS

# Drug_Target_40_Pathway:
Not Available

# Drug_Target_40_Pfam_Domain_Function:
PF00043	GST_C
PF02798	GST_N

# Drug_Target_40_Protein_Sequence:
>Glutathione S-transferase P
PPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDL
TLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVK
ALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYV
GRLSARPKLKAFLASPEYVNLPINGNGKQ

# Drug_Target_40_Reaction:
RX + glutathione = HX + R-S-glutathione

# Drug_Target_40_Signals:
None

# Drug_Target_40_Specific_Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles

# Drug_Target_40_SwissProt_ID:
P09211

# Drug_Target_40_SwissProt_Name:
GSTP1_HUMAN

# Drug_Target_40_Synonyms:
EC 2.5.1.18
GST class-pi
GSTP1-1

# Drug_Target_40_Theoretical_pI:
5.30

# Drug_Target_40_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Periplasm

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
Z48635

# Drug_Target_4_GenBank_ID_Protein:
1125639

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
nirK

# Drug_Target_4_Gene_Sequence:
>1137 bp
ATGACTGAACAACTTCAGATGACCCGCCGGACGATGCTTGCCGGCGCTGCCCTGGCGGGC
GCGGTTGCGCCGCTTCTCCACACCGCTCAGGCGCATGCCGCTGGCGCTGCCGCGGCAGCC
GGTGCTGCCCCCGTCGATATCTCGACCCTGCCTCGCGTGAAGGTCGACCTCGTCAAGCCG
CCTTTCGTGCACGCCCATGACCAGGTCGCCAAGACCGGACCGCGCGTCGTCGAGTTCACC
ATGACGATCGAGGAAAAGAAGCTGGTGATCGACCGCGAGGGCACTGAGATCCACGCGATG
ACCTTCAACGGTTCGGTGCCTGGTCCGCTGATGGTGGTGCATGAGAACGACTATGTTGAA
CTGCGGCTGATCAACCCTGACACCAACACGTTGCTGCACAACATCGACTTCCACGCCGCA
ACCGGTGCGCTCGGCGGCGGGGCGCTGACCCAGGTGAACCCGGGCGAGGAAACCACGCTT
CGTTTCAAGGCGACCAAGCCCGGCGTCTTCGTCTACCATTGCGCGCCGGAGGGCATGGTG
CCCTGGCACGTCACCTCGGGCATGAACGGCGCCATCATGGTGCTGCCGCGCGACGGACTG
AAGGACGAGAAGGGCCAGCCGCTGACGTACGACAAGATCTACTATGTCGGCGAGCAGGAC
TTCTACGTGCCGAAGGACGAGGCCGGGAACTACAAGAAGTACGAAACCCCCGGCGAAGCC
TATGAAGATGCTGTCAAGGCGATGCGCACGCTGACCCCGACCCACATCGTCTTCAACGGT
GCGGTCGGCGCGCTGACCGGCGACCATGCTTTGACTGCGGCCGTGGGCGAGCGTGTGCTC
GTCGTCCATTCGCAGGCCAACCGCGATACGCGGCCGCACCTGATCGGCGGGCATGGTGAC
TATGTCTGGGCGACCGGCAAGTTCCGCAACCCGCCGGATCTCGACCAGGAAACCTGGCTC
ATTCCGGGCGGAACCGCGGGCGCTGCCTTCTACACCTTCCGCCAGCCGGGTGTGTACGCC
TACGTCAACCACAACCTGATCGAGGCGTTCGAGCTGGGTGCCGCCGGCCACTTCAAGGTG
ACCGGCGAATGGAACGATGATCTGATGACATCGGTCGTCAAGCCGGCGTCGATGTAG

# Drug_Target_4_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_4_General_References:
1830217	Fenderson FF, Kumar S, Adman ET, Liu MY, Payne WJ, LeGall J: Amino acid sequence of nitrite reductase: a copper protein from Achromobacter cycloclastes. Biochemistry. 1991 Jul 23;30(29):7180-5.
1862344	Godden JW, Turley S, Teller DC, Adman ET, Liu MY, Payne WJ, LeGall J: The 2.3 angstrom X-ray structure of nitrite reductase from Achromobacter cycloclastes. Science. 1991 Jul 26;253(5018):438-42.
7499203	Adman ET, Godden JW, Turley S: The structure of copper-nitrite reductase from Achromobacter cycloclastes at five pH values, with NO2- bound and with type II copper depleted. J Biol Chem. 1995 Nov 17;270(46):27458-74.
8605003	Chen JY, Chang WC, Chang T, Chang WC, Liu MY, Payne WJ, LeGall J: Cloning, characterization, and expression of the nitric oxide-generating nitrite reductase and of the blue copper protein genes of Achromobacter cycloclastes. Biochem Biophys Res Commun. 1996 Feb 15;219(2):423-8.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
2720

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
40772

# Drug_Target_4_Name:
Copper-containing nitrite reductase

# Drug_Target_4_Number_of_Residues:
378

# Drug_Target_4_PDB_ID:
2NRD

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00394	Cu-oxidase
PF07732	Cu-oxidase_3

# Drug_Target_4_Protein_Sequence:
>Copper-containing nitrite reductase precursor
MTEQLQMTRRTMLAGAALAGAVAPLLHTAQAHAAGAAAAAGAAPVDISTLPRVKVDLVKP
PFVHAHDQVAKTGPRVVEFTMTIEEKKLVIDREGTEIHAMTFNGSVPGPLMVVHENDYVE
LRLINPDTNTLLHNIDFHAATGALGGGALTQVNPGEETTLRFKATKPGVFVYHCAPEGMV
PWHVTSGMNGAIMVLPRDGLKDEKGQPLTYDKIYYVGEQDFYVPKDEAGNYKKYETPGEA
YEDAVKAMRTLTPTHIVFNGAVGALTGDHALTAAVGERVLVVHSQANRDTRPHLIGGHGD
YVWATGKFRNPPDLDQETWLIPGGTAGAAFYTFRQPGVYAYVNHNLIEAFELGAAGHFKV
TGEWNDDLMTSVVKPASM

# Drug_Target_4_Reaction:
nitric oxide + H2O + ferricytochrome c = nitrite + ferrocytochrome c + 2 H+

# Drug_Target_4_Signals:
1-38

# Drug_Target_4_Specific_Function:
Nitric oxide + H(2)O + ferricytochrome c = nitrite + ferrocytochrome c + 2 H(+)

# Drug_Target_4_SwissProt_ID:
P25006

# Drug_Target_4_SwissProt_Name:
NIR_ACHCY

# Drug_Target_4_Synonyms:
Copper-containing nitrite reductase precursor
Cu-NIR
EC 1.7.2.1

# Drug_Target_4_Theoretical_pI:
6.26

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
single-pass type II membrane protein

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
HSD11B1

# Drug_Target_5_GenBank_ID_Gene:
M76665

# Drug_Target_5_GenBank_ID_Protein:
179475

# Drug_Target_5_GeneCard_ID:
HSD11B1

# Drug_Target_5_Gene_Name:
HSD11B1

# Drug_Target_5_Gene_Sequence:
>879 bp
ATGGCTTTTATGAAAAAATATCTCCTCCCCATTCTGGGGCTCTTCATGGCCTACTACTAC
TATTCTGCAAACGAGGAATTCAGACCAGAGATGCTCCAAGGAAAGAAAGTGATTGTCACA
GGGGCCAGCAAAGGGATCGGAAGAGAGATGGCTTATCATCTGGCGAAGATGGGAGCCCAT
GTGGTGGTGACAGCGAGGTCAAAAGAAACTCTACAGAAGGTGGTATCCCACTGCCTGGAG
CTTGGAGCAGCCTCAGCACACTACATTGCTGGCACCATGGAAGACATGACCTTCGCAGAG
CAATTTGTTGCCCAAGCAGGAAAGCTCATGGGAGGACTAGACATGCTCATTCTCAACCAC
ATCACCAACACTTCTTTGAATCTTTTTCATGATGATATTCACCATGTGCGCAAAAGCATG
GAAGTCAACTTCCTCAGTTACGTGGTCCTGACTGTAGCTGCCTTGCCCATGCTGAAGCAG
AGCAATGGAAGCATTGTTGTCGTCTCCTCTCTGGCTGGGAAAGTGGCTTATCCAATGGTT
GCTGCCTATTCTGCAAGCAAGTTTGCTTTGGATGGGTTCTTCTCCTCCATCAGAAAGGAA
TATTCAGTGTCCAGGGTCAATGTATCAATCACTCTCTGTGTTCTTGGCCTCATAGACACA
GAAACAGCCATGAAGGCAGTTTCTGGGATAGTCCATATGCAAGCAGCTCCAAAGGAGGAA
TGTGCCCTGGAGATCATCAAAGGGGGAGCTCTGCGCCAAGAAGAAGTGTATTATGACAGC
TCACTCTGGACCACTCTTCTGATCAGAAATCCATGCAGGAAGATCCTGGAATTTCTCTAC
TCAACGAGCTATAATATGGACAGATTCATAAACAAGTAG

# Drug_Target_5_General_Function:
Lipid transport and metabolism

# Drug_Target_5_General_References:
1885595	Tannin GM, Agarwal AK, Monder C, New MI, White PC: The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem. 1991 Sep 5;266(25):16653-8.

# Drug_Target_5_HGNC_ID:
HGNC:5208

# Drug_Target_5_HPRD_ID:
07042

# Drug_Target_5_ID:
364

# Drug_Target_5_Locus:
1q32-q41

# Drug_Target_5_Molecular_Weight:
32270

# Drug_Target_5_Name:
Corticosteroid 11-beta-dehydrogenase isozyme 1

# Drug_Target_5_Number_of_Residues:
291

# Drug_Target_5_PDB_ID:
1XU9

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_5_Protein_Sequence:
>Corticosteroid 11-beta-dehydrogenase isozyme 1
AFMKKYLLPILGLFMAYYYYSANEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHV
VVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHI
TNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMVA
AYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEEC
ALEIIKGGALRQEEVYYDSSLWTTLLIRNPCRKILEFLYSTSYNMDRFINK

# Drug_Target_5_Reaction:
an 11beta-hydroxysteroid + NADP+ = an 11-oxosteroid + NADPH + H+

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the reaction runs only in one direction, from 7- ketocholesterol to 7-beta-hydroxycholesterol

# Drug_Target_5_SwissProt_ID:
P28845

# Drug_Target_5_SwissProt_Name:
DHI1_HUMAN

# Drug_Target_5_Synonyms:
11-DH
11-beta-HSD1
11-beta-hydroxysteroid dehydrogenase 1
EC 1.1.1.146

# Drug_Target_5_Theoretical_pI:
8.77

# Drug_Target_5_Transmembrane_Regions:
7-23

# Drug_Target_6_Cellular_Location:
Cytoplasm

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
X01631

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
glmU

# Drug_Target_6_Gene_Sequence:
Not Available

# Drug_Target_6_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_6_General_References:
6395859	Walker JE, Gay NJ, Saraste M, Eberle AN: DNA sequence around the Escherichia coli unc operon. Completion of the sequence of a 17 kilobase segment containing asnA, oriC, unc, glmS and phoS. Biochem J. 1984 Dec 15;224(3):799-815.
7686882	Burland V, Plunkett G 3rd, Daniels DL, Blattner FR: DNA sequence and analysis of 136 kilobases of the Escherichia coli genome: organizational symmetry around the origin of replication. Genomics. 1993 Jun;16(3):551-61.
8083170	Mengin-Lecreulx D, van Heijenoort J: Copurification of glucosamine-1-phosphate acetyltransferase and N-acetylglucosamine-1-phosphate uridyltransferase activities of Escherichia coli: characterization of the glmU gene product as a bifunctional enzyme catalyzing two subsequent steps in the pathway for UDP-N-acetylglucosamine synthesis. J Bacteriol. 1994 Sep;176(18):5788-95.
8407787	Mengin-Lecreulx D, van Heijenoort J: Identification of the glmU gene encoding N-acetylglucosamine-1-phosphate uridyltransferase in Escherichia coli. J Bacteriol. 1993 Oct;175(19):6150-7.
8555230	Gehring AM, Lees WJ, Mindiola DJ, Walsh CT, Brown ED: Acetyltransfer precedes uridylyltransfer in the formation of UDP-N-acetylglucosamine in separable active sites of the bifunctional GlmU protein of Escherichia coli. Biochemistry. 1996 Jan 16;35(2):579-85.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
3697

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
49191

# Drug_Target_6_Name:
Bifunctional protein glmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase

# Drug_Target_6_Number_of_Residues:
456

# Drug_Target_6_PDB_ID:
1HV9

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00132	Hexapep
PF01128	IspD

# Drug_Target_6_Protein_Sequence:
>Bifunctional protein glmU [Includes: UDP-N-acetylglucosamine pyrophosphorylase
MLNNAMSVVILAAGKGTRMYSDLPKVLHTLAGKAMVQHVIDAANELGAAHVHLVYGHGGD
LLKQALKDDNLNWVLQAEQLGTGHAMQQAAPFFADDEDILMLYGDVPLISVETLQRLRDA
KPQGGIGLLTVKLDDPTGYGRITRENGKVTGIVEHKDATDEQRQIQEINTGILIANGADM
KRWLAKLTNNNAQGEYYITDIIALAYQEGREIVAVHPQRLSEVEGVNNRLQLSRLERVYQ
SEQAEKLLLAGVMLRDPARFDLRGTLTHGRDVEIDTNVIIEGNVTLGHRVKIGTGCVIKN
SVIGDDCEISPYTVVEDANLAAACTIGPFARLRPGAELLEGAHVGNFVEMKKARLGKGSK
AGHLTYLGDAEIGDNVNIGAGTITCNYDGANKFKTIIGDDVFVGSDTQLVAPVTVGKGAT
IAAGTTVTRNVGENALAISRVPQTQKEGWRRPVKKK

# Drug_Target_6_Reaction:
UTP + N-acetyl-alpha-D-glucosamine 1-phosphate = diphosphate + UDP-N-acetyl-D-glucosamine

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Catalyzes the last two sequential reactions in the de novo biosynthetic pathway for UDP-GlcNAc. Responsible for the acetylation of Glc-N-1-P to give GlcNAc-1-P and for the uridyl transfer from UTP to GlcNAc-1-P which produces UDP-GlcNAc

# Drug_Target_6_SwissProt_ID:
P0ACC7

# Drug_Target_6_SwissProt_Name:
GLMU_ECOLI

# Drug_Target_6_Synonyms:
EC 2.3.1.157]
EC 2.7.7.23
Glucosamine-1-phosphate N-acetyltransferase
N-acetylglucosamine-1-phosphate uridyltransferase

# Drug_Target_6_Theoretical_pI:
6.52

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasm

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
Z11975

# Drug_Target_7_GenBank_ID_Protein:
49286

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
hcp

# Drug_Target_7_Gene_Sequence:
>1638 bp
ATGAGTAATGCCATGTTCTGCTACCAGTGCCAGGAAACCGTGGGTAACAAAGGCTGCACC
CAGGTAGGCGTGTGCGGCAAAAAGCCTGAAACAGCCGCCCTTCAGGACGCGCTGATCTAT
GTGACCAAGGGCCTCGGCCAGATCGCCACGCGCCTGCGCGCCGAAGGCAAGGCCGTTGAC
CACAGGATAGACCGCCTGGTTACCGGCAACCTGTTTGCCACCATCACCAATGCCAACTTT
GACGACGACATCCTTGCCGAGCGTGTGCGCATGACCTGTGCCGCCAAAAAGGAACTGGCC
GCGTCCCTTACCGACAAGAGCGGCCTCAGCGATGCAGCCTTGTGGGAAGCATCCGAAAAG
TCCGCCATGCTGGCCAAGGCCGGAACCGTAGGCGTTATGGCCACCACCGATGATGATGTG
CGCTCCCTGCGCTGGCTCATCACCTTTGGGCTCAAGGGCATGGCGGCCTACGCCAAACAT
GCGGATGTGCTTGGCAAGCATGAAAACAGCCTTGACGCCTTCATGCAGGAAGCCCTTGCC
AAAACCCTGGATGACAGCCTGAGCGTGGCCGACCTTGTGGCCCTGACCCTTGAAACGGGC
AAGTTCGGCGTATCGGCCATGGCCCTGCTGGATGCTGCCAATACCGGTACCTACGGCCAC
CCAGAAATTACCAAGGTCAACATCGGCGTGGGCAGCAATCCCGGCATCCTCATTTCCGGG
CATGACCTGCGCGACCTTGAAATGCTGCTCAAGCAGACCGAAGGCACAGGCGTTGACGTG
TACACCCACTCTGAAATGCTGCCCGCCCATTACTACCCTGCCTTCAAGAAGTACGCGCAC
TTCAAGGGCAACTACGGCAATGCATGGTGGAAACAGAAAGAAGAATTTGAAAGCTTTAAC
GGCCCCGTGCTGCTGACCACCAACTGCCTTGTGCCGCCCAAGGACAGCTACAAGGACCGC
GTGTACACCACCGGCATCGTGGGTTTTACGGGCTGCAAGCATATCCCCGGTGAAATCGGC
GAACACAAGGACTTCAGCGCCATCATCGCCCATGCCAAGACCTGTCCCGCGCCTACGGAA
ATCGAATCCGGCGAAATCATCGGCGGCTTCGCGCACAATCAGGTACTGGCCCTGGCCGAC
AAGGTGATTGACGCGGTCAAATCCGGCGCCATCAAAAAGTTCGTGGTCATGGCCGGCTGC
GACGGCCGCGCCAAGTCCCGCAGCTACTACACCGACTTTGCCGAAGGCCTGCCCAAAGAC
ACGGTCATCCTTACCGCCGGTTGCGCCAAATATCGCTACAACAAGCTCAACCTGGGTGAC
ATCGGCGGCATCCCGCGCGTACTGGACGCCGGGCAGTGCAACGACTCCTACTCCCTGGCC
GTCATCGCCCTCAAGCTCAAGGAAGTATTCGGCCTCGAGGACGTCAACGACCTGCCCATC
GTCTACAATATCGCCTGGTACGAGCAGAAGGCCGTTATCGTGCTGCTGGCCCTGCTGAGC
CTCGGCGTGAAGAATATCCACCTCGGACCGACGCTGCCCGCCTTCCTTTCGCCCAACGTG
GCCAAGGTGCTGGTGGAACAGTTCAACATCGGCGGCATCACCAGTCCGCAGGACGACCTC
AAGGCGTTCTTCGGCTAA

# Drug_Target_7_General_Function:
Energy production and conversion

# Drug_Target_7_General_References:
11941509	Macedo S, Mitchell EP, Romao CV, Cooper SJ, Coelho R, Liu MY, Xavier AV, LeGall J, Bailey S, Garner DC, Hagen WR, Teixeira M, Carrondo MA, Lindley P: Hybrid cluster proteins (HCPs) from Desulfovibrio desulfuricans ATCC 27774 and Desulfovibrio vulgaris (Hildenborough): X-ray structures at 1.25 A resolution using synchrotron radiation. J Biol Inorg Chem. 2002 Apr;7(4-5):514-25. Epub 2002 Jan 23.
12764602	Aragao D, Macedo S, Mitchell EP, Romao CV, Liu MY, Frazao C, Saraiva LM, Xavier AV, LeGall J, van Dongen WM, Hagen WR, Teixeira M, Carrondo MA, Lindley P: Reduced hybrid cluster proteins (HCP) from Desulfovibrio desulfuricans ATCC 27774 and Desulfovibrio vulgaris (Hildenborough): X-ray structures at high resolution using synchrotron radiation. J Biol Inorg Chem. 2003 May;8(5):540-8. Epub 2003 Feb 15.
1311311	Moura I, Tavares P, Moura JJ, Ravi N, Huynh BH, Liu MY, LeGall J: Direct spectroscopic evidence for the presence of a 6Fe cluster in an iron-sulfur protein isolated from Desulfovibrio desulfuricans (ATCC 27774) J Biol Chem. 1992 Mar 5;267(7):4489-96.
1511014	Stokkermans JP, van den Berg WA, van Dongen WM, Veeger C: The primary structure of a protein containing a putative [6Fe-6S] prismane cluster from Desulfovibrio desulfuricans (ATCC 27774). Biochim Biophys Acta. 1992 Aug 17;1132(1):83-7.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
3274

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
58660

# Drug_Target_7_Name:
Hydroxylamine reductase

# Drug_Target_7_Number_of_Residues:
545

# Drug_Target_7_PDB_ID:
1UPX

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF03063	Prismane

# Drug_Target_7_Protein_Sequence:
>Hydroxylamine reductase
MSNAMFCYQCQETVGNKGCTQVGVCGKKPETAALQDALIYVTKGLGQIATRLRAEGKAVD
HRIDRLVTGNLFATITNANFDDDILAERVRMTCAAKKELAASLTDKSGLSDAALWEASEK
SAMLAKAGTVGVMATTDDDVRSLRWLITFGLKGMAAYAKHADVLGKHENSLDAFMQEALA
KTLDDSLSVADLVALTLETGKFGVSAMALLDAANTGTYGHPEITKVNIGVGSNPGILISG
HDLRDLEMLLKQTEGTGVDVYTHSEMLPAHYYPAFKKYAHFKGNYGNAWWKQKEEFESFN
GPVLLTTNCLVPPKDSYKDRVYTTGIVGFTGCKHIPGEIGEHKDFSAIIAHAKTCPAPTE
IESGEIIGGFAHNQVLALADKVIDAVKSGAIKKFVVMAGCDGRAKSRSYYTDFAEGLPKD
TVILTAGCAKYRYNKLNLGDIGGIPRVLDAGQCNDSYSLAVIALKLKEVFGLEDVNDLPI
VYNIAWYEQKAVIVLLALLSLGVKNIHLGPTLPAFLSPNVAKVLVEQFNIGGITSPQDDL
KAFFG

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Catalyzes the reduction of hydroxylamine to form NH(3) and H(2)O

# Drug_Target_7_SwissProt_ID:
Q01770

# Drug_Target_7_SwissProt_Name:
HCP_DESDA

# Drug_Target_7_Synonyms:
EC 1.7.-.-
HCP
Hybrid-cluster protein
Prismane protein

# Drug_Target_7_Theoretical_pI:
6.45

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
J01614

# Drug_Target_8_GenBank_ID_Protein:
455170

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
lysA

# Drug_Target_8_Gene_Sequence:
>1263 bp
TTAAAGCAATTCCAGCGCCAGTAATTCTTCGATGGTCTGGCGACGGCGAATCAACCGCGC
CTGACCATTATCAAACAGAACTTCTGGTAACAGCGGACGGCTATTGTAGTTGGATGACAT
TGATGCGCCATATGCCCCTGTATCATGCAGTACCAGATAATCACCTGCCTTCACTTCCGG
CAAGGCGCGGGTTTCAACATTTCCCCCTTCCTGCTGGGTAAAGACATCGCCCGATTCACA
TAACGGTCCGGCGACGACGGTTTCCACCGTTGGCGCGTGTTCCAGAGAACGACCATCAGC
TGCCAGGGCACTGATATGGTGGTAACTACCGTACATTGCCGGGCGCATCAGATCGTTGAA
CCCGGCATCAACCAGCACAAAGTGGCGGCTCCCCATTTGTTTGACGCTCCGCACCTGAGT
AATTAATACGCCAGACTGCGCTACCAGGAAGCGACCCGGTTCAATTTCCAGTTTCACAGG
GTGGCCCAAATGGCGGGCGATTTGCTCACGCGCGGCATTCCACAGACCATAATAATGTTC
GGTATCAACCGCCTCTTCACCCTGTTGATAAGGAACAGAAAGCCCACCGCCCGCAGAAAT
AGCCTGTAAATCCTGACCGAATTCGATGACCTGACGCACCATAGCACCACACACCTGTTC
CAGATGGGCATAATCAACGCCAGAACCAATGTGCATGTGAATGCCGACCAGCTGCAGATG
ATGACGTTGTATCACGTCCAGTGCGGCGGGCAGATCGGTGTACCAGATACCGTGCTTGCT
GTTTTCGCCACCGGTATTGGTTTTTTGGCTATGTCCGTGACCAAACCCCGGATTAACGCG
CAGCCATACCCGATGCCCTGGCGAAACCTGGCCCAGTTGGTCGAGCATATCAACAGAACC
CGCATTCACCGGAATTTGCAATTCACTGACGCGTTCAAGCGTCGCCTGATCGATAACATC
TGCCGTAAAAACAATATCATCGGGGTGCGTTTGCGGATTGTAACCCGCCGCCAACGCACG
CTCTATTTCGCCTAACGAGACGGAATCCACTTTCACGCCCTGCTCACGCATTAAGCGCAA
AATATGAATATTGGAACAGGCTTTCTGTGCAAAGCGCACCACATCAAACTGTTTCAGCGC
TGCAATCTGCCGACGAATAATTTGCGCATCGTAGACCCACACCGGGCAGCCAAATTCAGC
GGGCAAACGCAGCAGATTTTCGGCGGTGAGATCGGTATCGGTGCTGAACAGTGAATGTGG
CAT

# Drug_Target_8_General_Function:
Amino acid transport and metabolism

# Drug_Target_8_General_References:
6350601	Stragier P, Danos O, Patte JC: Regulation of diaminopimelate decarboxylase synthesis in Escherichia coli. II. Nucleotide sequence of the lysA gene and its regulatory region. J Mol Biol. 1983 Aug 5;168(2):321-31.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
3356

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
46178

# Drug_Target_8_Name:
Diaminopimelate decarboxylase

# Drug_Target_8_Number_of_Residues:
420

# Drug_Target_8_PDB_ID:
1KO0

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00278	Orn_DAP_Arg_deC
PF02784	Orn_Arg_deC_N

# Drug_Target_8_Protein_Sequence:
>Diaminopimelate decarboxylase
MPHSLFSTDTDLTAENLLRLPAEFGCPVWVYDAQIIRRQIAALKQFDVVRFAQKACSNIH
ILRLMREQGVKVDSVSLGEIERALAAGYNPQTHPDDIVFTADVIDQATLERVSELQIPVN
AGSVDMLDQLGQVSPGHRVWLRVNPGFGHGHSQKTNTGGENSKHGIWYTDLPAALDVIQR
HHLQLVGIHMHIGSGVDYAHLEQVCGAMVRQVIEFGQDLQAISAGGGLSVPYQQGEEAVD
TEHYYGLWNAAREQIARHLGHPVKLEIEPGRFLVAQSGVLITQVRSVKQMGSRHFVLVDA
GFNDLMRPAMYGSYHHISALAADGRSLEHAPTVETVVAGPLCESGDVFTQQEGGNVETRA
LPEVKAGDYLVLHDTGAYGASMSSNYNSRPLLPEVLFDNGQARLIRRRQTIEELLALELL

# Drug_Target_8_Reaction:
meso-2,6-diaminoheptanedioate = L-lysine + CO2

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Meso-2,6-diaminoheptanedioate = L-lysine + CO(2)

# Drug_Target_8_SwissProt_ID:
P00861

# Drug_Target_8_SwissProt_Name:
DCDA_ECOLI

# Drug_Target_8_Synonyms:
DAP decarboxylase
EC 4.1.1.20

# Drug_Target_8_Theoretical_pI:
5.97

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cytoplasmic

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
L10328

# Drug_Target_9_GenBank_ID_Protein:
290506

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
yicI

# Drug_Target_9_Gene_Sequence:
>2319 bp
TTACAACGTAATTGTCAGCGCATTCCCTTGAGGCTTCACCACCAGCCCCTGCTCACTTTC
AGCCTGCGAACCGTCTTGCAGACCATTTACTTTCACAACATTGCGCAGGCACAGTGTCCA
GTTCTTCGCCTCGCCCGCACCAGTCACAGTAATCGTGTTGCCAGTACGTGCTGCTTTTAA
AGTAAAGATCACCGATCCGTCAGCAGCGGGCACTTCACAGACGGCTTCATGCCCGTCTTG
CAGATTGAAGAGGTGGAATGCCGTGCCTTCGTGCCACACGTAATCGGGACGTTGATCGTT
GTTGCCCAGCGCCAGTAGAGTGTTATCACGCACATAAACGGGCAGACTCAGGAAGCCGTG
CTGCTGTTTATGCCAGCGACTACCGTCGAGTTCATCGTTGTGCCACAGGTGTGTCCAGCG
ACCTTCCGGCAGGTAGAACTGCACATCGCCCGCTTCAGTGAACACCGGCGCAACCATCAC
GTTGTCGCCTAACATGTATTGACGGTCAAGGTAATCACAAGCCGGATCGTCCGGGAACTC
CATCATCATGGCCCGCATCATCGGCGTACCCCGCGCGTTCGCACGCGNAGCTTCACGATA
CAGATACGGCATCATGCGGCATTTCAGTTGCGTGAAGAAGCGCACCACATCACAGGACTC
ATCATCGTAGGCCCACGNNACACGATAAGATTTGCTACCGTGTAAACGGCTATGGCTGGA
GAGCAAACCAAACGCGCACCAGCGTTTGTAAACGTGCGCCGGAGCGGTATTTTCAAAGCC
GCCGATATCGTGGCTCCAGAAGCCAAAACCTGAAAGGCCAATAGACAAACCACCGCGCAG
GCTTTCCGCCATTGATTCGTAGTTAGCGTAACAATCGCCACCCCAGTGTACCGGGAATTT
CTGCGCACCGACGGAGGCCGAGCGGGCAAACAAGACAGCTTCTTCCTCACCAACGGTGTC
CTTGAGCACGTTCCACACCAGTTCGTTGTAGATGTACGCATAATGGTTATGCATTTTCTG
CGGATCGGAACCGTCAAACCACTGAACATCAGTTGGGATACGTTCGCCAAAGTCGGTCTT
AAAGCAATCAACGCCCATCGCGACCAGACCTTTCAGTTTGTCGGCGTACCATTTGCAGGC
ATCCGGATTGGTAAAGTCATAAATCGCCAGACCTGGCTGCCATTTATCCCACTGCCATAG
CGAACCGTCCGGGCGTTTGAGTAAATAGCCTTTCTCTTGTAACTCTTTAAAGACGGGGGA
TTTTTGACCGATATAGGGGTTAATCCAGACGCAGATTTTCAGTCCTTTCGCTTTCAGGCG
GCGGATCATCCCTTCCGGGTCAGGGAAAGTCAGCGGGTCCCACTCAAAATCGCACCACTG
GAAGGCTTTCATCCAGAAACAGTCAAAGTGGAAAACATGCAGCGGCAGATTGCGTTCCGC
CATACCATCGATAAAGCTGTTTACCGTCGCTTCGTCGTAGTTGGTGGTAAATGAAGTGGT
TANNCACAGGCCGAAGGACCACGCGGGCGNCANNGCCGGACGACCAGTAAAGCGGGTATA
ACGATCAAGTACCGCTTTCGGCGTCGGGCCGTCGATAACAAAGTATTCGAGATATTCACT
CTCAACGCTGAACTGCACTTTGGAGACTTTCTCCGATCCCACTTCAAAAGAGACACACTG
GGGATGATTGACCAGTACCCCATAACCACGGTTAGTCATGTAGAACGGGATATTTTTATA
CGCCTGTTCAGTACTTGTGCCGCCGTCCCGGTTCCAGGTCTCTACCGTCTGGCCATTGCG
CACCAGGGCAGTAAAGCGCTCTCCCAGACCGTAAACTGTTTCGCCAACGCCAAGATCAAG
CCGCTCAAACATATAATTGCGTTGATTATTCGTGTCCTGCACGTAGCCATTATTTTTCAC
CTGACTACCGGTAATACGTTCGCCGTTGCGCAGAAAATCCAGTGACCAGAACTCACCTTT
GCTGACACGCGCGCTTAAGTTGCCACTTTTAAACTCAGCATAACGTTCTGTGTTTTCGAT
TGTGACCTTCACGTCCTGCAAAATATTGAGCGGATAATGAGGACCGTTATTCAGCGCCCC
CTGAAAATGCTCAATCCGCACACCGACAATACCTTCCTGTGGGGAGAAAAAGCGCAACGT
AAATAAAGGCGTATCAAGCTGCCAGGTACGTTCACGCACATCACGGGGGGCAGCATAGAC
CACCATTTCATTATCCTGCTGTTCAACCTCGAACACCTGAAGCGGGTGAATCAAATTGAG
GCCAGGTTGAATCAACCAGTTTCCATCGCTAATTTTCAT

# Drug_Target_9_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_9_General_References:
7686882	Burland V, Plunkett G 3rd, Daniels DL, Blattner FR: DNA sequence and analysis of 136 kilobases of the Escherichia coli genome: organizational symmetry around the origin of replication. Genomics. 1993 Jun;16(3):551-61.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
3500

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
88080

# Drug_Target_9_Name:
Putative family 31 glucosidase yicI

# Drug_Target_9_Number_of_Residues:
772

# Drug_Target_9_PDB_ID:
1XSK

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF01055	Glyco_hydro_31

# Drug_Target_9_Protein_Sequence:
>Putative family 31 glucosidase yicI
MKISDGNWLIQPGLNLIHPLQVFEVEQQDNEMVVYAAPRDVRERTWQLDTPLFTLRFFSP
QEGIVGVRIEHFQGALNNGPHYPLNILQDVKVTIENTERYAEFKSGNLSARVSKGEFWSL
DFLRNGERITGSQVKNNGYVQDTNNQRNYMFERLDLGVGETVYGLGERFTALVRNGQTVE
TWNRDGGTSTEQAYKNIPFYMTNRGYGVLVNHPQCVSFEVGSEKVSKVQFSVESEYLEYF
VIDGPTPKAVLDRYTRFTGRPALPPAWSFGLWLTTSFTTNYDEATVNSFIDGMAERNLPL
HVFHFDCFWMKAFQWCDFEWDPLTFPDPEGMIRRLKAKGLKICVWINPYIGQKSPVFKEL
QEKGYLLKRPDGSLWQWDKWQPGLAIYDFTNPDACKWYADKLKGLVAMGVDCFKTDFGER
IPTDVQWFDGSDPQKMHNHYAYIYNELVWNVLKDTVGEEEAVLFARSASVGAQKFPVHWG
GDCYANYESMAESLRGGLSIGLSGFGFWSHDIGGFENTAPAHVYKRWCAFGLLSSHSRLH
GSKSYRVPWAYDDESCDVVRFFTQLKCRMMPYLYREAARANARGTPMMRAMMMEFPDDPA
CDYLDRQYMLGDNVMVAPVFTEAGDVQFYLPEGRWTHLWHNDELDGSRWHKQQHGFLSLP
VYVRDNTLLALGNNDQRPDYVWHEGTAFHLFNLQDGHEAVCEVPAADGSVIFTLKAARTG
NTITVTGAGEAKNWTLCLRNVVKVNGLQDGSQAESEQGLVVKPQGNALTITL

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Not Available

# Drug_Target_9_SwissProt_ID:
P31434

# Drug_Target_9_SwissProt_Name:
XYLS_ECOLI

# Drug_Target_9_Synonyms:
Not Available

# Drug_Target_9_Theoretical_pI:
5.61

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB03814
